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1. QUORUM SENSING 
 
1.1. INTRODUCTION 
It was at the beginning of the previous century that the plant pathologist E.F. 
Smith suggested that “a number of bacteria are stronger than a few and thus are able to 
overcome obstacles too great for the few” (1). Despite this visionary statement, it was 
not until the 1970s that reports on intraspecies communication were first published (2). 
Nealson and Hastings described how bioluminescence in the marine bacterium Vibrio 
fischeri only occurred at high cell density, and that so-called autoinducers in the 
supernatant of a luminescent culture could activate luminescence in a non-luminescent 
culture (3, 4). In the early 1990s, the term quorum sensing (QS) was introduced by Clay 
Fuqua and Peter Greenberg, defining a quorum as a minimal unit of bacteria to 
efficiently perform a certain behavior (5). Nowadays, it is widely recognized that 
bacteria communicate with one another, allowing them to synchronize the expression of 
a variety of phenotypic traits. It has even been stated that QS blurs the distinction 
between prokaryotes and eukaryotes because it enables bacteria to act as multicellular 
organisms (6).  
 
1.2. N-ACYLHOMOSERINE LACTONE MEDIATED QS 
As mentioned above, bacterial cell-to-cell communication was first described in V. 
fischeri (2, 3, 7, 8). The autoinducer responsible for this cell population density-
dependent phenomenon was shown to be a N-acylhomoserine lactone (AHL), produced 
by a synthase called LuxI. Further biochemical studies revealed that this signaling 
molecule binds to LuxR, a cytoplasmic receptor protein and transcriptional activator 
(Fig. 1) (9, 10). This type of three-component regulatory network is commonly used by a 
variety of Gram-negative bacteria, many of which are pathogenic and use QS to 
synchronously activate virulence factor production (11-13). 
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Fig. 1. Simplified model of the three-component regulatory network for QS in Gram-
negative bacteria. 
 
1.2.1. AHL biosynthesis 
The signaling molecules most commonly found in Gram-negative bacteria are 
AHLs (Fig. 2). They are diffusible, low molecular weight molecules that are characterized 
by a conserved lactone moiety and a variable acyl side chain, linked together with an 
amide bond. Variations in side chain length, saturation and substitution at the third 
carbon atom occur in AHLs produced by different bacterial species, but also the 
production of multiple types of AHLs within one species is not uncommon. Acyl side 
chains ranging from 4 to 18 carbon atoms have been described in the literature, and 
they can be branched and/or (un)saturated at different positions. Furthermore, they 
may or may not contain a hydroxy or oxo group at the C3 position (14-16). In all cases, 
an intact lactonized homoserine is required for biological activity. However, as far as the 
acyl side chain is concerned, it was recently shown that aryl-HSLs, e.g. p-coumaroyl-HSL, 
also exist in nature (17).  
 
- 9 - 
 
   
LuxI homologues are AHL synthases that catalyze two reactions. They facilitate 
both the acylation of the amino group of S-adenosyl-L-methionine (SAM) and the 
subsequent intramolecular nucleophilic substitution and loss of methylthioadenosine 
(Fig. 3) (18). The acyl portion of the AHL is derived from fatty-acid precursors 
conjugated to the acyl carrier protein (acyl-ACP), and the HSL moiety is derived from 
SAM (12).  
 
 
 
Fig. 2. Examples of AHLs present in different bacteria. 
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Fig. 3. LuxI-catalyzed synthesis of AHLs from fatty acyl-acyl carrier protein (ACP) 
derivatives and SAM (18). 
 
 Acyl chain length is determined by the chemical reactions preceding these LuxI-
catalyzed reactions. They include the transfer of acetyl-CoA to the ACP by an enzyme 
called malonyl-acyltransferase (MAT) and subsequent chain elongation through the 
repeated incorporation of malonyl-CoA units that are loaded onto the ACP by MAT (18). 
This process results in the production of fatty acyl derivatives with an even number of 
carbon atoms. Nonetheless, it has to be mentioned that when in the rare case that 
propionyl-CoA is used as a starter unit, odd-numbered AHLs can also be found in trace 
amounts (19).  
 LuxI (V. fischeri), AinS/LuxM (V. fischeri / Vibrio harveyi) and HdtS (Pseudomonas 
fluorescens / Acidothiobacillus ferrooxidans) represent three different types of AHL 
synthases. These enzymes do not necessarily show significant sequence similarity with 
one another. The AinS protein for instance, shows no significant similarity with LuxI 
family members, but it does show similarity with the V. harveyi LuxM protein (20, 21) 
HdtS does not belong to either of the AHL synthase families (LuxI or LuxM) and may 
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therefore constitute a member of a third family capable of AHL biosynthesis (22). In 
2005, production of AHLs using one of the three types of enzymes had already been 
demonstrated in more than 70 bacterial species (6), and this number is still increasing. 
 
1.2.2. Transport of AHLs across cell membranes 
Upon synthesis, in most cases AHLs are expected to diffuse freely in and out of 
the cell because of their amphipathic nature. As cell density increases, AHL 
concentration in the extracellular environment increases as well (6).  
It was shown that within seconds after adding tritium-labeled 3-oxo-C6-
homoserine lactone (3OC6HSL) to suspensions of V. fischeri or Escherichia coli, cellular 
concentrations equaled external concentrations for both species. Since E. coli lacks 
homologues of the V. fischeri QS genes, this indicated that no specific system for uptake 
or export of the signaling molecules was involved for this short chain AHL (23). In 
contrast, Pearson et al. showed that this was not the case for 3H-labeled 3-oxo-C12-
homoserine lactone (3OC12HSL) in Pseudomonas aeruginosa (24). Although a steady 
state was reached within 30s after the addition of [3H]C4-homoserine lactone (C4HSL), 
with internal and external concentrations being nearly equal, it took about 5 minutes to 
reach a steady state for [3H]3OC12HSL, and cellular concentrations were 3 times higher 
than the extracellular level. Inhibiting the cytoplasmic membrane proton gradient with 
azide led to a strong increase in cellular accumulation of [3H]3OC12HSL, suggesting the 
involvement of active efflux systems. Indeed, when a mutant lacking the mexA-mexB-
oprM-encoded active-efflux pump was tested, [3H]3OC12HSL accumulated to levels 
similar to those in the azide-treated wild-type cells (24). Furthermore, P. aeruginosa 
mutants hyperexpressing the MexAB-OprM multidrug efflux system produced reduced 
levels of virulence factors known to be regulated by QS, again proving that active 
transport of AHLs takes place (25). Other examples of this mechanism also exist: in 
Burkholderia pseudomallei, a mutant lacking the BpeAB-OprB efflux pump was impaired 
in the export of multiple AHLs; and in Bacteroides fragilis, a BmeB pump was suggested 
to be involved in AHL export (25, 26). 
Altogether, it can be summarized that short chain AHLs diffuse freely and rapidly 
across cell membranes, whereas the more hydrophobic long chain AHLs are exported 
out of the cell by efflux pumps in addition to a slow and gradual release. This slow efflux 
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can be explained by partitioning of the long chain AHL due to interactions with the 
lipophilic cytoplasmic membrane (11). 
The specific mechanisms for cellular AHL uptake remain unknown, but it is 
generally assumed to occur by passive diffusion. 
 
1.2.3. AHL signal reception and signal transduction 
 Signaling molecule concentration increases with increasing cell density. Upon 
reaching a certain threshold concentration, the signals bind to the LuxR-type receptor to 
form a LuxR-AHL complex, which, in turn, acts as a transcriptional activator. LuxR 
homologues reside in the cytoplasm or they are loosely associated with the inner leaflet 
of the cytoplasmic membrane (27).  
  
Based on the mode of interaction with their cognate signals, three classes of 
LuxR-type receptors have been defined. The first class of proteins requires AHL for 
folding and binds AHLs irreversibly once folded. This class includes LasR (P. aeruginosa), 
TraR (Agrobacterium tumefaciens) and CepR (Burkholderia cenocepacia). A second class 
of proteins, including QscR (P. aeruginosa) and LuxR (V. fischeri), also requires AHL for 
folding, but the mature protein binds AHL reversibly. EsaR (Pantoea stewartii) and ExpR 
(Erwinia chrysanthemi) constitute members of the third class of LuxR-type receptors. 
They do not require AHL for folding, and the binding of AHL with the mature protein is 
reversible (28).  
Sequence conservation, biochemical analysis of LuxR, TraR and other family 
members, and the TraR crystal structure learned that LuxR-type proteins consist of two 
key functional domains: a regulator domain located at the N-terminal end of the protein, 
and an activator domain located at the C-terminal end (Fig. 4). The regulator domain 
represents the AHL-binding region. It comprises a conserved cluster of residues, and 
mutations in this region abolish the binding of 3OC6HSL to LuxR (29, 30). Sequence 
alignment of AhyR (Aeromonas hydrophila), LasR and RhlR (P. aeruginosa), LuxR (V. 
fischeri) and TraR (A. tumefaciens) revealed conserved amino acid residues necessary 
for the interaction with the AHL: Ala38 (Gly in LasR), Tyr53 (Cys in AhyR), Trp57, Asp70 
and Ser129 (Thr in TraR) (31). Vannini et al. determined the crystal structure of the 
transcriptional regulator TraR bound to its autoinducer and to target DNA. It revealed a 
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multitude of intermolecular interactions between the AHL and the protein. The AHL was 
shown to be completely embedded in an enclosed cavity, formed by a cluster of aromatic 
and hydrophobic residues. Furthermore, the autoinducer is stabilized by two hydrogen 
bonds between the amide nitrogen and Asp70, and between the carbonyl oxygen of the 
lactone moiety and Trp57 (32). The second key functional domain, located at the C-
terminal region, contains a helix-turn-helix motif that is required for DNA binding (30). 
The central part of the protein is essential for multimerization, which is an important 
consequence of AHL binding. It has indeed been shown in vivo with LuxR (V. fischeri) and 
LasR (P. aeruginosa), and in vitro with TraR (A. tumefaciens) and CarR (Erwinia 
carotovora) that oligomeric LuxR homologues are formed upon binding of the signal. 
The active, ligand-bound form of TraR is a dimer, for instance; whereas the CarR protein 
exists as a dimer in the absence of signal and is shifted towards a higher-order multimer 
in response to AHL addition (33, 34). Results with RhlR (P. aeruginosa) on the other 
hand, are more controversial. One study suggests that RhlR dimerizes in vitro in the 
absence of its cognate signal, C4HSL (35), whereas another one shows that C4HSL 
induces multimerization in vivo (28, 36).  
 
 
Fig. 4. Structure and key regions of LuxR-type transcription factors. 
 
 Although LuxR homologues only share an end-to-end sequence identity of 18-
23%, they all possess several conserved amino acids and an identical architecture. 
Furthermore, LuxR-type proteins of different bacteria can range in size from 70 up to 
300 amino acids (37).  
 Once the AHL has bound to the LuxR homologue, the signal-receptor complex 
binds to DNA promoter elements similar to the lux box in V. fischeri. This lux box is a 20 
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bp inverted repeat, located in the luxI promotor region and required for LuxR-
dependent induction of the luminescence genes. Many lux-type boxes are positioned just 
upstream of the -35 sequences of regulated promoters, suggesting that LuxR 
homologues can interact directly with RNA polymerase. It has been found that null 
mutations in genes encoding LuxR-type proteins generally result in a decreased target 
gene expression, indicating that most of the LuxR-type regulators function as 
transcriptional activators (37, 38). In contrast, several other LuxR-type proteins, from 
different species and subspecies of Erwinia, act as transcriptional repressors. For 
example, EsaR (P. stewartii, formerly known as E. stewartii) binds to DNA in the absence 
of AHLs. The EsaR-AHL complex however, has a reduced affinity for DNA, thereby 
terminating the repression (39, 40).  
 
A last and very peculiar type of LuxR homologues to be addressed here, are 
orphan LuxR regulators (41). These LuxR solos exist without the corresponding LuxI 
homologue, and may therefore function as detectors of AHLs produced by other 
bacterial species, or may play a role in interkingdom signaling (42, 43). These orphan 
proteins are both found in bacteria which possess (a) complete AHL QS system(s) as 
well as in bacteria that do not. ExpR of Sinorhizobium meliloti, BisR of Rhizobium 
leguminarosum, CepR2 of B. cenocepacia and QscR of P. aeruginosa are examples of LuxR 
solos in AHL producing bacteria (41, 44); whereas SdiA is an example of a LuxR solo 
described in non-AHL producing bacteria (Escherichia, Salmonella and Klebsiella species) 
(45).  
 
1.2.4. Biosensors for the detection of AHLs 
 Biosensors for the detection of AHLs are bacteria of which an easily detectable 
phenotypic trait is regulated by QS. They generally have a functional response regulator, 
allowing them to respond to the presence of exogenously added AHLs, but lack the 
cognate AHL synthase. The activated LuxR homologue binds to a QS-dependent 
promoter region (usually the promoter of the cognate luxI synthase) of a reporter 
operon, resulting in the production of a detectable signal (46). Most biosensors carry a 
recombinant plasmid in which lacZ, gfp or luxCDABE genes are fused to a QS-responsive 
promoter.  
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The lacZ gene encodes β-galactosidase, an exoglycosidase that is often used as a 
specific indicator of gene expression. It cleaves the synthetic substrate 5-bromo-4-
chloro-3-indolyl-β-D-galactopyranoside (X-gal), resulting in the production of a blue 
precipitate that can be detected visually or spectroscopically. Coupling lacZ to QS 
regulated genes allows for the detection of exogenous AHLs through measurement of β-
galactosidase activity (47). Another frequently used gene in whole-cell biosensors for QS 
is gfp, encoding green fluorescent protein (GFP) from the jellyfish Aequorea victoria (48). 
Since GFP is extremely stable once formed, Andersen et al. constructed a number of gfp 
genes each of which encoded proteins with different half-lives. This was done by 
manipulating gfp in such a way that the produced GFPs carried C-terminal peptide tags 
which are recognized and degraded by specific proteases (49). The construction of these 
gfp variants enabled AHL detection at the single-cell level and allowed for real-time 
measurements of fluctuations in AHL concentrations (50). The third common system 
used in QS biosensor assays relies on a plasmid construct harboring the luxCDABE 
operon of Photorhabdus luminescens, resulting in bioluminescence once induced (51).  
 
Each AHL biosensor relies on a particular LuxR-type protein, thus displaying a 
certain specificity towards its cognate AHL and in some cases, closely related AHLs. 
Many biosensors detect only a narrow range of signaling molecules, making the 
selection of the right type of biosensor to use in experimental procedures crucial (46). 
Below, the described biosensors have been grouped based on their specificity for certain 
AHLs. 
 
1.2.4.1. Biosensors for short and medium acyl chain AHLs 
 Chromobacterium violaceum is a Gram-negative bacterium that uses the CviI/R 
AHL system to regulate violacein (an antibacterial purple pigment) production. By 
subjecting this strain to mini-Tn5 transposon mutagenesis, an AHL-negative mutant was 
constructed: C. violaceum CV026 (52). Violacein production in this strain can be restored 
by adding exogenous signaling molecules. The most active agonist in this assay is C6-
homoserine lactone (C6HSL), which is the natural C. violaceum AHL. Nevertheless, this 
biosensor also detects C4HSL, C8-homoserine lactone (C8HSL), 3OC6HSL, 3-oxo-C8-
homoserine lactone (3OC8HSL) and 3-oxo-C4-homoserine lactone (3OC4HSL), albeit 
- 16 - 
 
with different degrees of activation. AHLs consisting of acyl side chains longer than 8 
carbon atoms are not detected by this biosensor strain. In addition, CV026 does not 
detect any 3-hydroxy-AHLs. Adding short chain AHLs simultaneously with long chain 
AHLs results in a decrease in activation by the short chain AHLs, implying that this 
mutant could also be exploited to detect AHLs with longer acyl side chains (C10 to C14) 
(52). 
  Several bioluminescence based biosensors also detect short and medium acyl 
chain AHLs. E. coli (pSB401) and E. coli (pHV200I) both use LuxR of V. fischeri and the 
cognate luxI promoter controlling luxCDABE expression. They are most sensitive to 
3OC6HSL and display good sensitivity towards C6HSL, 3OC8HSL and C8HSL. Little 
agonistic activity was observed for C4HSL, C10- and longer acyl chain AHLs. Both strains 
can be used for quantification of low AHL concentrations. However, it is obvious that a 
luminometer is necessary to measure luminescence (47, 53). Finally, E. coli strains 
harboring plasmids pSB536 and pAL101 are biosensors sensitive to C4HSL. The former 
plasmid was constructed using the ahyR of A. hydrophila and the cognate ahyI gene 
promoter fused to luxCDABE. The latter is constructed in a similar way but is composed 
of the RhlI/R QS system of P. aeruginosa (54, 55). 
 
1.2.4.2. Biosensors for long acyl chain AHLs 
 Biosensors for the specific detection of long chain AHLs are based on the LasI/R 
system of P. aeruginosa, which produces and detects 3OC12HSL. In E. coli pSB1075 the 
plasmid harbors the lasR gene and cognate lasI promotor controlling luxCDABE 
expression. This strain responds well to 3OC12HSL, 3-oxo-C10-homoserine lactone 
(3OC10HSL) and C12-homoserine lactone (C12HSL) (53). E. coli pKDT17 and P. 
aeruginosa PAO1 M71LZ are two β-galactosidase producing biosensors for long chain 
AHLs. The plasmid pKDT17 contains lasR under control of the lac promoter and a 
lasB::lacZ translational fusion. lasB is a gene encoding an elastase, which is regulated by 
the LasI/R QS system (47). The E. coli strain harboring this plasmid responds strongly to 
C12HSL, C10HSL and their 3-oxo derivatives (56). P. aeruginosa PAO1 M71LZ, on the 
other hand, is a lasI knock-out mutant containing a transcriptional fusion of the 
promotor of rsaL (a gene directly regulated by the LasI/R QS system) and reporter gene 
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lacZ (57-59). Adding 3OC12HSL to this strain will therefore result in rsaL transcription 
via LasR. This sensor also works well with 3OC10HSL. 
 
1.2.4.3. Biosensors that can detect a broad range of AHLs 
 Since AHL biosensors are always limited by the specificity of the LuxR 
homologues used, most of them are restricted in the range of signal molecules to which 
they can respond. Nevertheless, biosensors using the TraI/R system of A. tumefaciens 
are able to detect a broad range of AHLs. Furthermore, they display a great sensitivity 
towards these compounds (56, 60, 61). A. tumefaciens NT1 pZLR4 is a broad range AHL 
biosensor of which the Ti plasmid, responsible for AHL production under normal 
circumstances, has been cured and which has been provided with the pZLR4 plasmid. 
This plasmid harbors the traR gene and one of the tra operons, containing a traG::lacZ 
reporter fusion, the transcription of which is known to be controlled by the TraI/R QS 
system (56, 60). This β-galactosidase producing biosensor responds to an exceptional 
range of AHL signal molecules: it detects 3-oxo-substituted AHLs ranging from 4 to 12 
carbons, and also 3-unsubstituted AHLs with the exception of C4HSL. Moreover, it can 
detect a few hydroxy-substituted AHLs, more specifically 3-hydroxy-C6-homoserine 
lactone (3OHC6HSL), 3-hydroxy-C8-homoserine lactone (3OHC8HSL) and 3-hydroxy-
C10-homoserine lactone (3OHC10HSL) (56, 62). A similar biosensor is A. tumefaciens 
WCF47 (pCF218)(pCF372) (63). Recently, this strain has been modified in order to 
make it even more sensitive. Zhu et al. achieved this by overexpressing the TraR protein, 
as increased amounts of regulator in the cytoplasm result in a broader specificity and 
greater sensitivity towards AHLs (61). 
 
1.2.4.4. Biosensors for 3-hydroxy-AHLs 
 One example of a biosensor able to detect 3-hydroxy-AHLs has already been 
described above. Additionally, another specific sensor has been developed, which 
employs the PhzI/R system of P. fluorescens 2-79. This strain consists of a two-plasmid 
system harbored in a WT P. fluorescens 1855 strain which does not produce AHLs. 
Although PhzI produces 6 different AHLs, the quantitative dominant and cognate signal 
was determined to be 3OHC6HSL. The plasmid constructs in this biosensor strain allow 
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for AHL determination through the measurement of β-galactosidase and β-
glucuronidase activity (64). 
 
1.2.4.5. Quorum sensing inhibition selector systems 
Rasmussen et al. designed three assays for the rapid detection of AHLs and 
quorum sensing inhibition (QSI) (65) (Fig. 5). There are two mechanisms on which these 
quorum sensing inhibition selector (QSIS) systems are based. The first is the production 
of a lethal protein, the gene of which is fused to a QS-regulated promoter. QSIS1 uses 
phlA from Serratia liquefaciens, encoding a protein leading to cell lysis. QSIS2 uses sacB 
encoding Bacillus subtilis levan sucrase. These strains are thus unable to grow in the 
presence of AHLs unless a non-toxic QSI is present. The second mechanism is the 
employment of an antibiotic (AB) resistance gene controlled by a QS-regulated 
repressor. Gentamycin is used in QSIS2, kanamycin is used in QSIS3. In the presence of 
AHLs, production of the repressor inhibits the expression of of the AB resistance gene, 
resulting in growth inhibition. The QSIS2 system uses a lasB promoter fused to the sacB 
gene encoding levan sucrase, introduced in a P. aeruginosa lasI-rhlI mutant, and 
responds almost exclusively to 3OC12HSL. QSIS1 and QSIS3 respond to a broad range of 
AHLs and employ the luxR gene and the promoter region of luxI fused to the genes 
encoding lethal proteins. The QSIS1 and QSIS3 systems were established in E. coli, the 
QSIS2 system was established in P. aeruginosa (65). 
 
 
Fig. 5. The three QSIS systems: (A) QSIS1, (B) QSIS2, (C) QSIS3 (65). 
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1.3. PEPTIDE MEDIATED QS IN GRAM-POSITIVE BACTERIA 
 Gram-positive bacteria also regulate a variety of processes in response to 
increasing cell-population density. However, in contrast to Gram-negative bacteria, 
Gram-positive bacteria use post-translationally modified oligopeptides, commonly 
referred to as auto-inducing peptides (AIPs), as QS signal molecules. The AIPs range 
from 5 to 34 amino acids in length and typically contain unusual chemical architectures 
(66). QS systems in Gram-positive bacteria are much more diverse than the Gram-
negative AHL-mediated systems; hence, many variations in the nature of the QS signal 
exist (6). ATP-binding cassette transporters are commonly used to secrete these 
peptides. Besides the signal molecules themselves, a second major difference with QS in 
Gram-negative bacteria is the use of two-component systems (TCS) for detection of AIPs 
instead of LuxR-type receptors. These TCS generally consist of a membrane-bound 
histidine kinase sensor and an intracellular response regulator protein, and use 
phosphorylation as a means to transfer information (Fig. 6) (67, 68).  
  
 
Fig. 6. Simplified model of the general QS system in Gram-positive bacteria. 
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 Several processes in Gram-positive bacteria are known to be regulated in a cell-
density-dependent manner. Examples of these QS systems are the development of 
genetic competence in Bacillus subtilis and Streptococcus pneumoniae (69), virulence 
response in Staphylococcus aureus (70, 71), and the production of antimicrobial peptides 
(e.g. lantibiotics and subtilin) by several Gram-positive bacteria (68, 72, 73).  
Although a detailed overview of the current published data on AIP mediated QS 
falls beyond the scope of this manuscript, the interested reader can find additional 
information on this topic in several recent review papers (74-76). 
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1.4. AUTOINDUCER-2 MEDIATED INTERSPECIES QUORUM SENSING  
The first hint of bacteria signaling between species emerged from the work of 
Greenberg et al. in which the bioluminescent response of V. harveyi was triggered 
through the addition of cell-free culture supernatant from other bacterial species (77). 
Later, in 1993, it was discovered that V. harveyi mutants defective in AHL signaling 
remained capable of QS dependent gene activation (78). A chemical signal called 
autoinducer-2 (AI-2) was held responsible for this effect. Since AI-2 is released by many 
groups of bacteria, it implies the possibility of a universal chemical lexicon (79). This 
type of bacterial “Esperanto” is often called interspecies QS (80). 
 
1.4.1. AI-2 biosynthesis 
Insight in AI-2 biosynthesis came after genome analysis in Borrelia burgdorferi. It 
was demonstrated that its luxS gene was the third one in a three-gene operon (81). The 
other two genes, pfs and metK, encode enzymes involved in the activated methyl cycle 
(AMC), which is an important metabolic pathway for the recycling of SAM. When SAM is 
used as a methyl donor in several metabolic processes, a toxic intermediate called S-
adenosylhomocysteine (SAH) is formed. SAH in its turn is hydrolysed to S-
ribosylhomocysteine (SRH) by Pfs, which is a 5’-methylthioadenosine/S-
adenosylhomocysteine nucleosidase (MTAN) (82). Conversion of SRH to homocysteine 
by LuxS yields the AI-2 precursor 4,5-dihydroxy-2,3-pentanedione (DPD) (Fig. 7.). DPD 
is a very unstable molecule and spontaneously cyclizes in solution into different isomers 
(Fig. 8). This mixture of furanone molecules is collectively called AI-2, and the structure 
of one of these molecules was identified as (2S,4S)-2-methyl-2,3,3,4-
tetrahydroxytetrahydrofuran-borate (S-THMF-borate) (83). 
 
 
Fig. 7. DPD biosynthesis: SAH is detoxified to SRH by Pfs. Subsequently, SRH is 
converted to homocysteine and DPD by LuxS. 
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Fig. 8. Model showing proposed formation pathways for the AI-2 signaling molecules 
recognized by V. harveyi (upper branch) and S. Typhimurium (lower branch) (84). 
 
The incorporation of a boron atom could be relevant for marine bacteria, but it is 
very unlikely that other AI-2 producing bacteria produce exactly the same molecule. 
While investigating the role of various metals in AI-2 signaling, it was observed that the 
induction of bioluminescence in V. harveyi was a result of the addition of metal 
carbonates, leading to the conclusion that S-THMF-carbonate is an alternative for S-
THMF-borate (85) (Fig. 8). Other studies have shown that in S. Typhimurium, the DPD-
derived ligand bound to the AI-2 receptor (in this case LsrB, also involved in 
internalization of AI-2), lacks boron (Fig. 8). Therefore, it could be concluded that two 
different AI-2 receptors bind chemically distinct derivatives of DPD, and that the term 
“AI-2” does not exclusively refer to S-THMF-borate (84).  
 In contrast with the rather hydrophobic AHLs, AI-2 is thought not to diffuse freely 
across cell membranes. Indeed, while monitoring AI-2 concentrations, it was observed 
that intracellular AI-2 levels were about 20-fold higher than extracellular levels. 
Moreover, these levels peaked approximately 1h earlier. Although the E. coli protein 
YdgG had first been proposed as a potential AI-2 exporter, further reports state that its 
role is limited and that other mechanisms must exist. However, to this date, no other AI-
2 export mechanisms have been described (86, 87).  
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1.4.2. AI-2 signal reception and signal transduction 
Although luxS has been found in almost half of all the sequenced bacterial 
genomes (87, 88), evidence for AI-2 receptors and signal transduction pathways 
remains scarce. Below, three different groups of AI-2 signal reception types are 
described. 
 
1.4.2.1. LuxP AI-2 receptor 
 In Vibrio spp., AI-2 interacts with LuxP, which is a periplasmatic protein. Upon 
binding of AI-2, LuxP in its turn modulates the activity of a membrane-spanning sensor 
protein, LuxQ. Similarly to other two-component regulatory systems, LuxPQ regulates a 
phosphorylation signal cascade that controls the downstream AI-2 QS regulon (89). At 
low cell density, phosphate flows from the membrane receptors to LuxU and then LuxO. 
Accumulation of phosphorylated LuxO activates the transcription of five regulatory 
sRNAs (Qrr1-5; only four in V. cholerae). These sRNAs, together with the chaperone 
protein Hfq and the alternative sigma factor σ54 subsequently destabilize the luxR mRNA 
(90, 91) (Fig. 9.). At high cell density, the autoinducers accumulate in the surrounding 
media and bind to their corresponding receptors. Ligand binding promotes the 
phosphatase activity of the receptors, in such a way that phosphate flow through the 
pathway is reversed. The resulting dephosphorylated LuxO does not induce Qrr1-5 
transcription; LuxR is produced and activates the QS regulon (87) (Fig. 9.). Recently, a 
second master regulator (AphA) was discovered in addition to LuxR, and it has been 
reported that the sRNAs can directly affect the expression of certain genes by 
basebairing with their mRNA (92). For didactical reasons, this information is not 
depicted in Fig. 9. 
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(A)  
(B)  
Fig. 9. Simplified model of the V. harveyi QS system. (A) At low cell density. (B) At high 
cell density. A detailed explanation can be found in the text. 
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1.4.2.2. LsrB AI-2 receptors 
 Another high-affinity substrate-binding periplasmatic protein is LsrB, which 
interacts with the membrane components of an ABC transport system called Lsr (for 
LuxS regulated). It was suggested that the Lsr transporter imports AI-2 from the 
environment, since strains possessing mutations in the Lsr transporter do not remove 
AI-2 from the culture medium, whereas AI-2 disappears from culture fluids of S. 
Typhimurium strains possessing a wild-type Lsr transporter (93). LsrB has been found 
in S. Typhimurium, Sinorhizobium meliloti and Yersinia pestis, and in all cases the R-
THMF adduct of DPD was shown to bind to the receptor (84, 94, 95). Sequence similarity 
between LsrB and LuxP is only 11%, but the overall folding of the two AI-2 receptors is 
noticeably similar. This lack of sequence similarity could explain why novel classes of AI-
2 receptors are not easily found (96).  
 
1.4.2.3. RbsB AI-2 receptor 
 In Aggregatibacter actinomycetemcomitans, it was shown that besides LsrB, RbsB 
could as well be involved in AI-2 recognition. Both proteins appear to compete for the 
binding of AI-2 in vitro (97). A protein with 86% identity to RbsB was also found in 
Haemophilus influenzae 86-028NP, in which rbsB expression is upregulated by 
exogenously supplied AI-2. Furthermore, inactivation of this gene reduced AI-2 uptake 
and impaired biofilm formation, a defect similar to that observed in a luxS mutant (98). 
Although these findings suggest that RbsB-like proteins constitute a third class of AI-2 
receptors, further structural studies of the protein in complex with the signal molecule 
are needed to clarify this (87).  
 
1.4.3. Biosensors for the detection of AI-2 
 The most common bioassays for the detection of AI-2 use V. harveyi mutants. 
These methods are based on the feature of this species to become bioluminescent in 
response to AI-2 (89). Although this is a widely used detection system for AI-2, several 
shortcomings have been reported. These biosensors are sensitive to glucose and boric 
acid, and to changes in pH. They are also sensitive to QS signals indigenously produced 
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by the reporter strain (99-101). Additionally, several S. Typhimurium mutants have 
been developed to detect AI-2 with the Lsr QS system. These biosensors possess AI-2 
regulated β-galactosidase activity (102, 103). This method, however, is more time-
consuming than the LuxPQ-based assays. 
 Other methods that have been developed to detect AI-2 are fluorescence based. 
One sensor is based on ligand binding-induced changes in fluorescence resonance 
energy transfer (FRET) between a cyan and yellow fluorescent protein fused to the N- 
and C-termini of LuxP. This sensor can however not be used in biological samples, since 
the overall FRET changes between the bound and unbound state are very small (104). 
Finally, two other protein sensors for AI-2 have also been developed by modifying LuxP 
and LsrB with environmentally sensitive fluorescent dyes. These protein sensors bind 
specifically to AI-2 and produce dose-dependent changes in their fluorescence yield. 
This assay has been applied to monitor the enzymatic synthesis of AI-2 in real time and 
to determine both intracellular and extracellular concentrations in several bacterial 
culture fluids (86).   
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1.5. OTHER QS SYSTEMS 
Other QS systems besides the ones discussed above have also been described 
(105-109) (Table 1). P. aeruginosa, for example, produces more than 50 different 2-
alkyl-4-quinolones. 2-heptyl-3-hydroxy-4-quinolone, also known as the Pseudomonas 
Quinolone Signal (PQS), is probably the best studied of this group of molecules. 
Synthesis and bioactivity of PQS are mediated by the P. aeruginosa las and rhl systems 
respectively (110).  
In V. harveyi, three distinct signal molecules are sensed by three distinct 
membrane-bound receptors, but they all converge to the same signal transduction 
pathway (Fig. 9). The third molecule, (S)-3-hydroxytridecan-4-one is called cholera 
autoinducer-1 (CAI-1) and binds to CqsS (73, 105, 111, 112). Also V. cholerae uses CAI-1 
to regulate the expression of virulence factors.  
Thirdly, diffusible signal factors were first described in Xanthomonas campestris 
but are now considered to be widespread amongst Gram-negative bacteria.  
Two final examples are indole, which has been demonstrated to act as a signaling 
molecule in E. coli; and autoinducer-3 (AI-3), produced by a variety of species. The 
structure of AI-3 is believed to be similar to epinephrine and norepinephrine and is 
therefore considered to be a cross-kingdom signaling molecule (109). 
 
Table 1. Other QS signals. 
Signal type Example References 
Quinolones Pseudomonas quinolone signal 
(2-heptyl-3-hydroxy-4-quinolone) 
(110, 113, 114) 
α-hydroxy-ketones Cholera autoinducer-1 
((S)-3-hydroxy-tridecan-4-one) 
(105, 115-118) 
Diffusible signal factors Diffusible signal factor 
(cis-11-methyl-2-dodecenoic acid) 
(119-122) 
Indole Indole (108, 123) 
Autoinducer-3 Epinephrine 
((R)-4-[1-hydroxy-2-(methylamino)ethyl]- 
benzene-1,2-diol) 
(109, 124), (125-127) 
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1.6. THE ROLE OF QS IN VIRULENCE AND BIOFILM FORMATION 
Among the many traits controlled by QS in pathogenic bacteria is the expression 
of virulence factors. Some of the most infamous pathogens that use QS in such a way are 
S. aureus, Bacillus cereus, P. aeruginosa and V. cholerae. In summary, QS allows these 
pathogens to only execute energetically expensive processes when the impact of those 
processes on the environment (ie. the host) will be maximized (128). How QS plays a 
role in virulence and biofilm formation in a few well-known pathogens is described 
below. 
 
In P. aeruginosa, 3OC12HSL binds to the receptor protein LasR at high cell density, 
resulting in the transcription of target genes including those encoding virulence factors 
such as elastase, proteases and exotoxin A (129). Some other targets are lasI, leading to 
the establishment of a positive autoinducing feedback loop (130), and rhlI, a second luxI 
homologue. Genes that are under control of the rhlI QS system include those encoding 
elastase, proteases, pyocyanin and siderophores (131). Among these targets is also rhlI, 
again leading to autoinduction of this second QS circuit. It has been shown that the PQS 
system is involved in pyocyanin production as well. Additionally, other QS-regulated 
virulence factors such as type IV pili biosynthesis and type III secretion systems have 
been linked to QS in P. aeruginosa (132, 133). Besides the above mentioned in vitro 
evidence, the role of QS in the pathogenicity of P. aeruginosa has been demonstrated in 
several models of infection, since strains with mutations in the QS system were 
significantly less pathogenic compared to the WT. These in vivo virulence models 
included rat and mouse models of acute pneumonia and chronic lung infection, the 
burned-mouse model, the agar-bead mouse model, the Galleria mellonella larvae model 
and Caenorhabditis elegans nematode model (134-138). Further evidence for the 
involvement of QS in virulence is the fact that PQS, C4HSL and 3OC12HSL have been 
detected in the sputum, bronchoalveolar fluid and mucopurulent fluid from cystic 
fibrosis patients colonized with P. aeruginosa (139, 140).  
Another QS-controlled process in P. aeruginosa is biofilm formation. Despite the 
fact that additional environmental signals are involved in P. aeruginosa biofilm 
development, microarray analysis has shown that QS regulation of genes involved in the 
- 29 - 
 
production of rhamnolipids and siderophores, and in swarming motility also contributes 
to biofilm formation (141-144). Furthermore, it has been shown that these include 
genes important in all stages of biofilm development (145). It also has been observed 
that lasI mutants of P. aeruginosa formed unstructured rather than mushroom-shaped 
biofilms in a flow cell, and that this mutant biofilm was more susceptible to sodium 
dodecyl sulphate, tobramycin and phagocytosis (142, 144, 146). Additionally, gene 
clusters responsible for the production of important matrix components such as PEL 
and PSL polysaccharides are also regulated by QS (133, 147).  
Not only is QS involved in biofilm formation, it also plays an important role in 
biofilm resistance against antimicrobials. Brackman et al. investigated whether 
inhibiting QS enhances the susceptibility of bacterial biofilms to treatment with 
conventional antimicrobial agents (148). In their study, they have used QS inhibitors 
targeting AHL-based QS in P. aeruginosa and Burkholderia cepacia complex organisms as 
well as inhibitors targeting the peptide-based QS system in S. aureus. The effect of 
tobramycin (P. aeruginosa, B. cepacia complex) and clindamycin or vancomycin (S. 
aureus), alone or in combination with QSI, was evaluated in various in vitro and in vivo 
biofilm model systems, including two invertebrate models (G. mellonella and C. elegans) 
and one mouse pulmonary infection model. In vitro, the combined use of an antibiotic 
and a QS inhibitor generally resulted in increased killing compared to killing by an 
antibiotic alone, although reductions were strain and model dependent. The results from 
the in vivo experiments were encouraging as well, with a higher fraction of survival for 
those infected organisms that received combined treatment, as compared to those only 
receiving the antibiotic. Additionally, the combined use of tobramycin and baicalin 
hydrate (a QS inhibitor targeting AHL-based QS) reduced the microbial load in the lungs 
of BALB/c mice infected with B. cenocepacia more than tobramycin treatment alone 
(148). Finally, Christensen et al. have also demonstrated that synergistic antimicrobial 
efficacy can be achieved when treating mice with both a QSI and tobramycin, resulting in 
an increased clearance of P. aeruginosa in an intraperitoneal foreign-body infection 
model in BALB/c mice (149). 
 
The role of QS in the pathogenicity of Vibrio spp. has been extensively studied. V. 
cholerae, for instance, uses two parallel QS circuits to regulate the expression of 
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virulence factors and biofilm formation. One of the signals is CAI-1, synthesized by CqsA. 
The second signal is AI-2, which has been described above. At low cell density, V. 
cholerae activates the expression of virulence factors and forms biofilms. At high cell 
density however, the accumulation of the two autoinducers represses these traits. In this 
case, the signals function synergistically to control gene expression. Nevertheless, CAI-1 
is the stronger one of the two signals (105). Interestingly, V. cholerae expresses its suite 
of virulence factors at low cell density, along with its biofilm forming capacity. It is 
reasoned that this low cell-density lifestyle allows V. cholerae to remain attached to host 
tissue during the expression of virulence factors, whereas dispersal of the population is 
facilitated at high cell-density (150). This makes V. cholerae not the most representative 
example with respect to QS regulation of virulence and biofilm formation in vibrios. In 
most cases, there is a positive regulation of virulence factors by QS in this genus. The 
pathogenic phenotypic traits that are QS-controlled in V. cholerae are the production of 
cholera toxin (an enterotoxin causing severe diarrhea) and toxin-coregulated-pili 
production (151). 
 
Also Gram-positive bacteria employ QS to regulate virulence factor production 
and biofilm formation. When QS is switched on in S. aureus, the phosphorylated 
response regulator activates the transcription of two agr promoter regions P2 and P3, 
and the RNAIII regulatory RNA, respectively. RNAIII posttranscriptionally activates 
virulence factor production (hemolysins and toxins) and represses the expression of rot, 
fibronectin binding proteins A and B, coagulase and other surface proteins. Repression 
of rot, which encodes a repressor of toxins, leads to derepression of additional toxins, 
proteases, lipases, enterotoxins, superantigens and urease. This regulatory cascade 
results in a downregulation of surface virulence factors and upregulation of secreted 
virulence factors (such as toxins) (152-159). Biofilm development is another key 
component of the S. aureus virulence traits. In terms of biofilm development, S. aureus 
behaves in a similar way as V. cholerae: as the agr system inhibits biofilm formation, it is 
reasoned that establishing a biofilm at low cell density allows S. aureus time to grow to 
high cell density and, at that point, secrete virulence factors. At high cell density, S. 
aureus terminates biofilm production and decreases surface proteins and adhesions in 
order to facilitate dispersal (160).  
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2. INHIBITION OF AHL-MEDIATED QUORUM SENSING 
 
2.1. INTRODUCTION 
 Many (opportunistic) pathogenic bacteria make use of QS to regulate the 
synchronized expression of pathogenic traits. Hence, QS is considered a promising target 
for the development of novel antimicrobial drugs. As QS systems are not directly 
involved in essential cell processes such as those regulating bacterial growth, QS 
inhibition (QSI) is hypothesized not to impose harsh selective pressure on the 
population. Theoretically, “antipathogenic” strategies such as QSI are less likely to result 
in the development of resistance (161). 
 The process of interfering with or destroying the QS signals is known as QSI. QS 
systems in Gram-negative bacteria basically offer three points of attack: the signal 
synthase (LuxI homologue), the signal molecule (AHL) itself, and the signal receptor 
(LuxR homologue). Furthermore, QSI can be achieved in either a biotic or abiotic fashion. 
Nevertheless, other strategies such as inhibition of signal secretion or interference with 
downstream signaling events are also conceivable (162, 163). Inhibition of signaling 
molecule biosynthesis has for instance been achieved by substrate analogues (141). For 
inhibition at the level of signal reception, AHL analogues (164-169) as well as a 
multitude of QSI compounds isolated from natural sources such as plants and fungi have 
been used (170-174). Several recent papers offer a comprehensive review of the current 
knowledge on QSI in Gram-negative bacteria (27, 175, 176). However, the focus of this 
work will be on the degradation of signaling molecules, also known as quorum 
quenching (QQ). 
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2.2. DEGRADATION OF SIGNALING MOLECULES 
 One way to interfere with QS is through limitation of signal accumulation. The 
inactivation of AHLs can be achieved by both biotic (enzymatic degradation of the AHLs 
or AHL sequestration with antibodies) and abiotic mechanisms, which are described 
further in detail below.  
 
2.2.1. Biotic inactivation of AHLs 
 Three main enzymatic mechanisms for the degradation of AHLs have been 
described: lactone hydrolysis, amidohydrolysis and oxidoreduction (Fig. 10).  
 
Fig. 10. Enzymatic AHL-degradation points of attack (1: lactone hydrolysis, 2: 
amidohydrolysis, 3: oxidoreduction).  
 
2.2.2.1. Lactone hydrolysis 
Hydrolysis of the lactone moiety is catalyzed by enzymes called AHL lactonases. 
Ring opening results in the generation of acyl homoserine (acyl-HS) (Fig. 11), which 
cannot function as a QS signaling molecule. This process is reversible as the enzymatic 
reaction can be reversed by acidification of the medium (177).  
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Fig. 11. Degradation of AHLs by AHL-lactonase, yielding acyl-HS. 
 
 AHL-lactonase activity was first observed in a Bacillus sp. isolate. Dong et al. 
reported the presence of a gene (aiiA) encoding the enzyme AiiA with AHL degrading 
activity. Expression of aiiA in E. coli showed that this enzyme is able to hydrolyze a large 
range of AHLs, from C4- to C14-HSL, with or without a substitution at the third carbon 
atom (178). HPLC-MS revealed that enzymatic digestion of 3OC12HSL resulted in only 
one product fraction, which was more hydrophilic than the original compound. 
Furthermore, the mass increase of 18 in this product (equal to the mass of a water 
molecule) indicated the production of a lactone-opened AHL (178). Different 
homologues of the aiiA gene have been found in several Bacillus spp., including B. 
thuringiensis, B. cereus, B. mycoides and B. anthracis (179-182). The presence of this type 
of AHL-lactonases is not restricted to members of the genus Bacillus, however: AiiA-like 
lactonases are widespread in bacteria and have been characterized in Gram-positive and 
Gram-negative ones. These AiiA-like lactonases include AttM and AiiB in A. tumefaciens, 
AhlD in Arthrobacter spp., and AhlK in Klebsiella pneumoniae (183-185). It has been 
shown that the prototypic AiiA is a metallohydrolase of the β-lactamase family which 
requires two Zn2+ ions for full functionality. Furthermore, enzymes of this type are not 
affected by differences in acyl chain length and substitution in the AHLs (186). 
Interestingly, a conserved HXHXDH motif was shown to be essential for AHL degrading 
activity (187). In addition to the lactonases mentioned above, ahlD homologues are also 
present in Burkholderia fungorum, Bradyrhizobium japonicum, Thermoplasma volcanium 
and Sulfolobus solfataricus (185). Although the AhlD protein only shares 30-58% 
similarity in peptide sequence with the AiiA-like proteins, it does contain the highly 
conserved and essential HXHXDH motif (57). Experiments in which E. carotovora, P. 
fluorescens and A. tumefaciens were transformed with a plasmid carrying the aiiA gene 
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have resulted in reduced virulence of these pathogens towards various plants, indicating 
that enzymatic degradation of AHLs could be useful for biocontrol (161). 
 A third type of AHL-lactonase is represented by the QsdA lactonase from 
Rhodococcus erythropolis. Although it also is a Zn-dependent metalloprotein, it is not 
related to the AiiA AHL-lactonase family. The same can be said for QlcA, which was 
retrieved from the screening of a metagenomic library of 10.121 clones, generated from 
soil bacteria (188). Both enzymes have a broad AHL degrading spectrum. The latter 
enzyme was shown to quench QS-regulated virulence in E. carotovora: after the 
introduction of a plasmid harbouring the qlcA gene, a 1000-fold decrease of the 
concentration of AHLs in the culture supernatant was observed as compared with the 
WT. Furthermore, in contrast to the WT, the strain expressing qlcA did not provoke 
maceration symptoms on the host plant Solanum tuberosum (188). 
 Another metagenomic study, performed by Schipper et al., revealed two novel 
lactonase families. The open reading frames linked to the 3OC8HSL-degrading activities 
were designated bpiB01, bpiB04 and bpiB07. While the BpiB07 protein was similar to a 
known lactonase, no significant similarities were observed for BpiB01 and BpiB04. 
Expression of these clones in P. aeruginosa PAO1 clearly inhibited its biofilm formation 
capacity and its motility (189). 
 The previously reported, yet uncharacterized AHL-degrading activity from 
Ochrobacter spp. also turned out to be the result of lactonase activity, by an enzyme 
called AidH (190, 191). AidH shares no similarity with the AHL-lactonases described 
above, but is suggested to be a member of the α/β hydrolase fold family. Although this 
type of enzyme is not known to require co-factors, it was shown that AidH requires Mn2+ 
but not several other cations tested. It was also shown that production of this protein 
reduces biofilm formation by a Pseudomonas sp. strain and virulence of E. carotovora 
(191). Another member of the α/β hydrolase fold family that degrades AHLs is AiiM 
from Microbacterium testaceum (192). Besides having successfully been tested in E. 
carotovora, the effect of AiiM on the virulence of P. aeruginosa in a mouse model of acute 
pneumonia has also been examined: AiiM expression in P. aeruginosa PAO1 reduced 
murine lung injury and greatly improved the survival rates of the mice. Furthermore, 
proinflammatory cytokine levels and myeloperoxidase activity in bronchoalveolar 
lavage fluid were also significantly lower in mice infected with AiiM-expressing PAO1 
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compared to the WT. Since AiiM can strongly attenuate P. aeruginosa virulence, the 
authors concluded that it is a potential candidate for use as a therapeutic agent against P. 
aeruginosa infection (193). 
  
 In addition to lactonases produced by bacteria, eukaryotic organisms can also 
open the lactone moiety of AHLs. The first reports in this respect describe that 
differentiated human airway epithelial cells can inactivate 3OC12HSL. Inactivation was 
shown to be selective for certain AHLs, since C4HSL was not degraded by the epithelial 
cells. In addition, it was demonstrated that the signal molecules were inactivated by a 
cell-associated activity rather than a secreted factor. These data suggest that the ability 
of human airway epithelia to inactivate QS molecules could play a role in the innate 
defense mechanisms against bacterial infection (194). Another class of enzymes with 
AHL-lactonase activity produced by eukaryotic cells are the paraoxonases (PONs). 
Mammalian PONs are a unique, highly-conserved family of calcium-dependent esterases 
consisting of PON1, PON2 and PON3. All PONs, but mainly PON1, are associated with the 
hydrolysis of oxidized lipids (and thus with the protection against atherosclerosis) and 
with the hydrolysis of organophosphates. PON1 and PON3 are synthesized in the liver 
and transported to the blood, whereas PON2 is not detected in plasma (195, 196). These 
PONs seem to be most active against long-chain AHLs (194). A novel model was recently 
generated to study the effect of PON1 by transgenically expressing human PON1 in 
Drosophila melanogaster. Using this model, the authors showed that P. aeruginosa 
infection lethality is QS-dependent, and that expression of PON1 has a protective effect 
(197).  
Also plants have potentially evolved mechanisms to protect themselves from 
bacterial infections: Hordeum vulgarum, Lotus corniculatus and Pachyrhizus erosus 
degrade AHLs. Although the exact mechanisms of degradation remain unclear, 
preliminary investigations revealed that the origin probably was enzymatic (198, 199). 
Certain fungi can inactivate AHLs through ring opening as well. Three active isolates 
able to degrade C6HSL and 3OC6HSL were retained from the screening of a collection of 
root-associated fungi (200).  
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2.2.2.2. Amidohydrolysis 
 Another mechanism by which AHLs can be enzymatically degraded is 
amidohydrolysis. This reaction is catalyzed by AHL-acylases, resulting in the formation 
of the corresponding fatty acid and homoserine lactone (HSL) (Fig. 12). This way of 
inactivating the signal molecules can be considered as a form of metabolization: both 
Variovorax paradoxus and P. aeruginosa PAI-A are able to proliferate with AHLs as sole 
sources of carbon and nitrogen. After the cleavage of the molecule, the fatty acid part is 
used as carbon source, whereas the nitrogen from the amide bond is made available as 
ammonia via the action of lactonases. Subsequently, the remaining ring structure is used 
as energy source (201, 202).  
 
 
Fig. 12. Degradation of AHLs by AHL-acylase, yielding a fatty acid and HSL. 
 
 The first AHL-acylase to be identified was AiiD from Ralstonia sp. strain XJ12B, 
isolated from a mixed-species biofilm. The corresponding gene aiiD was succesfully 
cloned into E. coli and shown to be able to completely degrade three tested AHLs 
(3OC8HSL, 3OC10HSL and 3OC12HSL). Furthermore, expression of AiiD in P. aeruginosa 
PAO1 quenched QS by this bacterium, decreasing its ability to swarm, produce elastase 
and pyocyanin, and to paralyze nematodes (203). Database searches revealed that AiiD 
was most similar to aculeacin A acylase from the high-GC Gram-positive organism 
Actinoplanes utahensis. In addition, it also shared significant similarities with 
cephalosporin and penicillin acylases, which are members of the N-terminal hydrolase 
family (203).  
PvdQ, from P. aeruginosa, has been identified as a homologue of the AHL-acylase 
described above. E. coli expressing pvdQ rapidly inactivated long-acyl AHLs, and in a P. 
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aeruginosa strain engineered to constitutively express pvdQ no accumulation of 
3OC12HSL was observed. Nevertheless, pvdQ knockout mutants of P. aeruginosa were 
still able to grow by utilizing 3OC12HSL, indicating that P. aeruginosa encoded at least 
one additional acyl-degrading acylase enzyme (201, 204). Indeed, QuiP was later 
identified as being a second AHL-acylase of P. aeruginosa PAO1 (205). 
 Other microorganisms that produce AHL-acylases include Streptomyces sp., 
Rhodococcus erythropolis W2, Pseudomonas syringae, Shewanella sp. strain MIB105, 
Comamonas sp. strain D1 and Anabaena sp. PCC 7120 (206-211). AhlM, from 
Streptomyces sp., appears to be most effective in degrading AHLs with acyl chains longer 
than six carbons, and is particularly active against unsubstituted rather than 3-oxo-
substituted AHLs. Its activity is similar to that of PvdQ and QuiP. In contrast, other PvdQ 
homologues, AiiD in Ralstonia euthropa, AiiC in Anabaena spp. and AaC in Shewanella 
spp., degrade long chain as well as short chain AHLs. Furthermore, AhlM was reported to 
be a secreted enzyme (206), just like HacA, one of the two AHL-acylases produced by P. 
syringae. HacB, unlike HacA, is not secreted but is bound to the cell. Another difference 
between the two is that HacA degrades long-chain AHLs only, whereas HacB has a 
broader range of activity (209).  
 AHL-acylase activity is not limited to enzymes produced by bacteria. In 2003, Xu 
et al. reported that the commercially available porcine kidney acylase is able to 
deacylate C4HSL and C8HSL yielding L-homoserine (212). According to the authors, the 
optimal pH for this enzyme is 10 at 23°C and the optimal temperature is 76°C at pH 9. 
Immobilization of this enzyme on a nanofiltration membrane has resulted in great anti-
biofouling properties by suppressing the secretion of extracellular polymeric substances 
and thus biofilm maturation (213, 214).  
 
2.2.2.3. Oxidoreduction 
 In contrast to the above mentioned enzymes, AHL-oxidoreductases do not break 
down the AHLs into non-functional products. Oxidoreductases simply reduce the 3-oxo 
group of the AHL signal, generating 3-hydroxy derivatives. Depending on the specificity 
of the receptors, this modification may or may not affect the signaling activity of the AHL 
(215).  
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 AHL-oxidoreductase activity was first observed in R. erythropolis, which reduces 
AHLs with 3-oxo substituents to their corresponding 3-hydroxy counterparts. Since it 
can also reduce compounds such as N-(3-oxo-6-phenylhexanoyl)-homoserine lactone 
and 3-oxododecanamide, it is not specific for naturally occurring AHLs. Furthermore, it 
can also modify the (not naturally occurring) D-isomers of 3OC12HSL, indicating that 
the reaction was not stereospecific (207). The gene encoding this enzyme has not yet 
been identified. Another oxidoredactase, P-450/NADPH-P450 reductase, has been 
isolated from Bacillus megaterium CYP102A1 and characterized in detail (216). 
 
2.2.2.4. Antibody-mediated AHL sequestration 
 AHL-based QS systems are an ideal target for antibody-based anti-infective 
therapy due to the highly conserved molecular scaffold and the extracellular distribution 
of AHLs. After a few initial attempts to design stable haptens, three different haptens 
closely resembling C4HSL and 3OC12HSL yielded several monoclonal antibodies. For 
long term stability reasons, the lactone moiety of these haptens was replaced by a 
lactam functional group. All antibodies created in this study effectively inhibited QS in P. 
aeruginosa (217).  
 Another approach is the use of haptens to induce the production of antibodies 
capable of catalyzing AHL hydrolysis and subsequently inhibit QS (218). Initially, only 
haptens that were not specifically designed as structural mimics of the transition state 
for AHL hydrolysis were used, with limited success (218). Later, Kapadnis et al. 
synthesized sulfones that resembled transition state structures of lactone moiety 
hydrolysis. They demonstrated the ability of these compounds to detect human 
transition state binders capable of degrading AHLs (219). Although still premature, 
these findings indicate the potential of both active and passive immunotherapeutic 
strategies to combat QS-related infections in the future. 
 
2.2.2. Non-enzymatic degradation of signaling molecules 
 AHLs are also prone to abiotic degradation. They are extremely sensitive to 
alkaline pH and to elevated temperatures (177). Yates et al. demonstrated that AHL 
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levels in stationary-phase P. aeruginosa cultures were significantly lower than the levels 
in mid- to late-logarithmic-phase cultures, while no evidence for the presence of AHL-
degrading enzymes was found. Furthermore, when added to the supernatant of these 
stationary-phase cultures, exogenously provided AHLs were rapidly degraded by 
lactonolysis. Buffering the growth medium or acidifying stationary-phase supernatant to 
a pH below 2.0 however, resulted in a reduced AHL turnover or recovery of the AHLs, 
respectively. Similar findings were made in Yersinia pseudotuberculosis, a Gram-negative 
pathogen producing C6HSL and 3OC6HSL. As no enzymatic degradation could be 
demonstrated, the authors concluded that these effects were caused by a pH increase of 
the LB medium during growth (220). Comparable observations have been made in E. 
carotovora and in R. leguminosarum (221, 222). A number of higher organisms employ 
this strategy as a defense against invading QS bacteria. For instance, plants infected with 
E. carotovora will increase their pH at the site of attack as a first response (222). Ring 
opening as a consequence of changes in pH is highly dependent on side-chain length. A 
HSL ring is hydrolyzed above pH 2, whereas the lactone moiety of a C4HSL molecule is 
only opened between pH 5 to 8 (220). 
 It was also reported that C4HSL and C6HSL were degraded three and 1.5 times 
more rapidly at 37°C than at 22°C, respectively. This temperature-dependent effect is 
also dependent on the length of the acyl side chain: AHLs with the longest side chain 
tend to be more stable at higher temperatures (220).  
 Other environmental factors besides pH and temperature may also affect the 
stability of AHLs. Byers et al. discovered that AHLs are more stable in anaerobic 
conditions than in aerobic conditions (222), and some - but not all - AHLs are degraded 
by chemical agents such as HOBr and HOCl (223, 224). 
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3. BIOTHERAPEUTIC BACTERIA 
 
3.1. INTRODUCTION 
Biotherapeutics, also known as biotech drugs or biologics, are living organisms or 
products derived from living organisms that can treat illnesses and improve health. 
(225). The focus of this thesis will primarily be on the use of living organisms. An 
important group of living organisms that are being used or developed as biotherapeutics 
are probiotics, which will be discussed in further detail below. 
 
3.2. PROBIOTICS 
The concept of probiotics dates back to as early as 1908, when the Russian Nobel 
Prize laureate Eli Metchnikoff stated that the long life of Bulgarian peasants was due to 
their consumption of fermented milk products (226). The term “probiotic” itself 
however, was used for the first time in 1965. Lilly and Stillwell used it to describe 
substances secreted by one organism which stimulate the growth of another (227). 
Etymologically, the term is derived from Greek, meaning ‘for life’ (228). In 2001, an 
expert panel commissioned by the Food and Agriculture Organization and the World 
Health Organization defined probiotics as “live microorganisms which, when 
administered in adequate amounts confer a health benefit on the host” (229).  
 
3.3. CLINICAL RELEVANCE OF PROBIOTICS 
 The rationale of probiotic therapy is based on the correction of an unbalanced 
indigenous microbiota. Nowadays, it is widely recognized that the gut microbiota plays 
an important role in human health (230): indeed, alterations in gut microbiota 
composition have been documented in a broad variety of diseases, including antibiotic-
associated diarrhea, atopic eczema and inflammatory bowel disease (231). Probiotics 
may restore the composition of the gut microbiome and introduce beneficial functions to 
gut microbial communities, resulting in amelioration or prevention of gut inflammation 
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and other intestinal or systemic disease phenotypes (232). In a recent study, for instance, 
it was demonstrated that the administration of a probiotic yoghurt changed urinary 
tract metabolites, but not faecal bacterial community populations (233). Findings like 
these support the rationale that probiotics affect the function rather than the structure 
of the microbiome (232). Below, a non-exhaustive summary of evidence-based uses of 
probiotics is provided.  
 
3.3.1. Prevention and treatment of antibiotic-associated diarrhea 
 Antibiotic-associated diarrhea (AAD) is the most common adverse effect of 
antimicrobial therapy. It is an added burden on patients, the health care systems and 
health care workers because of increased hospital stay, higher risks for other infections, 
and an increase in mortality (234). A number of studies demonstrated the ability of 
probiotics to reduce the adverse effects associated with the clinical use of antibiotics. 
One study divided a group of 119 children receiving antibiotics into two: one group was 
given Lactobacillus rhamnosus GG (LGG), the placebo group did not receive treatment. 
During the first 2 weeks after antibiotic treatment was initiated, a 70% reduction in 
diarrheal symptoms was measured in the group receiving LGG compared to the placebo 
group (235). In two studies involving 60 and 120 adults receiving antibiotic treatment, a 
significantly lower number of patients suffered from nausea and diarrhea whilst 
simultaneously receiving LGG versus placebo (236, 237). Besides LGG and other 
bacterial probiotic strains, the nonpathogenic yeast Saccharomyces boulardii has also 
proven to be effective in the reduction of AAD (238). 
Overgrowth of Clostridium difficile is the most common cause of AAD in the 
hospital setting, accounting for 20% - 40% of all the cases (234). In this respect, it is 
encouraging that the authors of a recent meta-analysis of 23 randomized controlled 
trials including 4213 patients concluded that probiotics are both safe and effective for 
the treatment of AAD caused by C. difficile (239). 
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3.3.2. Prevention of traveler’s diarrhea 
 Traveler’s diarrhea typically affects people traveling to warmer climates and less-
developed countries. It is caused by the introduction, through food or water, of 
pathogenic bacteria that overwhelm the protective effects of the normal intestinal flora. 
At an average, around 40% of travelers are concerned, depending on the travel 
destination. A wide spectrum of enteropathogens are accountable, with enterotoxigenic 
E. coli being the major causative agent (240).  
A placebo-controlled double-blind study was performed to evaluate the efficacy 
of LGG in preventing traveler’s diarrhea. 756 Finns, traveling to two resorts in Turkey 
were divided into two groups. The authors found that, at 1 of 2 resorts, oral ingestion of 
LGG conferred a significant protection. In the other resort however, no protection from 
LGG consumption was noted (241). A second study reported on a group of 245 travelers 
from New York, who went to various developing countries for a period of 1-3 weeks. The 
risk of diarrhea on any given day was 3.9% for patients receiving LGG, as compared with 
7.4% for patients receiving placebo (242).  
 
3.3.3. Prevention and treatment of allergic disorders 
 Prospective studies have shown the association between allergic disorders and 
aberrant gut microbiota in infants (243). Furthermore, an increasing number of children 
develop allergy in a clinical progression of the so-called “atopic march”, resulting in 
asthma. Therefore, probiotics have been studied as a possible dietary intervention to put 
an end to this disease progression. Since most studies designed to assess prevention of 
atopic dermatitis (AD) with probiotics have been conducted during the last stages of 
pregnancy and during lactation, strategies using probiotics for prevention should begin 
early. Several studies have resulted in a persistent and significantly reduced rate of 
atopic dermatitis for up to 7 years. No effects on the expression of asthma in later 
childhood have however been observed (244). Moreover, a recent review compared the 
effect of nutrient supplementation with probiotics, prebiotics and fatty acids on the 
development of AD in children. The authors concluded that the best evidence for the 
prevention and reduction of the severity of AD lies with probiotic supplementation in 
mothers and infants. Specifically, LGG was most effective in long-term prevention of AD 
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development (245). In another study, 27 infants with AD were randomized into 3 groups, 
given LGG, Bifidobacterium lactis Bb12, or placebo. After 2 months, the extent and 
severity of the eczema were evaluated, and the results indicated a significant 
improvement in the skin condition of patients receiving probiotic supplementation 
(246). 
 
3.3.4. Treatment and prevention of relapses of inflammatory bowel disease 
 One of the major potential applications of probiotics is for the treatment and 
prevention of relapses of Crohn’s disease, ulcerative colitis and irritable bowel 
syndrome. Reports have been made of the beneficial effects for inflammatory bowel 
disease (IBD) that resulted from the administration of Lactobacillus salivarius, E. coli 
Nissle, S. boulardii and VSL#3 (VSL Pharmaceuticals), a mixture of probiotics (247). The 
administration of these probiotics resulted in fewer relapses and reduced steroid use, 
compared to the patients receiving placebo treatment (247). Still, probiotic treatments 
of IBD have yet to meet the high expectations predicted by mechanistic and animal 
studies, and more rigorous studies are needed to support the efficacy and safety of these 
agents (248, 249).  
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3.4. MECHANISMS OF ACTION OF PROBIOTIC BACTERIA 
 While clinical application and health effects of probiotics have been extensively 
studied, the molecular basis of their action is not yet fully understood. Thus far, six 
major mechanisms have been proposed for probiotic action: enhancement of the 
epithelial barrier, increased adhesion to intestinal mucosa, inhibition of pathogen 
adhesion, competitive exclusion of pathogenic microorganisms, production of 
antimicrobial substances and modulation of the immune system (Fig. 13) (250). Each 
one of these features is described briefly below.  
 
 
Fig. 13. Major mechanisms of action of probiotics (250). 
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3.4.1. Enhancement of the epithelial barrier 
 Integrity of the intestinal epithelial barrier is important to protect the host from 
the environment. The mucous layer, antimicrobial peptides, secretory IgA and the 
epithelial junction adhesion complex all contribute to the defenses of the intestinal 
barrier (251). Disruption of the barrier function implies that bacterial and food antigens 
are able to reach the submucosa, thereby possibly inducing intestinal disorders. It has 
been shown that the consumption of non-pathogenic bacteria can contribute to the 
intestinal barrier function. However, the mechanisms by which they enhance the barrier 
function are not fully understood (250). 
 Some studies have indicated that enhancing the expression of genes involved in 
tight junction signaling is a possible mechanism for Lactobacillus plantarum MB452 to 
reinforce intestinal barrier integrity (252). Recently, it has also been shown that E. coli 
Nissle 1917 not only prevents disruption of the mucosal barrier, but also that it restores 
mucosal integrity after damage caused by enteropathogenic E. coli (253, 254). Similar 
observations have been made for Lactobacillus casei DN-114001 and VSL3 (255). The 
use of probiotics to prevent cytokine-induced epithelial damage, which is typical for 
inflammatory bowel disease, has also been described: two purified peptides secreted by 
LGG prevent cytokine-induced cell apoptosis in vitro (256, 257). Finally, mucous 
secretion may be promoted by probiotics, resulting in the improvement of barrier 
function and the exclusion of pathogens (250).  
 
3.4.2. Increased adhesion to intestinal mucosa, inhibition of pathogen adhesion 
and competitive exclusion of pathogenic microorganisms 
 Adhesion to the intestinal mucosa is believed to be a prerequisite for colonization, 
and thus important for the interaction between probiotic strains and the host (258). It is 
also important for the modulation of the immune system and antagonism against 
pathogens.  
 The adhesion capacity and the ability to inhibit pathogen adhesion have been 
tested for various bifidobacteria in a study by Collado and co-workers. The authors 
reported that these traits were variable and clearly strain-dependent (259). This 
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example shows the importance of strain selection and the fact that adhesion is one of the 
main selection criteria for new probiotic strains. Additionally, lactic acid bacteria display 
various surface determinants that are involved in their interaction with intestinal 
epithelial cells and mucus. Several Lactobacillus proteins have been shown to promote 
mucous adhesion, and bacteria display surface adhesins that mediate attachment to the 
mucous layer. Although proteins are the principal mediators of this process, saccharides 
and lipoteichoic acids have also been mentioned in this respect (260-262). The proteins 
that facilitate adhesion are mainly secreted and surface-associated, and have not only 
been discovered in lactic acid bacteria, but in various bifidobacteria as well (250). 
Furthermore, probiotics such as L. plantarum have been reported to induce mucin 
production by the intestinal epithelial cells and to inhibit adhesion of enteropathogenic 
E. coli, resulting in an enhanced occupation of the microbial binding sites by beneficial 
bacteria, and protection against the invasion by pathogens (263). Not only do probiotics 
induce mucin production, they also cause qualitative alterations in intestinal mucin 
production, again resulting in the prevention of pathogen binding (264). Another feature 
of probiotics is the fact that they can induce the release of small peptides or proteins 
called defensins from epithelial cells. Defensins are active against bacteria, fungi and 
viruses, and have the property to stabilize gut barrier function (265). 
 Exclusion of pathogenic microorganisms is the result of various mechanisms and 
properties. It is based on a bacterium-to-bacterium interaction, mediated by 
competition for available nutrients and for mucosal adhesion sites. In order to gain a 
competitive advantage, beneficial bacteria can also modify their close environment, 
making it less suitable for competitors. The production of lactic and acetic acid, or other 
antimicrobial substances, is one example of this environmental modification (266). 
Generally, probiotic strains are also able to inhibit the attachment of pathogenic bacteria 
through steric hindrance at enterocyte pathogen receptors (250). 
 
3.4.3. Production of antimicrobial substances 
 The production of lactic and acetic acid has been briefly mentioned above, but 
these low molecular weight organic acids are not the only antimicrobial compounds 
produced by probiotic bacteria. 
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 Low molecular weight organic acids have a strong inhibitory effect on Gram-
negative bacteria and they have been considered the main antimicrobial compounds to 
have an inhibitory effect against pathogens (267, 268). 
 Additionally, antibacterial peptides are produced by many lactic acid bacteria. 
These peptides include bacteriocins, which have a narrow spectrum and are only 
effective against closely related bacteria. Usually, bacteriocin-mediated killing involves 
destruction of the target cells by pore formation and/or inhibition of cell wall synthesis 
(269). Examples of bacteriocins are lactacin B from Lactobacillus acidophilus, plantaricin 
from L. plantarum, nisin from Lactococcus lactis and bifidocin B from B. bifidum (250, 
270). It has been shown that within complex microbial environments, bacteriocin 
production confers a competitive advantage to the strains producing them. This 
competitive advantage is a direct consequence of the antimicrobial activity associated 
with bacteriocin production: it inhibits the growth of pathogens within the 
gastrointestinal tract, and at the same time increases the prevalence of producing 
strains (271). 
 Apart from the production of antimicrobial substances, intestinal bacteria also 
produce a variety of health-promoting fatty acids. Several intestinal bifidobacteria and 
lactobacilli have been shown to produce conjugated linoleic acid, which is a potent anti-
carcinogenic agent (271, 272), and has also been attributed an anti-obesity effect since it 
induced weight loss in diet-induced obese mice (273).  
 
3.4.4. Modulation of the immune system 
 Multiple studies describe how probiotic bacteria can have an immunomodulatory 
effect. These bacteria are able to interact with epithelial cells and dendritic cells, and 
with monocytes, macrophages and lymphocytes. Dendritic cells play an important role 
in the innate and adaptive immunity. They interact with and respond to gut 
microorganisms through their pattern recognition receptors, of which the toll-like 
receptors are the best-studied (274). A detailed description of how probiotics may 
interact with and modulate the immune system falls beyond the scope of this 
manuscript, but can be found in several recent review papers (250, 275, 276).  
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3.5. PROPOSED GUIDELINES FOR THE SELECTION OF PROBIOTICS 
 A set of parameters has been proposed for a microorganism (and therefore also 
for the product containing this organism) to be named ‘probiotic’. These guidelines do 
not only reflect our knowledge on the availability of evidence supporting specific health 
promoting properties, but they also include safety, functional and technological aspects. 
 
 The health benefit assessment can basically be divided into two research tasks. 
Not only are clinical trials (phase II, preferably double-blinded, placebo-controlled) 
needed to analyze the beneficial effects of the administration of the probiotic, but also 
the unraveling of underlying microbial, biochemical and molecular mechanisms is 
required (277). The outcome of the trials should be proven benefits such as 
improvement in condition, symptoms, signs or quality of life; prevention, reduced risk or 
longer period to next occurrence of disease; or faster recovery from illness. Unless a 
reference is made to curing or treating a disease (in which case the product is regarded 
as a drug), no phase III studies are generally performed on probiotics (277). In addition, 
there must not be any adverse effects after the administration of the probiotic.  
 
 Also certain safety aspects have to be taken into account when selecting 
probiotics. First and foremost, it is crucial that the taxonomic identity of the potential 
probiotic strain is determined. Since probiotic properties and safety aspects are strain-
dependent, proper identification using phenotypic and genotypic methods is required. 
This is also necessary to avoid the inclusion of pathogenic microoganisms in probiotic 
products. Generally, microorganisms used in the production of fermented foods have a 
long history of safe use and are therefore called GRAS organisms (generally regarded as 
safe) (278). Still, caution should be taken, since any microorganism may cause unwanted 
side effects when administered in sufficiently high doses. The highest risk associated 
with the consumption of microorganisms, particularly in immunocompromised 
individuals, is infection. Finally, due to the increasing problems associated with 
antibiotic resistance, strains that carry transferable mobile genetic elements such as 
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plasmids or transposons that could spread antibiotic resistance to other bacteria should 
not be used as probiotics (279). 
 
 Although it has been shown that dead bacteria are able to mediate some 
beneficial effects, it is reasoned that the majority of health promoting effects exerted by 
probiotics requires the presence of viable bacteria (280). This implies that these 
probiotics need to survive the transit through the gastro-intestinal tract after oral intake, 
having consequences regarding functional and technological aspects. In order to survive 
contact with the gastric juice, probiotic bacteria need to be able to tolerate highly acidic 
conditions. Generally, Bifidobacterium strains are less acid tolerant than Lactobacillus 
strains (281). Probiotic microorganisms also need the functional requirement to resist 
bile toxicity, in order to survive the transit through the small intestine. It is generally 
believed that after surviving the gastro-intestinal transit, probiotic strains need to 
adhere to the intestinal surface and temporarily colonize the gastro-intestinal tract in 
order to confer their beneficial effects (274). Besides the functional aspects, 
technological suitability concerning the industrial manipulation is of paramount 
importance in the selection process of probiotics as well. Viability and stability of the 
probiotic strains throughout the manufacturing process and subsequent storage are 
crucial parameters (282). It is essential that products sold with any health claims meet 
the criterion of a minimum 106 CFU/ml probiotic bacteria at the expiry date, because the 
minimum therapeutic dose per day is suggested to be 108-109 cells (283). Additionally, it 
is also desired that the probiotic cultures contribute to the good sensory properties of 
the final product.  
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Resistance against antibiotics is an ever growing problem. Besides increasing 
morbidity and mortality, infections caused by resistant bacteria also have economical 
implications. Several reasons, including a high cost of investment and insurmountable 
regulatory hurdles for pharmaceutical companies, and a swift development of resistance, 
contribute to the fact that very few new antibiotics will be introduced in the near future. 
Another important factor is the increasing awareness that the majority of infections are 
biofilm-related. This also creates new challenges, since bacterial cells in biofilms are 
more resistant to antimicrobials than their planktonic counterparts, resulting in 
infections that are harder to treat. Therefore, there is an urgent need for new 
therapeutical targets to combat infectious diseases. 
 
 Since it is generally recognized that a variety of pathogens uses QS to control 
biofilm formation and the expression of their virulence factors, interfering with the 
bacterial communication system is considered a promising new antipathogenic strategy. 
A lot of effort has been put into finding chemical inhibitors of the QS circuitry, and many 
components indeed exhibit QSI activity. Unfortunately, due to poor characterization 
and/or limited activity in vivo, the majority of these compounds are not very useful.  
 
The specific aim of this study was to explore the potential of interfering with QS 
by means of other bacteria. A number of recent studies have indeed shown that several 
probiotic bacteria produce components that interfere with QS, suggesting that they 
could be used as biotherapeutic microorganisms. Alternatively, characterized active 
compounds produced by these bacteria can be used as lead molecules for drug 
development. In order to investigate this, we approached this scientific question in two 
ways. The first objective was to develop a high-throughput method for the isolation of 
environmental bacteria that could potentially be used as biotherapeutics, and to validate 
our method and confirm our rationale by monitoring the effect of these isolates on 
certain virulence traits of pathogenic bacteria. A second objective was to evaluate if QS is 
used by certain probiotic strains to exert their beneficial effects, and if so: to elucidate if 
this effect is a true communication-related phenomenon, or rather a metabolic effect. 
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Abstract  
A large number of Gram-negative pathogens produce AHLs as signal molecules 
for QS. This cell–cell communication system allows them to coordinate gene expression 
and regulate virulence. Therefore, strategies to inhibit QS are promising for the control 
of infectious diseases. The aim of the present study was to develop a high-throughput 
method for the isolation and identification of AHL-degrading bacteria from 
environmental samples. Samples were cultured in a microtitre plate (MTP) in a minimal 
medium containing 1 mM 3OC12HSL and 2 mM 3OC6HSL as the sole sources of carbon 
and nitrogen. Isolates growing on this minimal medium were subcultured and identified 
by partial 16S rRNA gene sequencing. Subsequently, the AHL-degrading capacity of each 
isolate was evaluated in the P. aeruginosa QSIS2 biosensor assay, as such or after 
treatment with heat or proteinase K. The 16 samples tested yielded a total of 59 isolates 
which are, either alone or as part of a consortium, able to use AHL signal molecules as 
sole sources of carbon and nitrogen. Follow-up experiments have shown that in each 
sample there is at least one isolate with QQ activity, and that for all samples combined, 
41 isolates have QQ activity. Furthermore, heat treatment did not fully inhibit QQ 
activity in all isolates. In some isolates, QQ activity was lost after proteinase K treatment, 
while others remained able to quench QS. Therefore, it is likely that some isolates 
produce and secrete (a) heat-stable, low molecular weight inhibitory compound(s). 
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Introduction 
A large number of Gram-negative bacteria produce AHLs as signal molecules for 
QS (284). AHLs are diffusible, low molecular weight molecules that are characterized by 
a conserved lactone moiety and a variable acyl side chain. Signal molecules from 
different species typically differ in side chain length, saturation and substitution at the 
third carbon atom. AHLs are produced by a LuxI homologue and are subsequently 
released into the extracellular environment, resulting in the accumulation of the signal 
molecule. Once a certain threshold concentration has been reached, the AHLs bind to a 
cytoplasmatic LuxR homologue, serving as a transcriptional activator. Upon ligand 
binding, the LuxR-AHL complexes bind to promoter regions of target genes, resulting in 
the activation or repression of the expression of specific genes (11, 285). 
 
This type of cell–cell communication system allows bacteria to coordinate gene 
expression and regulate the production of virulence factors in a cell-density dependent 
way (11, 12, 286). Genes encoding these virulence factors controlled by QS regulation 
include, but are not limited to plasmid conjugation in Agrobacterium tumefaciens, 
biofilm formation and siderophore production in Burkholderia cenocepacia, exoprotease 
and exotoxin production in Pseudomonas aeruginosa and swarming motility in Serratia 
sp. (287-289). Therefore, QS is a potential therapeutic target, and the quenching of 
bacterial cell–cell communication could be a promising strategy to attenuate virulence 
and thus control infections. Furthermore, interfering with QS rather than using 
bactericidal or bacteriostatic drugs to combat bacterial infections is a highly attractive 
concept since it is less likely to induce the development of bacterial resistance (290-292). 
 
Besides the use of a wide range of small molecule inhibitors of QS (293, 294), the 
enzymatic degradation of AHLs has been described as a possible approach to interfere 
with QS (295-298). Thus far, two major types of AHL-degrading enzymes have been 
extensively studied: AHL acylases (or AHL amidases) and AHL lactonases. Members of 
the former family cleave the molecule into a free homoserine lactone and a fatty acid, 
while members of the latter family hydrolyze the lactone ring, yielding a homoserine. 
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Degradation products of both enzymes are no longer active, thus shutting down the QS 
circuitry (299, 300). Finally, AHL oxidoreductase, a third type of AHL inactivating 
enzyme, has also been described (301). 
 
The procedures described to isolate QQ bacteria mostly involve cultivation of 
isolates on general media and subsequent tests to check whether or not the isolates 
possess AHL-degrading activity (302). This implies that a lot of time, effort and costs are 
put in testing non-QQ bacteria, since not all environmental isolates are capable of 
degrading AHLs. Another approach is the cultivation of samples in a minimal medium 
supplemented with a single AHL as the sole source of carbon and nitrogen (303). 
Although this method already narrows down the number of isolates to be screened, it is 
likely that a large number of QQ positive strains will go undetected because AHL 
degradation specificity is dependent on side chain length. In the present study we report 
the development of a novel approach for the isolation and identification of QQ bacteria, 
and its validation based on the isolation of QQ bacteria from 16 environmental samples. 
 
Materials and methods 
 
Sample preparation and isolation of QQ consortia from environmental samples 
Locations from which samples were taken are listed in Table 1. 1 g of sample 
material (soil or water) was suspended in 10 ml of saline (0.9% NaCl) and subjected to 
three cycles of 30 s vigorous vortexing and 30 s sonication. After briefly spinning down 
the sample at 3000 rpm to remove larger particles and debris, 2 ml of the resulting 
supernatant (SN) was centrifuged for 4 min at 4500 rpm. Subsequently, pellets were 
resuspended in 5 ml saline and 250 µl of this inoculum suspension was added to the 
wells of a 24-well MTP. Subsequently, 200 µl of a minimal medium was added, together 
with 50 µl of a mixture of AHLs (final concentrations: 2 mM N-(3-oxo-hexanoyl)-L-
homoserine lactone (3OC6HSL) and 1 mM N-(3-oxododecanoyl)-L-homoserine lactone 
(3OC12HSL); Sigma-Aldrich, Bornem, Belgium). The minimal isolation medium (MIM), 
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based upon a previously described medium (303) contained (per litre) NaCl, 1 g; KCl, 0.5 
g; MgCl2, 0.4 g; CaCl2, 0.1 g; Na2SO4, 0.15 g; KH2PO4, 2 g; Na2HPO4, 2.25 g. Subsequently, 
the medium was acidified to pH 5.5 with 1 M HCl, and trace elements were added to final 
concentrations of 1 mg FeCl3, 0.1 g MnCl2 and 46 mg ZnCl2 per litre. Finally, the medium 
was filter sterilized through a 0.22 µm filter. After incubation for 3 days at room 
temperature, 100 µl of the cultures was transferred to 1 ml fresh medium for 
enrichment. This was repeated and after the third enrichment cycle, an aliquot of 100 µl 
was taken from the samples and streaked on tryptone soy agar (TSA, Lab M, Bury, 
United Kingdom). After incubation for 48 h at room temperature, colonies with different 
morphological appearance were separated, subcultured on TSA and stored at -80 °C in 
Microbank vials (Pro-Lab Diagnostics, Richmond Hill, Canada). 
 
Table 1. Samples taken from various locations with their specifications. 
Sample Code  Location  Specifications 
     
P  Desk plant LPM  Cactaceae rhizosphere 
     
Li1  Botanical Garden UGent (indoor)  Araceae rhizosphere 
Li2  Botanical Garden UGent (indoor)  Rutaceae rhizosphere 
Li3  Botanical Garden UGent (indoor)  Asteraceae rhizosphere 
Li4  Botanical Garden UGent (indoor)  Caricaceae rhizosphere 
     
MP1  City Park Ghent  Fagaceae rhizosphere 
MP2  City Park Ghent  Gramineae rhizosphere 
MP3  City Park Ghent  pond water 
     
Le1  Botanical Garden UGent (outdoor)  Plumbaginaceae rhizosphere 
Le2  Botanical Garden UGent (outdoor)  Brassicaceae rhizosphere 
Le3  Botanical Garden UGent (outdoor)  Aristolochiaceae rhizosphere 
Le4  Botanical Garden UGent (outdoor)  Geraniaceae rhizosphere 
Le5  Botanical Garden UGent (outdoor)  Fabaceae rhizosphere 
     
TC1  Home aquarium  water 
     
Lw1  Botanical Garden UGent (outdoor)  outdoor pond 
Lw2  Botanical Garden UGent (indoor)  indoor pond 
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Detection of QQ in bacterial consortia 
 The quorum sensing inhibition selector strain P. aeruginosa QSIS2 was cultured 
aerobically at 37°C in ABT minimal medium (AB medium, containing 2.5 mg/l of 
thiamine), supplemented with 0.5% glucose, 0.5% casamino acids and 80 μg/ml 
gentamicin (304). This reporter strain is a P. aeruginosa lasI rhlI double mutant 
harboring pLasB-SacB1 encoding an AHL-induced killing system. A QSIS2 assay was 
developed in MTP format based on the assay described by Rasmussen et al. (2005) and 
was performed as described previously (293). To detect AHL degradation in the minimal 
medium after each enrichment cycle, the spent medium was filter sterilized and diluted 
(1:100). Subsequently, 50 µl of the sterile supernatant was added to the well of a MTP, 
containing the QSIS2 biosensor (total volume 200 µl). Non-inoculated MIM with AHLs 
served as a positive control. 
 
Detection of QQ activity in bacterial isolates  
 To detect total QQ activity of the isolates, 900 µl of 24 h cultures in tryptone soy 
broth (TSB, Lab M, Bury, United Kingdom), obtained after incubation at 37°C, was mixed 
with a mixture of N-butyryl-DL-homoserine lactone (C4HSL) and 3OC12HSL (final 
concentration of 800 nM for each AHL in the reaction mixture). After 24 h incubation at 
30°C, the reaction mixtures were filter sterilized and 50 µl was added to the wells of a 
MTP containing the QSIS2 biosensor, as described above. Non-inoculated TSB mixed 
with sterile MilliQ water or AHLs served as negative controls (0% activation of the QS 
system) and positive controls (100% activation of the QS system), respectively. To 
detect the presence of extracellular QQ activity, 24 h old cultures (TSB, 37°C) were filter 
sterilized before being mixed with the AHLs. 
 
Elucidation of the mechanism of the QQ activity 
 To determine whether the QQ activity is due to enzymatic degradation of the AHL 
molecules, samples of QQ positive isolates were heat-treated or treated with proteinase 
K prior to the QSIS2 assay. For heat treatment, samples were autoclaved (121°C, 20 min) 
before addition to the AHL mixture. For the proteinase K treatment, 850 µl of a 24 h old 
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culture in TSB (37°C) was mixed with 100 µl of a proteinase K solution (500 µg/ml) 
(Sigma Aldrich, Bornem, Belgium) and incubated for 24 h at 37°C, before 
supplementation with AHLs. To further investigate the mechanisms of QQ activity, the 
supernatant of Le1-2 and Lw1-1 (two of the most active isolates) with extracellular QQ 
activity) was fractionated by size exclusion chromatography (SEC). To this end gravity 
flow columns with a cut-off value of 6000 Da (Econo-Pac 10DG) were used according to 
the minimal dilution protocol instructions supplied by the manufacturer (Bio-Rad 
Laboratories SA/NV, Eke, Belgium). In brief, 3 ml of sterile supernatant was poured onto 
the column and a first fraction, containing the higher molecular weight components 
(>6000 Da), was eluted with 4 ml MilliQ water. Subsequently, lower molecular weight 
components were eluted with 8 ml of MilliQ water, yielding 4 subsequent fractions of 2 
ml each. The fractions obtained were then again tested for QQ activity in the same way 
as described above.  
 
Identification of the isolates  
 Total DNA of the isolates was obtained by alkaline lysis. Isolates were tentatively 
identified by partial 16S rRNA gene sequencing (Big Dye Terminator, Applied 
Biosystems, Halle, Belgium) using pA (5'-AGA GTT TGA TCC TGG CTC AG-3') and pD (5'-
GTA TTA CCG CGG CTG CTG-3') as forward and reverse primers, respectively (305). 
Sequencing was performed using a 96-capillary 3730xl DNA Analyzer (Applied 
Biosystems). Sequence data were processed with the BioEdit software application to 
align and make consensus sequences. The closest related sequences were obtained using 
BLAST (http://blast.ncbi.nlm.nih.gov/Blast.cgi). 
 
Statistical analysis 
 Statistical analysis was performed using SPSS 16.0 software. The non-parametric 
Mann-Whitney test was used to compare the results. 
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Results and discussion 
 
Detection of AHL degradation by bacterial consortia from environmental samples 
 In Fig. 1 the remaining AHL levels for each sample in the diluted sterile 
supernatant from the microbial consortia after the first, second, and third enrichment 
cycle are shown. Compared to a non-inoculated control (100% QS), all samples show a 
decrease in AHL levels in the spent medium after culture and enrichment. As would be 
expected, for most samples AHL levels decrease further with every enrichment cycle. 
Furthermore, these results indicate the presence of bacteria able to use AHLs as sole 
sources of C and N in every sample investigated. However, these data do not allow us to 
differentiate between isolates that are able to degrade AHLs on their own, or those that 
can use degradation products of AHLs produced by other members of the consortium. 
 
 
Fig. 1. Remaining AHL levels for all samples in the diluted sterile supernatant of the microbial 
consortia cultures after the first (white bars), second (grey bars), and third (black bars) 
enrichment cycle, compared to a non-inoculated control (n ≥ 12, means ± standard deviation). 
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Identification of the isolates  
The results of the partial 16S rRNA gene sequencing experiments are shown in 
Table 2. The 59 isolates were classified in 21 genera. 75 % (44) of the isolates were 
Gram-negative. Most frequently encountered genera are Pseudomonas (11 isolates), 
Arthrobacter (10), Aeromonas (6), Delftia (5) and Stenotrophomonas and Achromobacter 
(4 isolates each). 
 
Detection of QQ activity in bacterial isolates 
 The results of the experiments on the QQ activity of the individual isolates are 
shown in Table 2. Additionally, the extracellular QQ activity of isolates for which the 
remaining AHL levels are significantly (p ≤ 0.05) lower than the positive control (100% 
QS) is shown in Fig. 2.  
 
Fig. 2. Extracellular QQ activities of the isolates. Data shown are the averages (± SEM) of the 
remaining AHL levels in the sterile supernatant of the isolates after incubation of the AHL 
mixture with sterile culture supernatant (n ≥ 12). For isolates Le2-5 and Le4-4 no remaining 
AHL levels could be detected in the sterile SN. 
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Adding isolates cultured in TSB to an AHL mixture leads to quenching of QS for 41 
of the 59 isolates. Furthermore, our results indicate that among the taxa recovered, 
Pseudomonas spp., Arthrobacter spp., and Delftia spp. showed the highest QQ activity. 
Remarkably, most genera to which QQ isolates obtained in the present study belong, 
have previously been described in the literature for their ability to degrade AHLs, 
supporting the hypothesis that our method is indeed a valid high-throughput alternative 
for time-consuming and more expensive protocols (210, 302, 306, 307). 
We also tested the co-incubation of the cell-free supernatant with an AHL mixture. 
A limited number of isolates (14) produced and secreted molecules interfering with QS. 
The majority of the isolates with extracellular QQ activity belonged to the genera 
Pseudomonas and Delftia (7 and 3 isolates, respectively). 
 
 
Table 2. Results of the partial 16S rRNA gene sequencing experiments and remaining AHL levels 
as measured in the QSIS2 assay (n ≥ 12). Data shown are the average (± SEM) of the remaining 
AHL levels in the sterile supernatant of the isolates after incubation of the AHL mixture with 
isolate cultures. Values that are significantly lower (p ≤ 0.05) than these from positive controls 
are marked with an asterisk. Isolates for which no remaining AHL levels could be detected are 
marked with ND (could not be detected). 
Sample Isolate code Identity of closest match Accession n° Remaining AHL 
levels 
 
P P1 Leifsonia sp.  JN014009 106 ± 5%  
 P2 Kocuria rhizophila JN014010 101 ± 5%  
 P3 Microbacterium shrimpcida JN014011 28 ± 5% * 
Li1 Li1-1 Arthrobacter sp. JN014012 37 ± 3% * 
 Li1-2 Comamonas sp. JN014013 90 ± 4% * 
 Li1-3 Advenella incenata JN014014 103 ± 4%  
Li2 Li2-1 Arthrobacter nicotinovorans JN014015 70 ± 5% * 
 Li2-2 Comamonas testosteroni JN014016 4 ± 3% * 
 Li2-3 Agrobacterium tumefaciens JN014017 104 ± 5%  
Li3 Li3-1 Arthrobacter nicotinovorans JN014018            ND   * 
 Li3-2 Pseudomonas putida JN014019 6 ± 6% * 
 Li3-3 Sinorhizobium sp. JN014020 120 ± 8%  
Li4 Li4-1 Ochrobactrum anthropi JN014021 107 ± 4%  
 Li4-2 Pseudomonas sp. JN014022            ND   * 
 Li4-3 Arthrobacter sp. JN014023 5 ± 4% * 
MP1 MP1-1 Pseudomonas putida JN014024 58 ± 7% * 
 MP1-2 Arthrobacter sp. JN014025            ND   * 
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 MP1-3 Stenotrophomonas rhizophila JN014026 76 ± 11% * 
 MP1-4 Stenotrophomonas rhizophila JN014027 103 ± 2%  
MP2 MP2-1 Pseudomonas putida JN014028            ND   * 
 MP2-2 Pseudomonas sp. JN014029 89 ± 4% * 
 MP2-3 Stenotrophomonas rhizophila JN014030 32 ± 8% * 
 MP2-4 Delftia sp. JN014031 15 ± 4% * 
 MP2-5 Achromobacter xylosoxidans JN014032 72 ± 4% * 
 MP2-6 Alcaligenes sp. JN014033 44 ± 8% * 
MP3 MP3-1 Pseudomonas sp.  JN014034 52 ± 6% * 
Le1 Le1-1 Staphylococcus sp.  JN014035 88 ± 6% * 
 Le1-2 Delftia sp.  JN014036 2 ± 5% * 
 Le1-3 Arthrobacter nicotinovorans JN014037 4 ± 8% * 
 Le1-4 Arthrobacter aurescens JN014038 46 ± 6% * 
Le2 Le2-1 Arthrobacter sp. JN014039 4 ± 6% * 
 Le2-2 Achromobacter xylosoxidans JN014040 97 ± 4%  
 Le2-4 Delftia sp. JN014041 13 ± 6% * 
 Le2-5 Delftia sp. JN014042            ND   * 
 Le2-6 Kocuria sp. JN014043 112 ± 9%  
Le3 Le3-1 Stenotrophomonas rhizophila JN014044 65 ± 18% * 
 Le3-2 Aeromonas hydrophila JN014045 116 ± 16%  
 Le3-3 Arthrobacter sp. JN014046 2 ± 7% * 
 Le3-4 Pseudomonas sp. JN014047 9 ± 9% * 
 Le3-5 Pseudomonas sp. JN014048 15 ± 6% * 
Le4 Le4-1 Achromobacter denitrificans JN014049 102 ± 3%  
 Le4-2 Achromobacter denitrificans JN014050 4 ± 7% * 
 Le4-3 Pseudomonas sp. JN014051            ND   * 
 Le4-4 Pseudomonas alcaligenes JN014052 5 ± 6% * 
 Le4-5 Pseudomonas putida JN014053            ND   * 
Le5 Le5-1 Paracoccus yeei JN014054 106 ± 5%  
 Le5-2 Arthrobacter nicotinovorans JN014055 4 ± 6% * 
 Le5-3 Brevundimonas sp. JN014056 8 ± 4% * 
 Le5-4 Brevundimonas bullata JN014057 0 ± 3% * 
TC TC1 Agrobacterium tumefaciens JN014058 114 ± 4%  
 TC2 Aeromonas sp. JN014059 120 ± 5%  
 TC3 Shewanella xiamenensis JN014060 24 ± 4% * 
Lw1 Lw1-1 Diaphorobacter sp. JN014061 27 ± 5% * 
 Lw1-2 Aeromonas media JN014062 127 ± 4%  
 Lw1-3 Aeromonas hydrophila JN014063 116 ± 4%  
Lw2 Lw2-1 Aeromonas media JN014064 127 ± 4%  
 Lw2-2 Delftia sp. JN014065 47 ± 3% * 
 Lw2-3 Citrobacter sp. JN014066 128 ± 4%  
 Lw2-4 Aeromonas sp. JN014067 132 ± 4%  
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Remaining QQ activity after heat treatment 
In Fig. 3 the remaining AHL levels in the heat-treated culture supernatant are 
shown for isolates yielding significantly (p ≤ 0.05) higher values for heat-treated 
samples than untreated ones. Some isolates retained QQ activity, suggesting the 
production of a heat-stable QQ molecule. The existence of thermal resistance and 
thermophilicity within the family of microbial lactonases in thermophilic archaea has 
recently been shown by Mandrich et al. (2010) (308). Our findings suggest that other 
microbial lactonases might also be thermostable. Isolates still able to quench QS after 
heat treatment mainly belonged to the genera Arthrobacter, Pseudomonas and Delftia. 
 
 
Fig. 3. Remaining AHL levels after heat treatment. Data shown are the remaining AHL levels 
(averages ± SEM) in the sterile supernatant of the isolates after incubation of the AHLs with 
untreated (black bars) and heat-treated cell cultures (white bars) (n ≥ 12). In the sterile SN of 
untreated cultures of isolates MP2-1, Le4-3, Le5-2 and Le5-3 no remaining AHL levels could be 
detected. 
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Remaining QQ activity after treatment with proteinase K 
 The results of the experiments with proteinase K are shown in Fig. 4 for isolates 
yielding significantly (p ≤ 0.05) higher values for proteinase K treated samples than 
untreated ones. We can clearly distinguish between isolates that are still able to quench 
QS after treatment with proteinase K (data not shown), and those whose QQ activity is 
completely abolished by proteinase K. We hypothesize that the latter isolates use 
lactonases or acylases for QQ, while non-enzymatic mechanisms are likely to be involved 
in the former group. A third group of isolates are those whose QQ activity is reduced, but 
not fully inhibited by proteinase K treatment. A possible explanation for these findings is 
the production of a combination of active compounds and/or the presence of enzymes 
that are not degraded by proteinase K. 
 
 
Fig. 4. Remaining AHL levels after proteinase K treatment. Data shown are remaining AHL levels 
(averages ± SEM) in the sterile supernatant of the isolates after incubation of the AHLs with 
untreated cell cultures (black bars) and cell cultures treated with proteinase K (white bars) (n ≥ 
12). In the sterile SN of the untreated culture of MP1-2, no remaining AHL levels could be 
detected. 
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QQ activity in various fractions obtained with SEC 
 The remaining AHL levels in the different fractions of supernatant treated with 
size exclusion chromatography are shown in Fig. 5. For Delftia sp. Le2-4 the QQ activity 
is only present in the fraction containing molecules larger than 6000 Da, indicating that 
the QQ activity in this isolate is most likely due to enzymatic degradation of the signal 
molecules. In contrast, for Diaphorobacter Lw1-1, no detectable QQ activity was present 
in the fraction containing the large molecules (>6000 Da). However, two fractions of the 
supernatant of this isolate containing lower molecular weight compounds did exhibit QQ 
activity, indicating the secretion of a low molecular weight inhibitory compound (Fig. 5).  
 
 
Fig. 5. Remaining AHL levels of untreated supernatant and the different fractions obtained after 
SEC of the culture supernatant. Data shown are averages ± SEM. 
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Conclusions 
In the present study we developed and evaluated a high-throughput approach for 
the isolation of QQ bacteria from environmental samples. We applied this method to 16 
samples and isolated a total of 59 strains able to use AHLs as sole sources of C and N, 
either alone or as part of a consortium. Of these 59 isolates, 41 were able to quench QS 
in the absence of other partners and 14 possess extracellular QQ activity. Heat treatment 
did not fully inhibit QQ activity in all isolates, indicating the production of (a) heat-stable 
QQ molecule(s). Some isolates lose QQ capacity after proteinase K treatment, while 
others remain able to quench QS. Therefore, it seems plausible that some isolates 
produce and secrete heat-stable, low molecular weight inhibitory compounds. The 
results of the SEC experiments further support this hypothesis. Future research will 
have to reveal the chemical structure of these active molecules as well as their 
mechanism of action. 
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Abstract  
In the present study we investigated the biotherapeutic potential of previously 
isolated quorum quenching (QQ) bacteria. Some of them produce and secrete small 
compounds that inhibit quorum sensing, others quench quorum sensing by enzymatic 
degradation of N-acylhomoserine lactones (AHLs). The supernatant of cultures of these 
isolates was tested for inhibitory properties against P. aeruginosa PAO1 biofilms. Most 
isolates had a moderate effect on biofilm formation, as shown by viability staining 
and/or staining of the biofilm biomass. A substantial part of the isolates reduced P. 
aeruginosa elastase production in a concentration dependent manner. Using C. elegans 
as an in vivo model system for virulence testing, we found that some of the isolates were 
able to increase survival of P. aeruginosa PAO1 and Burkholderia cenocepacia LGM16656 
infected nematodes when co-administered with the pathogen. Altogether, these data 
indicate that some quorum quenching bacteria, or the active compounds they produce, 
could be useful to attenuate virulence of P. aeruginosa PAO1 and possibly also other 
Gram-negative pathogens that use AHLs to regulate the production of virulence factors.  
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Introduction 
Many bacteria use quorum sensing (QS) to monitor cell density and to coordinate 
their behavior (288). Gram-negative bacteria contain a three component network for QS, 
consisting of a signal synthase, the signal molecule itself, and a cytoplasmatic receptor 
(12, 286). As cell density increases, the concentration of diffusible signal molecules 
increases as well, and upon reaching a certain threshold concentration, binding of the 
signal molecules to the receptor will result in a significant induction or repression of QS-
regulated genes. The signal molecules most often used by Gram-negative bacteria are N-
acylhomoserine lactones (AHLs), which contain a conserved lactone moiety, but may 
vary in length, as well as the degree of oxidation and saturation of the acyl side chain 
(285).  
In various pathogenic Gram-negative bacteria the production of virulence factors, 
and biofilm formation and maturation are (co-)regulated by QS (11, 129, 145, 284). 
Pseudomonas aeruginosa, an opportunistic pathogen which commonly infects 
immunocompromised patients (309), uses two hierarchical QS regulatory systems (Las 
and Rhl) to regulate the expression of many of its virulence factors (310), including 
elastase, proteases, exotoxin A, pyocyanin and siderophores (129, 131). Therefore, 
strategies interfering with this cell-to-cell signaling system are a promising novel 
approach to combat bacterial disease (290). Indeed, it has already been shown in vitro 
and in vivo that inhibiting QS decreases the production of virulence factors of pathogenic 
bacteria (148, 292, 293). Furthermore, as QS systems are not directly involved in 
essential cellular processes, QS inhibition (QSI) is hypothesized not to impose harsh 
selective pressure on the population. Theoretically, “antipathogenic” strategies such as 
QSI are less likely to result in the development of resistance (161).  
Taking the architecture of the three-component network into account, QS 
systems in Gram-negative bacteria basically offer three points of attack: the signal 
synthase (LuxI homologue), the signal molecule (AHL) itself, and the signal receptor 
(LuxR homologue) (175). Inhibition of the biosynthesis of the signaling molecule has 
been achieved by substrate analogues (141), whereas some AHL analogues are 
reportedly able to interfere with signal reception (164, 165, 167). A third mechanism is 
degradation of the signaling molecules. AHLs are prone to enzymatic degradation, and 
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two major classes of AHL inactivating hydrolases have been described thus far: AHL 
acylases and AHL lactonases. Members of the former family cleave the molecule into a 
free homoserine lactone and a fatty acid, while members of the latter family hydrolyze 
the lactone ring, yielding a homoserine. Degradation products of both enzymes are no 
longer active, thus shutting down the QS circuitry (299, 300). 
We previously reported on the isolation and identification of bacteria with QSI 
activity from environmental samples. Some isolates were shown to secrete QSI 
compounds and therefore have extracellular QSI activity. Others did not show activity in 
their supernatant, but were able to degrade AHLs when whole cell cultures were 
incubated with synthetic signal molecules. Experiments in which the samples were 
treated with heat or proteinase K allowed us to further differentiate between isolates 
with enzymatic activity or isolates producing small molecule QS inhibitors (311). In the 
present study, we wanted to evaluate the biotherapeutic potential of these isolates in 
vitro and in vivo. Therefore, the isolates were tested for their ability to inhibit biofilm 
formation and elastase production  in P. aeruginosa PAO1. Additionally, the effect of co-
administering QSI isolates with the pathogenic bacteria P. aeruginosa PAO1 or 
Burkholderia cenocepacia LMG16656 in a nematode model, was also investigated. 
 
Materials and methods 
 
Organisms and culture conditions 
A selection of isolates which had previously been shown to produce QSI 
compounds was made from a larger collection of QSI isolates (311, 312). Selection 
criteria were the ability to decrease AHL levels with more than 50 %, and the presence 
of extracellular QSI activity. The isolate codes, their identity, the source of isolation, 
country of origin and culture conditions are listed in Table 1. P. aeruginosa PAO1 and B. 
cenocepacia LMG16656 were chosen as model pathogens as both of them use QS to 
regulate the production of virulence factors and biofilm formation. They were cultured 
aerobically at 37°C in Mueller Hinton Broth (MH). P. aeruginosa QSIS2 was used as a QS 
biosensor strain and cultured as described previously (304). Escherichia coli OP50 was 
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grown aerobically in TSB at 37°C. Caenorhabditis elegans N2 (glp-4; sek-1) was 
propagated under standard conditions, synchronized by hypochlorite bleaching, and 
cultured on nematode growth medium using E. coli OP50 as a food source (313, 314).  
 
Biofilm formation 
Biofilms were formed as described previously (293). In brief, P. aeruginosa PAO1 
was grown overnight in MH, centrifuged, resuspended in double-concentrated MH (2 x 
MH) and diluted to an OD590nm = 0.1 in 2 x MH. Fifty microliters of the standardized cell 
suspension were transferred to the wells of a round-bottom 96-well MTP. To the wells 
of the test conditions, 50 µl of the supernatant of the quorum sensing inhibitory isolates 
(QSI SN) was added. Negative controls contained 50 µl non-inoculated medium. Bacteria 
were allowed to adhere and grow without agitation for 4 h at 37°C. After 4 h, plates were 
emptied and washed with sterile physiological saline (PS; 0.9 % NaCl). To test the 
influence of the QSI SN on the adhesion of P. aeruginosa PAO1, 100 µl MH was added to 
each well after this washing step. To test the influence on the entire process of biofilm 
formation (adhesion and maturation), the wells were filled as described above for the 
first 4 h of biofilm formation, washed with PS and filled again with QSI SN (test 
conditions) or non-inoculated medium (for negative controls). Plates were incubated for 
another 20 h of biofilm maturation at 37°C. After 24 h, the medium was removed, the 
wells were rinsed with PS, and both cell viability and biofilm biomass were determined 
by resazurin (CellTiter-Blue, CTB) staining and crystal violet (CV) staining, respectively 
(315). Briefly, for CTB staining, 100 µl PS was added to the wells, followed by the 
addition of 20 µl CTB solution (Promega, Leiden, The Netherlands). After 60 min, 
fluorescence was measured (λexc = 535 nm, λem = 590 nm) using a microtiter plate reader 
(Envision, Perkin Elmer, USA). For CV staining, biofilms were fixed by adding 100 µl 
methanol (15 min), after which supernatants were removed and the plates were air-
dried. Then, 100 µl of a CV solution was added to all wells (Pro-lab Diagnostics, 
Richmond Hill, ON, Canada). After 20 min, the excess CV was removed by washing the 
plates under running tap water and wells were filled with 150 µl 33% glacial acetic acid 
(Sigma-Aldrich, Bornem, Belgium). The absorbance was measured at 590 nm using the 
Envision. Each SN was tested 12 times in each assay and each assay was carried out 
twice (n = 24). 
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Table 1. Isolates with extracellular intracellular QSI activity. Isolates codes, identity, source of isolation and culture conditions are given (TSB = Tryptic Soy Broth; 
MB = Marine Broth). 
 
QSI activity Code Name Source  Country  Medium Temp (°C) 
Extracellular Li3-2 Pseudomonas putida Rhizosphere (Asteraceae) Belgium TSB 37 
 Li4-2 Pseudomonas sp. Rhizosphere (Caricaceae) Belgium TSB 37 
 MP2-1 Pseudomonas putida Rhizosphere (Gramineae) Belgium TSB 37 
 MP2-6 Alcaligenes sp. Rhizosphere (Gramineae) Belgium TSB 37 
 Le1-2 Delftia sp. Rhizosphere (Plumbaginaceae) Belgium TSB 37 
 Le2-1 Arthrobacter sp. Rhizosphere (Brassicaceae) Belgium TSB 37 
 Le2-4 Delftia sp. Rhizosphere (Brassicaceae) Belgium TSB 37 
 Le2-5 Delftia sp. Rhizosphere (Brassicaceae) Belgium TSB 37 
 Le3-4 Pseudomonas sp. Rhizosphere (Aristolochiaeceae) Belgium TSB 37 
 Le4-4 Pseudomonas alcaligenes Rhizosphere (Geraniaceae) Belgium TSB 37 
 Le4-5 Pseudomonas putida Rhizosphere (Geraniaceae) Belgium TSB 37 
 Lw1-1 Diaphorobacter sp. Pond water Belgium TSB 37 
 NFMI-T Pseudomonas fluorescens Tetraselmis culture Belgium TSB 37 
 Th111 Pseudoalteromonas paragorgicola Mucus of healthy flounders China MB 25 
 Th120 Muricauda olearia Mucus of healthy flounders China MB 25 
 Th27 Pseudoalteromonas paragorgicola Mucus of healthy flounders China MB 25 
 T53 Pseudoalteromonas marina Intestines of healthy flounders China MB 25 
 T96 Pseudoalteromonas marina Intestines of healthy flounders China MB 25 
 T153 Pseudoalteromonas marina Intestines of healthy flounders China MB 25 
Intracellular Le1-3 Arthrobacter nicotinovorans Rhizosphere (Plumbaginaceae) Belgium TSB 37 
 Le1-4 Arthrobacter aurescens Rhizosphere (Plumbaginaceae) Belgium TSB 37 
 Le3-3 Arthrobacter sp. Rhizosphere (Aristolochiaceae) Belgium TSB 37 
 Le3-5 Pseudomonas sp. Rhizosphere (Aristolochiaceae) Belgium TSB 37 
 Le4-2 Achromobacter denitrificans Rhizosphere (Geraniaceae) Belgium TSB 37 
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 Le4-3 Pseudomonas sp. Rhizosphere (Geraniaceae) Belgium TSB 37 
 Le5-3 Brevundimonas sp. Rhizosphere (Fabaceae) Belgium TSB 37 
 Li1-1 Arthrobacter sp. Rhizosphere (Araceae) Belgium TSB 37 
 Li4-3 Arthrobacter sp. Rhizosphere (Caricaceae) Belgium TSB 37 
 MP2-4 Delftia sp. Rhizosphere (Gramineae) Belgium TSB 37 
 LCDR16 Bacillus sp. Digestive tract of Penaeus vannamei Belgium TSB 37 
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Elastin Congo Red assay 
Elastase production of P. aeruginosa PAO1 grown in the presence of increasing 
concentrations of QSI SN was determined with the Elastin Congo Red (ECR) assay as 
described earlier, with slight modifications (316, 317). P. aeruginosa PAO1 was cultured 
at 37°C for 48 h in TSB containing 25%, 50% or 75% QSI SN isolate supernatant. Next, 
150 µl of sterile supernatant of these cultures was added to eppendorf tubes containing 
20 mg of ECR (Sigma-Aldrich). Following addition of 850 µl of 100 mM Tris-Cl/1 mM 
CaCl2 pH 7.5, overnight incubation at 37°C with agitation, and removal of insoluble 
particles by centrifugation (13,000 x g, 1 min), the absorbance at 495 nm was measured.  
 
Caenorhabditis elegans assay 
C. elegans survival experiments were performed as described earlier, with minor 
modifications (148). Synchronized worms (L4 stage) were suspended in a medium 
containing 95% M9 buffer, 5% brain heart infusion broth, and 10 µg/ml cholesterol 
(Sigma-Aldrich) and 250 µl of this nematode suspension was transferred to the wells of 
a 24-well MTP. Stationary phase cultures of P. aeruginosa PAO1, B. cenocepacia 
LMG16656, and the QSI isolates were centrifuged, resuspended in the assay medium, 
standardized to OD590nm = 0.1 and finally diluted 1:100. 250 µl aliquots of these 
standardized suspensions were added to each of the appropiate wells. In this way, three 
test conditions were obtained: one receiving only P. aeruginosa PAO1 or B. cenocepacia 
LMG16656, another receiving only the QSI isolate, and one condition in which both 
suspensions were added. Subsequently, assay medium was added to each well to obtain 
a final volume of 1 ml per well. Nematodes not being administered any bacteria were 
used as a control to correct for spontaneous mortality. Finally, the plates were incubated 
at 25°C and the fraction of dead nematodes was determined after 24 h and 48 h by 
counting the number of dead worms and the total number of worms in each well, using a 
dissection microscope. Isolates of which the administration as such resulted in 
nematode killing, were omitted for further data analysis. For the isolates that did not 
affect nematode survival, the increase in survival compared to as to when the pathogen 
is administered alone, was calculated. 
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Size exclusion chromatography 
For the isolates with known extracellular QSI activity, the sterile SN of 24 h old 
cultures was fractionated by size exclusion chromatography (SEC). To this end, gravity 
flow columns with a cut-off value of 6000 Da (Econo-Pac 10DG) were used according to 
the minimal dilution protocol instructions supplied by the manufacturer (Bio-Rad 
Laboratories SA/NV, Eke, Belgium). In brief, 3 ml of sterile supernatant was poured onto 
the column and a first fraction, containing the higher molecular weight components (> 
6000 Da), was eluted with 4 ml MilliQ water. Subsequently, lower molecular weight 
components were eluted with 8 ml of MilliQ water, yielding 4 subsequent fractions of 2 
ml each. To determine which fraction contained the active compound, 900 µl of each 
fraction was mixed with a mixture of N-butyryl-DL-homoserine lactone and N-(3-
oxododecanoyl)-L-homoserine lactone (final concentrations of 800 nM for each AHL in 
the reaction mixture). After 24h incubation at 30°C, 50 µl of the reaction mixtures was 
added to the wells of a MTP containing the P. aeruginosa QSIS2 biosensor, as described 
previously (293, 304). Simultaneously, non-fractionated SN was also tested for QSI 
activity. Non-inoculated medium with sterile MilliQ water or AHLs served as negative 
controls (0% activation of the QS system) and positive controls (100% activation of the 
QS system), respectively.  
 
Statistical analysis 
Statistical analysis was performed using SPSS 17.0 software. The non-parametric 
Mann-Whitney test was used to compare the results. 
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Results and discussion 
 
QSI isolates inhibit biofilm formation of P. aeruginosa PAO1 
The purpose of these experiments was to assess whether the SN of isolates with 
known extracellular QSI activity could inhibit biofilm formation and maturation. 
Eighteen isolates previously shown to produce and secrete compounds that interfere 
with QS have been selected from a larger collection of QSI isolates. In Fig. 1A, the effect 
of adding QSI SN during the biofilm adhesion phase of P. aeruginosa PAO1 is shown, as 
quantified by CV staining and CTB staining. The relative biofilm formation in the 
presence of QSI SN during both biofilm adhesion and maturation is shown in Fig. 1B. 
Biofilms grown in the absence of QSI SN were used as a control (=100 %). From the data 
in Fig. 1, it is obvious that the influence of QSI SN on biofilm adhesion and/or maturation 
is strain-dependent. Furthermore, isolates influencing total biofilm biomass do not 
necessarily affect viability of the P. aeruginosa PAO1 biofilm, or vice versa. Additionally, 
QSI isolates may primarily affect cell adhesion, primarily affect biofilm maturation, or 
affect both stages of biofilm formation. Isolates Lw1-1 (Diaphorobacter sp.) and Le2-5 
(Delftia sp.) are the most active strains tested. These isolates significantly reduced both 
P. aeruginosa PAO1 cell adhesion and biofilm maturation. Furthermore, they decrease 
total biofilm biomass as well as cell viability of the P. aeruginosa PAO1 biofilm. However, 
in general, reductions in cell adhesion or biofilm maturation are moderate at best, with 
most isolates reducing biofilm adhesion or formation by approximately 20 % - 30 %. 
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A. 
 
B. 
Fig. 1. Relative biofilm formation of P. aeruginosa PAO1 grown in the presence of QSI SN, measured by CV 
staining (effect on biofilm biomass) and CTB staining (effect on cell viability), compared to a biofilm 
grown in the absence of SN (= 100 %). The influence of QSI SN on biofilm adhesion (Fig. 1A) and biofilm 
maturation (Fig. 1B) is shown (n = 24; means ± sem; * = significantly lower than control biofilm, p ≤ 0.05). 
QSI isolates decrease elastase production by P. aeruginosa PAO1 
These experiments were conducted to evaluate whether QSI SN could influence 
the production of the virulence factor elastase. The results of the ECR assay for the 
isolates that significantly (p < 0.05) decrease elastase production are shown in Fig. 2. 
Isolates for which no significant decrease in elastase production was observed, are not 
included in the figure. Isolates Li3-2 (Pseudomonas putida), Le2-5 (Delftia sp.), Lw1-1 
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(Diaphorobacter sp.), NFMI-T (Pseudomonas fluorescens), Th111 and Th27 
(Pseudoalteromonas paragorgicola), Th120 (Muricauda olearia) and T96 
(Pseudoalteromonas marina) all decreased elastase production by P. aeruginosa PAO1 in 
a concentration dependent manner. As the amount of QSI SN in the growth medium of P. 
aeruginosa PAO1 increased, elastase production decreased. Since culturing P. aeruginosa 
PAO1 in the presence of QSI SN does not has a relevant impact on its growth (data not 
shown), we conclude that decreases in elastase production are to be attributed to 
interference with its QS system. Delftia sp. isolates have previously been reported to 
quench QS and thus reduce virulence of Gram-negative pathogens (190, 318). P. 
fluorescens strains have been reported to harbour the pvdQ gene for AHL-acylase (319). 
Furthermore, Chernin et al. have recently shown that rhizobacterial volatiles of a P. 
fluorescens strain may also act as QS inhibitors (320). 
 
 
Fig. 2. Elastase production of P. aeruginosa PAO1 (as measured by the absorbance after the reaction after 
the reaction of its supernatant with ECR) in the presence of isolate SN. The different bars represent the 
control (0 %) and three test conditions, in which P. aeruginosa PAO1 was grown in the presence of 25 %, 
50 % and 75 % QSI SN, respectively (n = 3; means ± sem). 
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Administration of QSI isolates increases survival of infected nematodes 
Virulence of P. aeruginosa and B. cenocepacia towards C. elegans is regulated by 
QS (321, 322). Therefore, this nematode was selected as an in vivo model organism to 
investigate the effect of simultaneous administration of isolates with QSI activity on 
survival of P. aeruginosa PAO1 and B. cenocepacia LMG16656 infected nematodes. For 
14 isolates (Li3-2, Li4-2, MP2-1, Le1-2, Le2-4, Le2-5, Le3-4, Lw1-1, NFMI-T, Th111, 
Th120, Th27, T53, T96), a significant (p < 0.05) increase in survival was observed when 
the isolate was administered to the nematodes at the same time as P. aeruginosa PAO1, 
as compared to the administration of the pathogen only (Fig. 3). To demonstrate that the 
principle of using biotherapeutic microorganisms for prevention or treatment of 
bacterial diseases can be extended towards Gram-negative pathogens other than P. 
aeruginosa PAO1, B. cenocepacia LMG16656 was also used to infect the nematodes. In 
this case, administration of 9 isolates (Li4-2, MP2-1, Le3-4, Lw1-1, NFMI-T, Th120, Th27, 
T53, T96) resulted a significant increase in survival when the isolate was administered 
at the same time as the pathogen (Fig. 3). The experiments with P. aeruginosa PAO1 and 
B. cenocepacia LMG16656 confirm the proof-of-concept that a broad variety of 
environmental bacteria have the potential to be developed as biotherapeutics. 
To confirm that not only environmental QSI isolates with extracellular activity 
increase survival of infected nematodes, isolates with previously shown intracellular QSI 
activity (311), were also tested. In Fig. 4, the relative increase in survival of infected 
nematodes due to the administration of these isolates is shown. Again, diverse 
environmental isolates with QSI activity were able to significantly increase survival of 
infected nematodes. 
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Fig. 3. Increase in survival of infected nematodes after co-administration of the isolate with extracellular 
QQ activity and the pathogen, relative to the survival in the absence of the isolate. Black bars represent P. 
aeruginosa PAO1 infected nematodes, white bars represent B. cenocepacia LMG16656 infected nematodes. 
Only isolates of which administration to the nematodes resulted a significant (p < 0.05) increase in 
survival for at least one of the two pathogens are displayed (n = 3; means ± sem; * = significant increase in 
survival, p ≤ 0.05). 
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Fig. 4. Increase in survival of infected nematodes after co-administration of the isolate with intracellular 
QQ activity and the pathogen, relative to the survival in the absence of the isolate. Black bars represent P. 
aeruginosa PAO1 infected nematodes, white bars represent B. cenocepacia LMG16656 infected nematodes. 
Only isolates of which administration to the nematodes resulted a significant (p < 0.05) increase in 
survival for at least one of the two pathogens are displayed (n = 3; means ± sem; * = significant increase in 
survival, p ≤ 0.05). 
 
QSI SN activity in various fractions obtained with SEC 
To determine whether the QS inhibitory activity in the QSI SN is caused by 
secreted enzymes or small molecules, SEC was used to separate the SN in a fraction 
containing the molecules > 6000 Da, and fractions containing smaller molecules. For 
isolates Le1-2, Le2-4 and Le2-5, belonging to the genus Delftia, QSI activity was only 
present in the fraction containing molecules larger than 6000 Da, indicating that the QSI 
activity in this isolate is most likely due to enzymatic degradation of the signal molecules 
(Fig. 5). This is in agreement with previous studies (190, 311). The fact that for Le2-5 
the level of remaining AHLs in the fractions is not as low as in the untreated sample is 
probably due to dilution of the sample. In contrast, for all other isolates, no detectable 
QSI SN activity was present in the fraction containing the large molecules (> 6000 Da) 
under the conditions tested. However, several fractions of the supernatant of these 
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isolates containing lower molecular weight compounds did exhibit QSI activity, 
indicating the secretion of a low molecular weight inhibitory compound (Fig. 6). 
Although strains from the genus Pseudomonas and Arthrobacter have previously been 
shown to enzymatically degrade AHLs (with the enzymes PvdQ and AhlD, respectively), 
our data indicate that Pseudomonas sp. strains and Arthrobacter sp. strains also produce 
and secrete low molecular weight compounds with QSI activity. 
 
 
Fig. 5. Remaining AHL levels (as measured with the P. aeruginosa QSIS2 biosensor) in the reaction 
mixture after incubating synthetic AHLs with the untreated supernatant of isolates belonging to the genus 
Delftia (Le1-2, Le2-4, Le2-5), and the different fractions obtained after SEC of the culture supernatant of 
Lw1-1  (mean ± sem; * = significant decrease in AHL levels, p ≤ 0.05). 
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Fig. 6. Remaining AHL levels (as measured with the P. aeruginosa QSIS2 biosensor) in the reaction 
mixture after incubating synthetic AHLs with the untreated supernatant of isolates Li4-2, Lw1-1 and T96 
and the different fractions obtained after SEC of their culture supernatant (mean ± sem; * = significant 
decrease in AHL levels, p ≤ 0.05). 
 
Concluding remarks 
In order to find a durable solution for the growing problem of bacterial resistance, 
the discovery of new, alternative therapeutic approaches is required (323). Targeting 
bacterial virulence is such an approach, since it inhibits pathogenesis and its 
consequences rather than placing life-or-death pressure on the target bacterium. Since it 
is generally recognized that a variety of pathogens use QS to control biofilm formation 
and the expression of their virulence factors, interfering with the bacterial 
communication system is considered as a promising new antipathogenic strategy (144, 
324). Much effort has already been put into finding chemical inhibitors of the QS 
circuitry (325, 326). Unfortunately, due to poor characterization and/or limited activity 
in vivo, the majority of these compounds are not very useful. Recently however, various 
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studies reported on the fact that probiotic bacteria produce compounds that interfere 
with QS (327, 328). Together with the growing interest in the application of bacteria as 
biotherapeutic microorganisms (228), this raised the question whether QSI plays a role 
in the biotherapeutic effects of some bacteria in diverse microbial environments. 
Furthermore, observations in aquaculture, where probiotics are already used as 
biological control agents (329), suggested that QSI by bacteria is also relevant in 
important economic ecosystems, besides in human health care (330). The data 
presented in the present study confirm the enormous biotherapeutic potential of 
bacteria. Still, future research is needed to determine whether these bacteria could be 
used as biotherapeutic microorganisms as such, or if the characterized active 
compounds produced by these bacteria could be used as lead molecules for drug 
development. 
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Abstract  
In the present study we show that luxS of Bifidobacterium breve UCC2003 is 
involved in the production of the interspecies signaling molecule autoinducer-2 (AI-2) 
and is not only required for providing protection against Salmonella infection in 
Caenorhabditis elegans, but also for gut colonization of a murine host. Transcriptome 
data obtained for both B. breve UCC2003 wild-type (WT) and a luxS-insertion mutant 
grown under in vitro conditions suggest that LuxS has a metabolic role that impacts on 
iron metabolism. In line with this, we demonstrate that the luxS mutant is significantly 
more susceptible to iron chelators than the WT strain and that this sensitivity can be 
partially reverted in the presence of the AI-2 precursor DPD. Furthermore, we show that 
several genes of an iron starvation-induced gene cluster, which are downregulated in 
the luxS-insertion mutant and which encodes a presumed iron-uptake system, are 
transcriptionally upregulated under in vivo conditions. Mutations of two genes in this 
cluster in B. breve UCC2003 renders the derived mutant strains sensitive to iron 
chelators while deficient in their ability to confer gut protection to Salmonella-infected 
nematodes. Since a functional luxS gene is present in all members of the genus 
Bifidobacterium, our findings provide detailed insights into a LuxS-mediated general 
molecular mechanism underlying gut colonization and pathogen protection by 
bifidobacteria that is correlated with iron acquisition. 
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Introduction 
 Various beneficial or probiotic effects have been attributed to strains belonging to 
the genera Bifidobacterium and Lactobacillus. Probiotic bacteria have been used to treat, 
among others, antibiotic-associated diarrhea, food allergies, atopic eczema, 
inflammatory bowel disease and arthritis (331-336). In addition, several studies have 
inferred a role for probiotic bacteria as antagonists of pathogenic bacteria (337, 338). 
Proposed mechanisms of action include competition for the same attachment sites as 
pathogenic bacteria, competition for nutrients, production of growth-inhibitory 
compounds and stimulation of the immune system (339-342). Whether probiotics need 
to adhere to the epithelial cells of the human gut in order to exert their beneficial effect 
is still a matter of debate, but it is clear that close contact between the two is required at 
a certain stage (274). Bacterial adhesion to the gut epithelium is a complex process in 
which host, bacterial and environmental factors interact, and it is reasoned that 
adhesion and associated probiotic activities are regulated by bacterial cell-to-cell 
communication systems.   
Quorum sensing is a cell-to-cell communication system which allows (pathogenic) 
bacteria to coordinate gene expression and regulate virulence factor production in a 
cell-density dependent manner (6, 343-345). Many Gram-negative pathogens (e.g. 
Pseudomonas aeruginosa) use N-acylhomoserine lactones as signaling molecules (346-
349), whereas some Gram-positive bacteria use species-specific oligopeptides (350, 
351). A third type of signal is autoinducer-2 (AI-2), produced by a variety of Gram-
negative and Gram-positive bacteria. AI-2 is therefore often called an interspecies 
signaling molecule. A few well-known pathogens, including Vibrio spp. and Salmonella, 
use AI-2 as a cue to sense population density (352-355). The key enzyme for AI-2 
production is LuxS, which is an essential part of the activated methyl cycle, involved in 
recycling S-adenosylhomocysteine. More specifically, LuxS catalyzes the cleavage of S-
ribosyl-homocysteine to homocysteine and 4,5-dihydroxy-2,3-pentanedione (DPD), 
which subsequently leads to the production of AI-2 (82). A wide range of bacterial 
species produce AI-2, but evidence for the presence of signal reception and signal 
transduction pathways in organisms besides Escherichia coli, Vibrio spp. and Salmonella 
is lacking (356). While this lack of evidence is sometimes used to question the role of AI-
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2 in interspecies signaling (96), an alternative explanation is that other types of 
receptors and signal transduction pathways are yet to be discovered (88). 
Although the interspecies signaling molecule AI-2 is commonly linked to 
virulence and pathogenicity, it has recently been shown that the probiotic strain 
Lactobacillus acidophilus NCFM harbors a functional luxS gene and produces AI-2 (357). 
Whether this signaling molecule plays a role in the beneficial effects elicited by probiotic 
bacteria remains to be determined. Indeed, it was suggested that the ability to produce 
AI-2 affects attachment of L. acidophilus to intestinal epithelial cells, as a mutation in luxS 
resulted in decreased adherence to Caco-2 cells (357). Additionally, luxS has been 
attributed a central metabolic role in Lactobacillus reuteri 100-23 and Lactobacillus 
rhamnosus GG, and has been shown to influence adherence, biofilm formation and 
exopolysaccharide production in the latter (358-360).  
In the present study we show that a functional luxS gene is widespread in the 
genus Bifidobacterium and that AI-2 production by Bifidobacterium breve UCC2003 
protects Caenorhabditis elegans against Salmonella infection, a property which is linked 
to iron acquisition. Our data furthermore demonstrate that a functional luxS gene is 
required for murine gastrointestinal colonization by B. breve UCC2003. 
 
Materials and methods 
 
Organisms, plasmids and culture conditions 
The Bifidobacterium strains used in this study are listed in Table S1. 
Bifidobacteria were cultured anaerobically at 37°C in modified Columbia Broth (mCol). 
Galactose was used to replace glucose as a carbon source since the latter has been 
reported to possibly interfere with the AI-2 biosensor assay (361). All strains were 
grown until they reached the stationary phase.  
All other bacterial strains, as well as the plasmids used in this study, are listed in 
Table S5. B. breve UCC2003 and derivative mutant strains were routinely cultured in 
Reinforced Clostridial Medium (RCM), supplemented with the appropriate antibiotics 
(10 μg ml-1 tetracycline, 3 μg ml-1 chloramphenicol). E. coli strains were cultured in LB 
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broth at 37°C. The V. harveyi BB170 biosensor strain was grown in Marine Broth at 25°C 
with agitation (21). 
Caenorhabditis elegans N2 (glp-4; sek-1) was propagated under standard 
conditions, synchronized by hypochlorite bleaching, and cultured on nematode growth 
medium using E. coli OP50 as food source (313, 314). 
 
Detection of AI-2 production by bifidobacteria 
A stationary phase culture of a given Bifidobacterium strain was centrifuged twice 
(5000 rpm, 5 min, room temperature). Culture supernatant was neutralized (pH 7.0) 
with 5 M NaOH to exclude any possible pH effects, filter sterilized and subsequently 
diluted to final concentrations of 20 % (v/v) with sterile deionised milliQ water. AI-2 
levels were determined in a V. harveyi BB170 assay as described previously (362). 
Briefly, an overnight culture of the reporter strain was diluted 1:5000 into fresh sterile, 
double concentrated MB medium and 100 µl of this cell suspension was added to the 
wells of a black 96-well MTP (Perkin Elmer). Subsequently, 100 µl of the appropriate 
sterile supernatant dilution was added to the wells, the plates were incubated at 30°C 
and bioluminescence was measured after 5 hours using the EnVision Multilabel Reader 
(Perkin Elmer). Bioluminescence was expressed as the fraction of bioluminescence 
measured in the positive control reaction. 
 
Detection of luxS in bifidobacteria 
First, an extensive search of the NCBI Genome Project database 
(http://www.ncbi.nlm.nih.gov/sites/entrez?db=genome) provided us with the available 
sequences of luxS homologs in bifidobacteria. Subsequently, a nucleotide BLAST 
generated a series of additional sequences with high similarity to the sequences found. A 
set of degenerate primers (5’-CCC GGY TAC ACA TCG ACT GCT C-3’ and 5’-GTG GTC GCG 
RTA GTT GCC GC-3’) was then designed, using the ClustalX software package as an 
alignment tool. 
Extraction of total bacterial DNA was performed as described previously (363). In 
brief, cells grown overnight were harvested and washed in 500 µl TE-buffer (1 mM 
EDTA pH 8.0; 10 mM Tris-HCl pH 8.0) after which the cell suspension was centrifuged 
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for 2 minutes at 13,000 rpm. Following the removal of the supernatant, the resulting 
pellet was frozen at -20°C for at least one hour. The thawed pellet was then resuspended 
in 150 µl lysozyme-solution 5 mg lysozyme (Serva) in 150 µl of TE buffer followed by 
an incubation step at 37°C during 40 minutes. The remaining steps of the procedure 
were performed according to Pitcher et al. (364). Subsequently, the resulting DNA pellet 
was dissolved in 200 µl TE-buffer and kept overnight at 4°C. An RNA digesting step was 
then performed by adding 2 µl of an RNase solution 10 mg RNase (Sigma) dissolved in 1 
ml milli-Q water followed by an incubation step of 90 minutes at 37°C. Quality of the 
DNA samples was verified by spectrophotometric measurements at 260/280/234 nm. 
Finally, the DNA was diluted to a working concentration of 50 ng/µl. 
PCRs were performed with the following conditions: initial denaturation at 94°C 
for 3 minutes was followed by 30 cycles of denaturation at 94°C for 30s, primer 
annealing at 56°C for 30s and elongation at 72°C for 30s. The PCR reactions were 
terminated with a final elongation of 10 minutes at 72°C. The obtained products were 
separated by electrophoresis on 1.5 % agarose gels and stained with GelRed (Biotium). 
 
Construction of B. breve UCC2003 mutants 
The general procedures for the construction of B. breve UCC2003 mutants have 
previously been described by O’Connell Motherway et al. (365). 
 
i. DNA manipulations and transformation 
The general procedures used for DNA manipulation were essentially those 
described previously (366). Restriction enzymes and T4 DNA ligase were 
obtained from Roche Diagnostics and used according to the manufacturer's 
instructions. PCRs were performed using Taq PCR master mix (Qiagen 
GmbH). Synthetic oligonucleotides were synthesized by MWG Biotech AG and 
are listed in Table S6. PCR products were purified by using a High-Pure PCR 
product purification kit (Roche). Plasmid DNA was introduced into E. coli and 
B. breve by electroporation; large-scale preparation of chromosomal DNA 
from Bifidobacterium spp. was performed as described previously (367). 
Plasmid DNA was obtained from B. breve and E. coli using a QIAprep spin 
plasmid miniprep kit (Qiagen GmbH). An initial lysis step was performed 
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using 30 mg/ml of lysozyme for 30 min at 37°C as part of the plasmid 
purification protocol for B. breve. Where appropriate growth media contained 
tetracycline (Tet; 15 mg ml-1), chloramphenicol (Cm; 10 mg ml-1 for E. coli or 3 
mg ml-1 for bifidobacteria ), erythromycin (Em; 100 mg ml-1 for E. coli) or 
kanamycin (Km; 50 mg ml-1 for E. coli). Recombinant E. coli cells containing 
pORI19 were selected on LB agar containing Em, and supplemented with X-
gal (5-bromo-4-chloro-3-indolyl-b-D-galactopyranoside) (40 mg ml-1) and 1 
mM IPTG (isopropyl-b-D-galactopyranoside). 
ii. Bioinformatics 
Sequence data were obtained from the Artemis-mediated (368) 
annotations of the B. breve UCC2003 genome (369). Database searches were 
performed using the sequence database accessible at the National Centre for 
Biotechnology Information website (http://www.ncbi.nlm.nih.gov) using 
TBLASTN, BLASTX and BLASTP (370).  
iii. Construction of insertion mutants and UCC2003-luxS complemented 
strain  
Internal fragments of luxS (277 bp), Bbr_0221 (440 bp) or Bbr_0223 (457 
bp) were amplified by PCR using B. breve UCC2003 chromosomal DNA as the 
template and the oligonucleotide primers luxS-277-f-hindIII and luxS-277-r-
xbaI, 221IMhd3 and 221IMxba or 223IMhd3 and 223Imxba, respectively (see 
Table S6). The generated PCR products were cloned into pORI19, an Ori+ 
RepA− integration plasmid (371) using the unique PstI and XbaI restriction 
sites that were incorporated into the primers, and introduced into E. coli 
EC101 by electroporation. The expected structure of the recombinant 
plasmid, designated pORI19-luxS, pORI19-221 and pORI19-223 was 
confirmed by restriction mapping and sequencing. The tet(W) gene, amplified 
by PCR using pAM5 plasmid DNA as the template (372) and primers tetWf 
and tetWr (see Table S6), thereby incorporating flanking SalI sites in the 
amplicon, was cloned into the SalI-cut pORI19-luxS, pORI19-221 and pORI19-
223 plasmids to generate plasmid pORI19-tet-luxS, pORI19-tet-221 and 
pORI19-tet-223, respectively. The latter plasmids were introduced into E. coli 
EC101 harboring pNZ-M.BbrII-M.BbrIII to facilitate methylation (365), and 
the resulting methylated plasmids were then introduced into B. breve 
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UCC2003 by electroporation and subsequent selection on RCA plates 
supplemented with the appropriate antibiotics. For the construction of the 
complementation construct pBC1.2luxS, a DNA fragment encompassing luxS, 
including its native promoter region was generated by PCR amplification from 
chromosomal DNA of B. breve UCC2003 using Pfu DNA polymerase (Agilent) 
and primer combination luxS-compl-f-xbaI and luxS-compl-r-xbaI (see Table 
S6). The luxS-containing amplicon was digested with XbaI, and ligated to 
similarly digested pBC1.2. The ligation was introduced into E. coli EC101 by 
electroporation. For all cloning experiments, the plasmid content of a number 
of transformants was screened by restriction analysis and the integrity of 
positively identified clones was verified by sequencing. 
 
Determination of colonization of B. breve UCC2003 and derivatives in the 
gastrointestinal tract of nematodes and mice 
To prepare conditioning plates, WT B. breve UCC2003, B. breve UCC2003-luxS, B. 
breve UCC2003-0221 or B. breve UCC2003-0223 were grown anaerobically in RCM at 
37°C until reaching stationary phase. 500 μl of the cell suspension was spread on a 
nematode growth medium (NGM) plate and dried for 3h at 37°C (373). Conditioning 
plates were used directly after preparation by transferring fresh hypochlorite-treated 
nematodes to these plates. After conditioning for 72h, worms were washed three times 
with M9 buffer supplemented with 1 mM sodium azide to prevent expulsion of the 
intestinal load and to remove surface-attached bacteria (374). The number of 
nematodes was then determined microscopically and nematodes were lysed in 
phosphate-buffered saline containing 400 mg 1.0 mm silicon carbide beads (BioSpec 
Products, Inc.) and mechanically disrupted using a pestle. Subsequently, the worm 
lysates were serially diluted, plated on RCA and incubated anaerobically at 37°C. After 
48h, CFU were determined and the number of bacteria per nematode was calculated 
(375).  
Seven-week-old female, BALB/c mice were housed in individually vented cages 
(Animal Care Systems) under a strict 12 h light cycle. Mice (n = 7 per group) were fed a 
standard polysaccharide-rich mouse chow diet and water ad libitum. Mice were 
inoculated by oral gavage (109 cfu of B. breve UCC2003PK1, B. breve UCC 2003-luxS or a 
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mixture of B. breve UCC2003PK1 and B. breve UCC 2003-luxS in 100 μl of PBS). Fecal 
pellets were collected at intervals during 18 days to enumerate bacteria. Eighteen days 
after inoculation, mice were sacrificed and their intestinal tracts quickly dissected. The 
small intestine, cecum and large intestine were harvested for determination of CFU 
(serial dilution plating on RCA agar plates with appropriate antibiotics).  
 
Protective effect of B. breve UCC2003 against Salmonella-induced mortality in C. 
elegans 
C. elegans survival experiments were performed as described earlier, with slight 
modifications (148). Synchronized worms (L4 stage) were suspended in a medium 
containing 95% M9 buffer, 5% brain heart infusion broth, and 10 μg/ml cholesterol 
(Sigma-Aldrich). Then, 250 μl of this nematode suspension was transferred to the wells 
of a 24-well MTP. Stationary phase cultures of E. coli OP50, B. breve UCC2003, B. breve 
UCC2003-luxS, B. breve UCC2003-luxS [pBC1.2luxS], B. breve UCC2003-0221 or B. breve 
UCC2003-0223 were centrifuged, resuspended in the assay medium, and standardized 
to 106 CFU/ml. Next, 250 μl aliquots of these standardized suspensions were added to 
each well. Subsequently, 500 μl of the assay medium was added to each well to obtain a 
final volume of 1 ml per well, and the plates were incubated at 25°C to allow 
colonization of the nematode gut. After 24h incubation, an overnight culture of S. 
Typhimurium NCTC13348 was standardized as described above, and 250 μl of the 
suspension was added to the wells to establish gastro-intestinal infection. Nematodes 
not being administered any bifidobacteria were used as a control. Sterile assay medium 
was added to non-infected nematodes to correct for spontaneous mortality, not caused 
by S. Typhimurium infection. Finally, the plates were incubated at 25°C and the fraction 
of dead nematodes was determined after 24 h and 48 h by counting the number of dead 
worms and the total number of worms in each well, using a dissecting microscope. 
To determine whether the addition of DPD (OMM Scientific) could increase 
survival, similar experiments were carried out in the presence of 5 μM DPD. 
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Transcriptome analysis of B. breve UCC2003 and its luxS mutants  
In order to compare global transcription patterns of the B. breve UCC2003-luxS 
insertion mutant with the B. breve UCC2003 WT strain, cells grown to early exponential 
phase were collected and resuspended in DEPC-treated water. Cell disruption, RNA 
isolation, RNA quality control, cDNA synthesis and indirect labeling were performed as 
described previously (376). DNA microarrays containing oligonucleotide primers 
representing each of the 1,864 annotated genes in the genome of B. breve UCC2003 were 
obtained from Agilent Technologies (Palo Alto). Labeled cDNA was hybridized using the 
Agilent gene expression hybridization kit (number 5188-5242) as described in the 
Agilent two-color microarray-based gene expression analysis v4.0 manual (publication 
number G4140-90050). Following hybridization, microarrays were washed as described 
in the manual and scanned using Agilent’s DNA microarray scanner G2565A. The scans 
were converted to data files with Agilent’s Feature Extraction software (version 9.5). 
DNA microarray data were processed as previously described (376, 377). Differential 
expression tests were performed with the Cyber-T implementation of a variant of the t 
test (378). A gene was considered differentially expressed between a mutant and the 
WT when a transcription ratio of 2 relative to the result for the WT was obtained, with a 
corresponding p-value equal to or less than 0.01. The transcriptional array data have 
been deposited in the GEO database under accession number GSE49880. 
 
Gene expression in B. breve UCC2003 grown in C. elegans by qRT-PCR 
A synchronized nematode population was transferred to conditioning plates, and 
after 72h incubation at 25°C, RNA isolation of in vivo grown WT B. breve UCC2003 was 
performed as described earlier, with slight modifications (341). After collection of the 
nematodes, total RNA was quickly isolated following the protocol of the TRIzol reagent 
(Invitrogen) and purified using the RNeasy minikit (Qiagen) including an on-column 
DNase digestion with RNase-free DNase (Qiagen). Next, qScript cDNA Supermix (Quanta 
Biosciences) was used to obtain cDNA. After development of forward and reverse 
primers for the reference genes and the genes of interest and after testing their 
specificity, real-time PCR (CFX96 Real Time 116 6 System, Bio-Rad) was performed 
using the iQ SYBR Green Supermix (Bio-Rad). The expression levels of the genes of 
interest were normalized using 5 reference genes by geometric averaging of multiple 
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internal control genes with the GeNorm software package (379). Primers were designed 
using Primer-Blast and are listed in Table 2. To ensure the specific amplification of 
Bifidobacterium RNA, primers were also BLASTed to the C. elegans and E. coli OP50 
genome. 
 
Determination of the role of LuxS in iron uptake and metabolism 
In order to examine the possible role of LuxS in iron uptake and metabolism, the 
MIC for the iron chelators 2,2-dipyridyl, ciclopirox olamine and phenanthroline was 
determined according to the European Committee on Antimicrobial Susceptibility 
Testing (EUCAST) standard broth microdilution protocol, with minor modifications 
(380). Instead of Mueller-Hinton broth, RCM was used. A two-fold dilution series of 2,2-
dipyridyl, ciclopirox olamine and phenanthroline, ranging from 1000 μM to 2 µM was 
tested. MICs were determined for WT B. breve UCC2003 as well as for the insertion 
mutants and the complemented strain. To assess whether DPD complementation could 
restore growth of the insertion mutant in the presence of the iron chelators, MICs were 
also determined in the presence of 50 µM and 100 µM DPD. 
 
Statistical data analysis 
Statistical data analysis was carried out using the SPSS Statistics 17.0 software 
package. To assess if means were statistically significantly different from one another, a 
non-parametric Mann-Whitney U test was performed (significance level 0.05%). 
 
Results 
 
A functional luxS gene is widespread amongst bifidobacteria 
The availability of whole genome sequences of a number of Bifidobacterium spp. 
revealed the presence of the AI-2 synthase gene luxS in these strains. To verify if a 
functional luxS gene is widespread amongst bifidobacteria, phenotypic and genotypic 
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experiments were performed. Using Vibrio harveyi BB170 as a biosensor, we 
demonstrated that all (n = 59) Bifidobacterium spp. strains tested produce AI-2 during 
stationary phase planktonic growth, with the supernatant of B. breve UCC2003 inducing 
most bioluminescence (Table S1). Using primers developed against conserved regions of 
the luxS gene we showed that this gene is present in nearly all (n = 55) species 
investigated, except Bifidobacterium angulatum and Bifidobacterium catenulatum (Table 
S1). However, homologues of luxS have been found in all currently available genome 
sequences of Bifidobacterium spp. (img.jgi.doe.gov), including those of the two species 
mentioned above (Table S2), suggesting that negative PCR results were due to 
differences in the primer binding site. A map comparing the genomic context of luxS in 
different Bifidobacterium genomes is provided in SI and shows that the organization of 
luxS and its neighboring genes is conserved in the genus Bifidobacterium. In particular 
the presence and location of four genes, encoding a serine O-acetyltransferase, alanine 
racemase, DNA primase and triphosphohydrolase, are highly conserved (Fig. S1).  
In B. breve UCC2003, inactivation of luxS by insertional mutagenesis (creating a 
strain designated as B. breve UCC2003-luxS) resulted in a drastic and significant 
decrease (p ≤ 0.05) in AI-2 production (Fig. 1), thus providing further evidence that 
luxS is crucial for AI-2 production in the WT. This was substantiated by providing a 
functional luxS gene on a plasmid in trans in the luxS-insertion mutant (strain B. breve 
UCC2003-luxS [pBC1.2luxS]), which restored AI-2 production to WT levels (Fig. 1).  
 
luxS is needed for bifidobacteria to confer protection against Salmonella infection 
In order to examine the potential role of LuxS in providing a host-protecting 
effect against pathogenic bacteria, an in vivo infection experiment in a Caenorhabditis 
elegans model was performed. Indeed, a positive influence of bifidobacterial 
administration on the longevity of Salmonella infected nematodes has previously been 
described (381). The relative survival of Salmonella-infected C. elegans worms that were 
administered B. breve UCC2003, B. breve UCC2003-luxS and B. breve UCC2003-luxS 
[pBC1.2luxS] is shown in Figure 2. Relative survival of infected nematodes that were fed 
the WT was significantly higher than survival of the infected nematodes that had not 
received B. breve UCC2003 (p ≤  0.05) or any other bacterial food source. 
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Administration of the luxS insertion mutant resulted in a decreased survival of infected 
nematodes compared to those that received WT B. breve UCC2003, whereas 
administration of the complemented strain resulted in an increased survival compared 
to the WT (p ≤ 0.05). This clearly indicates that LuxS is a prerequisite for B. breve 
UCC2003 to confer protection against Salmonella infection.  
  
Figure 1. Luminescence signal of the V. harveyi BB170 biosensor strain in the presence of sterile 
and neutralized supernatant of B. breve UCC2003, the insertion mutant B. breve UCC2003-luxS 
and the complemented strain B. breve UCC2003-luxS [pBC1.2luxS]. Data shown are means ± SEM. 
(*, p < 0.05, compared to WT; n = 3) 
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Figure 2. Relative survival of Salmonella-infected C. elegans nematodes to which B. breve 
UCC2003, B. breve UCC2003-luxS or B. breve UCC2003-luxS [pBC1.2luxS] were administered (24 
h and 48 h after Salmonella infection). Data shown are means ± SEM. Control: infected 
nematodes that have not been administered any bifidobacteria. (*, p < 0.05; n = 3) 
 
The presence of luxS is required for gut colonization 
 To verify whether a functional luxS gene is required for gut colonization in a 
competitive and iron-limited environment, the gut colonization capacity of B. breve 
UCC2003 and B. breve UCC2003-luxS was tested in C. elegans and in BALB/c mice. In the 
nematode, the colonization capacity of B. breve UCC2003-luxS [pBC1.2luxS] was also 
determined. When administered separately, the average number of WT B. breve 
UCC2003 able to colonize the C. elegans gut was about 1x103 CFU/nematode. The 
numbers for the insertion mutant B. breve UCC2003-luxS (1.2x103 CFU/nematode) and 
for the complemented strain B. breve UCC2003-luxS [pBC1.2luxS] (0.82x103 
CFU/nematode) were not significantly different. However, simultaneous administration 
of a mixture of equal numbers of both WT and B. breve UCC2003-luxS revealed that the 
WT had a competitive advantage (Table 1). 
 
Table 1. Colonization trial in nematodes and mice. LOG CFU of B. breve UCC2003 or B. breve 
UCC2003-luxS, retrieved in nematodes and murine small intestine, cecum and large intestine (15 
days after the last administration). Data are shown for single strain administration as well as for 
the simultaneous administration of equal numbers of both strains. Numbers shown are means ± 
SEM. BDL: below detection limit. (*, significantly lower than WT; p < 0.05, n = 3 for nematodes, n 
= 7 for mice) 
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In conventional BALB/c mice with a resident microbiota (i.e. in a competitive 
environment), WT B. breve UCC2003 was able to colonize the gastrointestinal tract, as 
was shown by plating of fecal samples (1x105 CFU/g feces retrieved 15 days after last 
administration; Fig. 3) and platings of the contents of the small intestine, large intestine 
and cecum of individual mice confirmed these findings (Table 1). In contrast, the luxS 
insertion mutant was unable to stably colonize the murine gastrointestinal tract. To 
examine whether the presence of the WT was able to rescue the luxS mutant's ability to 
colonize, co-administration experiments were carried out. When equal numbers of B. 
breve UCC2003 and B. breve UCC2003-luxS were administered simultaneously, only the 
WT was able to colonize the gastrointestinal tract, once more confirming that a 
functional luxS gene is required for successful colonization of the gastrointestinal tract 
in a competitive environment. 
 
 
Figure 3. Mice colonization trial. CFU / g feces of B. breve UCC2003 and B. breve UCC2003-luxS 
administered individually, or simultaneously (a mixture of equal numbers of B. breve UCC2003 
and B. breve UCC2003-luxS). Administration started at day 0 and was continued for 3 
consecutive days. Data shown are means ± SEM. (n = 7) 
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The inactivation of luxS has a global impact on gene expression in B. breve 
UCC2003 
 To investigate the impact of the inactivation of luxS on gene expression in B. breve 
UCC2003, comparative transcriptome analysis between in vitro grown WT B. breve 
UCC2003 and B. breve UCC2003-luxS was carried out. Microarray analysis showed that 
1.47 % of the genes (27/1843) were significantly upregulated in B. breve UCC2003-luxS 
(Table S3A), while 5.70 % (105/1843) were significantly downregulated (2-fold cut-off, 
p ≤ 0.05) compared to the WT (Table S3B). Most (18.52 %) of the upregulated genes 
were involved in transcription, and 11.11 % of the upregulated genes were involved in 
defense mechanisms. One fifth (21.90 %) of the downregulated genes were involved in 
carbohydrate transport and metabolism. These data suggest that the role of LuxS is 
metabolic.  
Interestingly, the microarray analysis showed that a cluster of six genes was 
downregulated in B. breve UCC2003-luxS (Table S4), which had previously been shown 
to be induced under iron-starvation conditions (382), suggesting that the luxS mutation 
affects the mutant's ability to acquire iron. 
 
LuxS affects iron metabolism in B. breve UCC2003 
 In order to investigate the importance of these iron-regulated genes for B. breve 
UCC2003 when grown under conditions in which iron is limited, qRT-PCR experiments 
were performed. Expression levels of these genes was compared between in vitro and in 
vivo (i.e. in the C. elegans gut) grown B. breve UCC2003. These experiments showed that 
Bbr_0221 (bfeU, encoding an assumed high affinity iron permease), Bbr_0222 (bfeO, 
encoding a secreted protein with iron-binding domain) and Bbr_0226 (encoding an ABC-
type transporter) were significantly overexpressed when B. breve UCC2003 was grown 
under in vivo conditions relative to the in vitro conditions (Fig. 4). These findings are in 
full agreement with previously obtained in vivo transcriptome data (GEO database 
accession no. GSE27491), showing that six of the seven genes of this iron-regulated 
cluster also exhibit increased transcription in the nematode gut relative to in vitro 
conditions. 
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To confirm the involvement of LuxS in iron metabolism, the tolerance of the B. 
breve strains towards iron chelators that specifically chelate ferrous iron (2,2-dipyridyl), 
ferric iron (ciclopirox olamine), or both (phenanthroline) was determined. Minimal 
inhibitory concentration (MIC) values were considerably higher for B. breve UCC2003 
and B. breve UCC2003-luxS [pBC1.2luxS] than for B. breve UCC2003-luxS (Table 2), 
demonstrating that the insertion mutant is more susceptible to iron chelators that 
chelate ferrous and/or ferric iron than WT B. breve UCC2003. Addition of the AI-2 
precursor DPD to the growth medium partially restored growth of the insertion mutant 
in the presence of the chelators, thereby supporting the notion that LuxS is involved in 
iron acquisition (Table 2). 
 
Figure 4. Relative normalized expression levels (obtained with qRT-PCR) of the iron regulated 
genes in B. breve UCC2003 retrieved from C. elegans gut, compared to in vitro grown B. breve 
UCC2003. Data shown are means ± SEM. (*, p < 0.05, compared to in vitro expression levels; n = 3) 
 
 In order to confirm the involvement of the predicted iron-uptake genes in iron 
acquisition and gut pathogen protection, two mutant strains, B. breve UCC2002-0221 
and B. breve UCC2003-0223, were constructed that harbor an insertion in the predicted 
iron-uptake genes Bbr_0221 and Bbr_0223, respectively. As expected, both of these 
mutants were found to be more susceptible to the three iron chelators as compared to 
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the parent WT strain (data not shown). Similar to the luxS insertion mutant, B. breve 
UCC2003-0221 and B. breve UCC2003-0223 each have a significantly decreased ability 
to confir protection to Salmonella-infected nematodes as compared to the WT (data not 
shown), thereby confirming the importance of iron acquisition in gut pathogen 
protection. Furthermore, as both mutants colonized C. elegans to a similar level as the 
WT, this decreased protective effect is not due to the decreased ability to colonize the 
nematodes. 
 
Table 2. MIC values of 2,2-dipyridyl, ciclopirox olamine and phenanthroline for B. breve 
UCC2003, B. breve UCC2003-luxS and B. breve UCC2003-luxS [pBC1.2luxS], and for B. breve 
UCC2003-luxS supplemented with DPD (50 µM and 100 µM). 
 
 
Discussion 
 
Members of the genus Bifidobacterium are recognized as being numerically 
dominant representatives of the microbiota of healthy breast-fed infants (383, 384). 
Colonization of the newborn infant gut commences during and after birth by microbes 
from the mother and the environment. A succession in the colonization of healthy 
vaginally delivered infants has been reported whereby initial colonization is by 
facultative anaerobes that include enterobacteria, staphylococci and streptococci. Once 
the available oxygen is consumed the newly created anaerobic environment supports 
the establishment of strict anaerobes of the genera Clostridium, Bacteroides and 
Bifidobacterium (385). While this microbiota is recognized as optimal for healthy infants 
an in depth understanding of molecular players involved in gut colonization and host 
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protection in particular with respect to Bifidobacterium sp. remains to be elucidated. The 
intricacies of host-microbe interactions in early life cannot be underestimated and the 
precise mechanisms by which elements of the infant gut microbiota contribute to health 
maintainence and promotion in early life are only beginning to emerge (384, 386).  
The bacterial interspecies signaling molecule AI-2 is now well recognized for its 
role in the regulation of virulence factor production in pathogenic Gram-negative and 
Gram-positive bacteria (87). These virulence associated features include biofilm 
formation, toxin production, adherence to epithelial cells, motility as well as the 
metabolism of heavy metals and carbon (352-354). In addition, the AI-2 synthase LuxS 
plays an important role in central metabolism, more specifically in the detoxification and 
recycling of S-adenosylhomocysteine (82). Interestingly all Bifidobacterium strains, 
sequenced to date, harbour a luxS gene and our investigations demonstrated that all 
tested bifidobacterial strains, representing 11 species of this genus, were capable of 
producing AI-2. In this respect it seemed intriguing that a gut commensal, dominant in 
the infant microbiota, would produce a molecule that could potentially promote the 
production of virulence factors in (opportunistic) gastrointestinal pathogens. 
To further investigate this, B. breve UCC2003 was chosen as a representative of 
probiotic bifidobacteria. This strain, in addition to being the strain that produced most 
AI-2 in the biosensor assay, is a generally accepted model probiotic Bifidobacterium (338, 
369). Transcriptome analysis of B. breve UCC2003-luxS versus UCC2003, grown under in 
vitro conditions, revealed that the inactivation of luxS has a global impact on gene 
expression and suggested that the role of LuxS is primarily metabolic. These findings are 
supported by the fact that no AI-2 signal transduction pathways have previously been 
described in bifidobacteria and that a protein with high similarity to the known AI-2 
receptor LuxP has not been identified from the genome of B. breve UCC2003. UCC2003-
luxS conferred less protection against Salmonella infection in a nematode model, was 
more sensitive to various iron chelators, and was unable to colonize the murine 
gastrointestinal tract. These data demonstrate that LuxS plays a crucial role for 
bifidobacteria in their ability to establish themselves as gut commensals, which also 
includes their beneficial effect pertaining to pathogen protection. Furthermore, our 
results show that LuxS activity is involved in iron acquisition and metabolism, and we 
propose that this property gives B. breve UCC2003 a competitive advantage in iron-
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limited environments such as the gastrointestinal tract. It has previously been shown 
that LuxS affects genes involved in iron metabolism (387) in Porphyromonas gingivalis 
(388), Vibrio vulnificus (389), Mannheimia haemolytica (390) and Actinobacillus 
pleuropneumoniae (391), while it was also demonstrated that iron availability increases 
the pathogenic potential of several gastrointestinal pathogens including S. Typhimurium, 
Citrobacter freundii, E. coli (392) and Listeria monocytogenes (393, 394). Our results 
demonstrate that bifidobacteria can confer gut pathogen protection by a nutritional 
immunity approach and this in turn suggests that LuxS and AI-2 can be versatile in 
various bacterial species and conditions. Since the colonization capacity of a (putative) 
probiotic bacterium is considered to be a prerequisite to exert its beneficial effects, the 
observation that bifidobacteria with a functional luxS gene outcompete the ones lacking 
this gene contributes to the elucidation of molecular players and mechanisms of 
colonization requirements and probiotic effects (395).  
Indeed one group where administration of bifidobacterial strains may positively 
influence health is in the prevention of necrotizing enterocolitis (NEC) in premature 
infants. The precise causative agent of NEC is unknown, however, the preterm infant 
microbiota has been found to be dominated by pathogenic genera with Proteobacteria 
and Enterobacteriaceae dominating rather than characteristic species belonging to 
Bacteroidetes, Clostridium and Bifidobacterium (396-398). The dominance of potentially 
pathogenic bacteria may increase the risk of infection in this vulnerable group. Neonatal 
nurseries in Finland, Italy and Japan have been using probiotics routinely as prophylaxis 
against NEC for over a decade and have reported no adverse effects. Despite the safe use 
of practice and numerous randomized clinical trials that indicate that probiotics can 
reduced the incidence of NEC by at least 30%, clinical guidelines by the American 
Society for Parenteral and Enteral Nutrition (A.S.P.E.N) have the view that there is 
insufficient data to recommend the use of probiotics in infants at risk of NEC (399). 
Indeed, integral to the resistance to adopt probiotics as a prophylaxis against NEC in 
premature infants is the lack of knowledge on the mechanism of action (400). While the 
data presented here is merely one molecular mechanism and one probiotic attribute 
that is conserved among all bifidobacteria, this research provides a key insight into a 
mechanism of gut pathogen protection conferred by bifidobacteria that is of clinical 
relevance. 
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Supporting information 
 
Table S1. List of Bifidobacterium strains, with additional information on the source of isolation. 
For each strain, the relative levels of AI-2 production (means +/- SEM) in the diluted 
supernatant are given compared to AI-2 levels produced by the biosensor itself (=100%). In 
addition, the results for the PCR assay with primers directed against luxS are shown. (* +, PCR 
positive result, -, PCR negative result; ** T, type strain of the species) 
Species Strain**  Source of isolation AI-2 
production 
PCR* 
    Mean 
(%) 
SEM 
(%) 
 
       
B. adolescentis LMG 10502T  Adult, intestine 226 12 + 
 LMG 10733  Adult, intestine 128 5 + 
 LMG 10734  Adult, intestine 155 9 + 
 LMG 11579  Bovine, rumen 138 7 + 
 LMG 18897  Human, faeces 126 5 + 
 LMG 18898  Human, faeces 135 16 + 
       
B. angulatum LMG 11039T  Human, faeces 129 2 - 
 LMG 11568  Sewage 126 12 - 
       
B. animalis 
subsp. animalis 
LMG 10508T  Rat, faeces 237 4 + 
 LMG 18900  Rat, faeces 250 11 + 
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B. animalis 
subsp. lactis 
LMG 25734  Yoghurt (Yogosan)  242 7 + 
 LMG 25755  Yoghurt (Teddi)  207 4 + 
 LMG 25756  Food supplement 
(Hygiaflora)  
175 3 + 
 LMG 25757  Food supplement 
(Friendly bifidus)  
320 16 + 
 LMG 11580  Chicken, faeces 124 6 + 
 LMG 18314T  Yoghurt 165 3 + 
 LMG 18906  Rabbit, faeces 171 5 + 
 LMG 23512  Human, faeces 284 10 + 
 LMG 24384  Milk 272 23 + 
       
B. bifidum LMG 25758  Pharmaceutical 
preparation (Infloran 
Berna)  
208 4 + 
 LM 381 R-33262 Food supplement 
(Friendly bifidus)  
447 20 + 
 LM 588 R-33263 Food supplement 
(Biodophilus)  
216 4 + 
 LMG 11041T  Breast-fed infant, 
faeces 
149 3 + 
 LMG 11582  Adult, intestine 152 12 + 
 LMG 11583  Adult, intestine 210 7 + 
 LMG 13195  Infant, intestine 121 5 + 
       
B. breve LMG 25761  Food supplement 
(Yakult bifiel) 
265 4 + 
 LMG 11040 UCC2003 Nursing stool 496 41 + 
 LMG 11084  Blood 218 4 + 
 LMG 11613  Infant, intestine 132 18 + 
 LMG 13194  Infant, intestine 447 37 + 
 LMG 13208T  Infant, intestine 378 14 + 
 LMG 23729  Infant, faeces 224 4 + 
       
B. catenulatum LMG 11043T  Adult, intestine or 
faeces 
205 4 - 
 LMG 18894  Sewage 173 20 - 
       
B. dentium LMG 10507  Human, faeces 126 7 + 
 LMG 11045T  Dental caries 140 3 + 
 LMG 11585  Dental caries 141 11 + 
       
B. gallicum LMG 11596T  Adult, intestine 137 3 + 
       
B. longum LMG 25762  Pharmaceutical 209 4 + 
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subsp. infantis preparation 
(Probiotical)  
 LMG 8811T  Infant, intestine 248 7 + 
 LMG 11570  Infant, intestine 152 10 + 
 LMG 11588  Infant, faeces 180 5 + 
 LMG 13204  Infant, intestine 169 5 + 
 LMG 18901  Infant, faeces 119 5 + 
 LMG 23728  Infant, faeces 335 13 + 
       
B. longum 
subsp. longum 
LMG 25765  Yoghurt (Lactoferrin)  260 9 + 
 LMG 25766  Food supplement 
(Lola)  
269 9 + 
 LMG 11047  Human 121 4 + 
 LMG 11589  Calf, faeces 197 5 + 
 LMG 13196  Infant, intestine 120 7 + 
 LMG 13197T  Adult, intestine 207 5 + 
 LMG 18899  Adult, faeces 189 19 + 
       
B. 
pseudocatenulat
um 
LMG 10505T  Infant, faeces 189 6 + 
 LMG 11593  Sewage 169 17 + 
 LMG 18903  Human, faeces 134 4 + 
 LMG 18910  Sewage 161 7 + 
       
B. scardovii LMG 21589T  50-year-old woman, 
blood 
257 5 + 
 LMG 21590  44-year-old woman, 
hip 
260 6 + 
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Table S2. luxS in sequenced genomes of bifidobacteria. Locus tags (when available) and E-values 
(following BLAST with luxS sequence of B. breve UCC2003 as query) are shown for each strain.
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Figure S1. Map comparing the genomic context of luxS and its neighbouring genes in different 
Bifidobacterium genomes. 
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Table S3. Transcriptomic analysis of B. breve UCC2003-luxS versus UCC2003 
(A) 
      Functional group  Locus 
Tag 
Gene ID Function Fold 
upregulation 
P-value 
Carbohydrate transport and 
metabolism 
    
 Bbr_1422 rbsK3 Ribokinase 2.20 5.8E-06 
 Bbr_1742  L-fucose permease  2.01 1.8E-06 
Coenzyme transport 
and metabolism 
     
 Bbr_1333 - Hypothetical protein  2.06 2.9E-06 
Transcription      
 Bbr_0201 - DNA-binding protein  2.07 3.2E-05 
 Bbr_0499 rpoC DNA-directed RNA polymerase beta' chain  2.06 3.4E-13 
 Bbr_0732 greA  Transcription elongation factor 2.32 3.7E-09 
 Bbr_1033 - Transcriptional regulator  2.30 2.6E-11 
 Bbr_1828 - Transcriptional regulator, MarR family  2.06 2.0E-05 
Posttranslational modification, protein turnover, chaperones   
 Bbr_0643 - Conserved hypothetical protein 2.63 4.9E-09 
 Bbr_1320 - Neuroserpin precursor  2.10 2.2E-05 
Secondary metabolites biosynthesis, transport and catabolism   
 Bbr_0209 - Phosphopantetheinyl transferase component 
of siderophore synthetase  
2.14 8.2E-11 
 Bbr_1559 - ATP-binding protein of ABC transporter 
system 
2.18 1.6E-15 
Intracellular trafficking, secretion, and vesicular transport   
 Bbr_0133 - Conserved hypothetical secreted protein 
similar to type II/IV secretion system protein  
2.48 3.8E-05 
 Bbr_0134 - Conserved hypothetical membrane spanning 
protein  
2.16 8.6E-07 
 Bbr_0273 - ATP-binding protein of ABC transporter 
system  
5.79 5.4E-10 
 Bbr_1501 - ATP-binding protein of ABC transporter 
system  
3.03 8.6E-10 
 Bbr_1560 - ATP-binding protein of ABC transporter 
system 
2.43 5.5E-14 
General function 
prediction only 
     
 Bbr_1691 -  Beta-phosphoglucomutase  2.19 1.1E-05 
 
(B) 
Functional group  Locus 
tag 
Gene ID Function Fold 
downregulation 
P-value 
Energy production and 
conversion  
     
 Bbr_0324 atpE ATP synthase C chain  2.04 8.4E-15 
 Bbr_0772 pta Phosphate acetyltransferase  2.09 5.0E-04 
 Bbr_0997 ldh1 L-lactate dehydrogenase  2.26 4.5E-06 
 Bbr_1195 acn Aconitate hydratase  2.03 2.0E-05 
 Bbr_1505 fucO fucO Lactaldehyde reductase 3.30 5.8E-08 
 Bbr_1850 Chromate reductase/NADPH-dependent FMN 
reductase/Oxygen-insensitive NADPH 
nitroreductase 
2.77 1.5E-08 
Amino acid transport and 
metabolism  
    
 Bbr_0348 ansB Aspartate ammonia-lyase  3.11 1.0E-05 
 Bbr_0508 dapB Dihydrodipicolinate reductase 2.23 5.4E-08 
 Bbr_0807 metY O-acetylhomoserine 
aminocarboxypropyltransferase  
2.38 6.8E-05 
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 Bbr_0813 proC Pyrroline-5-carboxylate reductase  2.15 3.1E-08 
 Bbr_0860 - Narrowly conserved hypothetical protein  2.32 8.3E-06 
 Bbr_0988 - Aminotransferase  2.09 2.3E-07 
 Bbr_0991 aroE Shikimate 5-dehydrogenase  2.15 2.8E-04 
 Bbr_1478 livH Branched-chain amino acid transport system 
permease protein 
2.82 2.6E-07 
 Bbr_1479 - Leucine-, isoleucine-, valine-, threonine-, and 
alanine-binding protein  
3.57 1.3E-05 
 Bbr_1750 thrB Homoserine kinase 2.27 4.6E-09 
Nucleotide transport and 
metabolism  
    
 Bbr_1377 purB Adenylosuccinate lyase  2.64 7.8E-12 
 Bbr_1447 nrdD Anaerobic ribonucleoside-triphosphate 
reductase  
2.29 4.2E-12 
 Bbr_1898 nrdF  Ribonucleoside-diphosphate reductase beta 
chain  
7.47 1.7E-09 
 Bbr_1899 nrdE  Ribonucleoside-diphosphate reductase alpha 
chain  
3.76 4.8E-11 
Carbohydrate transport and 
metabolism 
    
 Bbr_0027 - Permease protein of ABC transporter system 
for sugars  
5.29 3.5E-11 
 Bbr_0060 glgP1 Glycogen phosphorylase  3.21 4.0E-15 
 Bbr_0116 malQ1 4-alpha-glucanotransferase  2.29 4.9E-09 
 Bbr_0117 agl3 Alpha-glucosidase  2.42 2.0E-05 
 Bbr_0118 malE  Maltose/maltodextrin-binding protein  2.56 1.1E-12 
 Bbr_0119 malC  Maltodextrin transport system permease 
protein 
2.92 5.3E-06 
 Bbr_0123 apuB  Amylopullulanase  2.88 8.5E-07 
 Bbr_0530 - Solute-binding protein of ABC transporter 
system for sugars  
2.07 7.1E-13 
 Bbr_0559 agl4 Alpha-glucosidase  2.07 1.1E-03 
 Bbr_0861 - Conserved hypothetical protein in 
phosphoglycerate mutase family  
2.03 8.5E-03 
 Bbr_1111 - Narrowly conserved hypothetical secreted 
protein  
2.38 3.4E-04 
 Bbr_1237 - Aldose 1-epimerase  2.43 1.1E-04 
 Bbr_1252 - Fructokinase  5.67 1.7E-09 
 Bbr_1556 nagZ Beta-N-acetylhexosaminidase  2.23 6.7E-05 
 Bbr_1589 - Permease protein of ABC transporter system 
for sugars  
2.30 1.9E-07 
 Bbr_1710 rbsK5 Ribokinase 4.79 2.9E-11 
 Bbr_1756 - Macrolide-efflux protein  2.49 1.2E-05 
 Bbr_1844 - Permease protein of ABC transporter system 
for sugars 
2.03 8.2E-13 
 Bbr_1847 - Solute binding protein of ABC transporter 
system for sugars 
2.72 1.8E-15 
 Bbr_1865 - Raffinose transport system permease protein 6.32 9.4E-11 
 Bbr_1866 - Raffinose transport system permease protein 6.67 1.2E-12 
 Bbr_1867 - Raffinose-binding protein 5.28 1.2E-08 
 Bbr_1869 aga Alpha-galactosidase 2.59 2.5E-03 
Coenzyme transport 
and metabolism 
     
 Bbr_0401 pncB  Nicotinate phosphoribosyltransferase 2.08 2.2E-05 
 Bbr_1312 thiE/thiC  Thiamine biosynthesis protein thiC 3.34 8.3E-09 
 Bbr_1723 - Conserved hypothetical protein with possible 
biotin-(acetyl-CoA carboxylase) ligase domain  
2.28 6.4E-05 
Lipid transport and 
metabolism 
     
 Bbr_0826 - Conserved hypothetical protein  3.56 7.1E-07 
Translation, ribosomal structure and 
biogenesis 
   
 Bbr_0495 - RNA methyltransferase 2.07 5.1E-05 
 Bbr_0753 rpsA SSU ribosomal protein S1P  2.03 1.6E-13 
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 Bbr_1396 fmt Methionyl-tRNA formyltransferase  2.52 3.7E-06 
Transcription      
 Bbr_0122 - Transcriptional regulator, LacI family  3.12 1.8E-09 
 Bbr_0181 - Transcriptional regulator, LacI family  2.27 2.8E-08 
 Bbr_1004 hrcA Heat-inducible transcription repressor hrcA 2.04 3.7E-05 
 Bbr_1755 - Transcriptional regulator, TetR family  3.16 5.6E-08 
 Bbr_1891 - Transcriptional regulator, GntR family  2.09 5.2E-05 
Replication, recombination and 
repair 
    
 Bbr_0691 - Transposase 2.39 3.0E-13 
 Bbr_0894 - Hypothetical protein  2.79 4.9E-07 
Cell wall/membrane/envelope 
biogenesis 
    
 Bbr_0224 - Permease protein of ABC transporter system  5.39 8.2E-12 
 Bbr_0563 - Conserved hypothetical membrane spanning 
protein 
2.68 1.9E-05 
 Bbr_0580 - Phosphoglycerol transferase 2.05 1.6E-03 
 Bbr_0601 - Glycosyltransferase  8.09 3.6E-11 
 Bbr_0886 - Permease protein of ABC transporter system 2.77 6.4E-05 
 Bbr_1042 lgt Prolipoprotein diacylglyceryl transferase  3.03 6.9E-06 
 Bbr_1506 - Cyclopropane-fatty-acyl-phospholipid 
synthase  
3.51 3.0E-05 
Posttranslational modification, protein turnover, chaperones   
 Bbr_0089 degP DO serine protease containing PDZ domain  2.44 6.7E-09 
 Bbr_0126 dnaJ1 Chaperone protein dnaJ  2.04 1.9E-05 
Inorganic ion transport and 
metabolism 
    
 Bbr_0221 - Conserved hypothetical membrane spanning 
protein with iron permease FTR1 family 
domain 
3.32 3.4E-08 
 Bbr_0222 - Conserved hypothetical secreted protein 5.38 7.8E-16 
 Bbr_0749 - Permease protein of ABC transporter system 
for metals 
2.02 5.9E-04 
 Bbr_0943 - ATP-binding protein of ABC transporter 
system 
2.23 2.2E-05 
 Bbr_1682 pstS Phosphate-binding protein  2.22 1.2E-04 
Signal transduction 
mechanisms 
     
 Bbr_0541 luxS  Autoinducer-2 production protein luxS  2.22 2.7E-10 
 Bbr_1360 - Two component system histidine kinase  2.27 2.8E-04 
 Bbr_1583 - Histidine kinase sensor of two component 
system  
2.05 3.7E-12 
Intracellular trafficking, secretion, and vesicular transport   
 Bbr_1923 yidC Inner membrane protein (Preprotein 
translocase subunit YidC)  
2.28 1.0E-08 
 Bbr_0226 - ATP-binding protein of ABC transporter 
system  
3.15 8.0E-06 
 Bbr_0562 - ATP-binding protein of ABC transporter 
system  
3.78 6.8E-07 
 Bbr_0887 - ATP-binding protein of ABC transporter 
system  
2.74 6.2E-07 
 Bbr_1433 - ATP-binding protein of ABC transporter 
system 
3.55 5.8E-09 
 Bbr_1434 - ATP-binding protein of ABC transporter 
system  
2.09 3.2E-05 
General function 
prediction only 
     
 Bbr_0249 - ABC1 family protein kinase 3.72 9.7E-13 
 Bbr_1581 - Narrowly conserved hypothetical membrane 
spanning protein  
2.17 1.7E-11 
 Bbr_1739 - Transporter  2.26 8.4E-05 
 Bbr_1758 - nox NADH oxidase H2O-forming  2.80 1.4E-05 
 Bbr_1873 - Phospholipase/carboxylesterase  2.00 7.8E-05 
Function unknown      
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 Bbr_0018 - Narrowly conserved hypothetical membrane 
spanning protein  
2.70 3.4E-06 
 Bbr_0227 - Conserved hypothetical protein  2.11 7.6E-05 
 Bbr_0248 - Conserved hypothetical protein 2.12 1.2E-11 
 Bbr_0374 lemA lemA LemA protein  2.83 1.0E-06 
 Bbr_0788 pflA1 Pyruvate formate-lyase activating enzyme  2.29 3.4E-04 
 Bbr_1293 - Myosin-crossreactive antigen  6.56 1.6E-10 
 
 
Table S4. Relative normalized gene expression levels of a cluster of iron regulated genes as 
expressed in vitro in B. breve UCC2003-luxS compared to B. breve UCC2003. 
 
 
 
 
Table S5. Strains and plasmids used in this study. 
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Table S6. Primers used in this study.  
Purpose Primer Sequence (5'-3') 
   
Confirmation of presence of luxS  luxS-fw cccggytacacatcgactgctc 
 luxS-rev gtggtcgcgrtagttgccgc 
   
   
Cloning of luxS in pORI19 luxS-277-f-hindIII tgcggaaagcttgatcacaccaaggtcaag 
 luxS-248-r-xbaI ctatgctctagagagtgcgtgccccaggtc 
Cloning of luxS in pBC1 luxS-compl-f-xbaI ctatgctctagacattgcctatagcgaatc 
 luxS-compl-r-xbaI ctatgctctagagcaatcaccagtacaggaac 
Cloning of TetR gene in pAM5 tetWf tcagctgtcgacatgctcatgtacggtaaggaagca 
 tetWr  gcgacggtcgaccataacttctgattgttgccg 
Insertion in Bbr_0221 221IMhd3 ctgcgcaagcttgaatgacgcctactaccagcac 
 221IMxba ttgacgtctagacaccgaacgcgaccatgaag 
Insertion in Bbr_0223 223IMhd3 ctgcgcaagcttcatcgacatcgcgctcaccctgttc 
 223IMxba ttgacgtctagagaatgccttgtgtttgcgtc 
   
   
Test genes qRT-PCR Bbr_0221-fw cgattggcttggcttctacc 
 Bbr_0221-rev gaatccgactacgaacagcg 
 Bbr_0222-fw ctccatggctgtttcgatgg 
 Bbr_0222-rev ctgaatcgtccttcttggcg 
 Bbr_0223-fw tgcttgaacaattcgtggca 
 Bbr_0223-rev tagttgacgaatgtgcgctg 
 Bbr_0224-fw agaacctgaagctctccacc 
 Bbr_0224-rev ctcgtcaccggaatcgtaga 
 Bbr_0225-fw cagtcgtcctcaagccaaac 
 Bbr_0225-rev gatgatcgaatcctcgctgc 
 Bbr_0226-fw gctgtggaaaacgtgatggt 
 Bbr_0226-rev cagaccaactttctccagcg 
Reference genes qRT-PCR atpD-fw cgtatgccttccgccgtgggttac 
 atpD-rev acgtagatggcttgcagcgaggtg 
 rpoB-fw cacgatggtgctgcgaccttccc 
 rpoB-rev gacctgacggatacgacggttgcc 
 ldh-FW gtgatgggcgagcatggcgactc 
 ldh-rev ggaggcgaagcggtcttggttggtc 
 pdxS-fw gatcaagggcattcaggaag 
 pdxS-rev cgaactggttcttgtcgatc 
 gluC-fw cttcgccacgaacttcttct 
 gluC-rev gttcttgagcagtgcgatca 
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CHAPTER VI:  
GENERAL DISCUSSION AND FUTURE PERSPECTIVES 
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Although bacterial resistance to antimicrobial agents is not a recent phenomenon, 
it has become a critical health issue and a worldwide health threat. Over the past 
decades, bacteria causing common infections have developed resistance to each new 
antibiotic (401). In fact, every major group of pathogenic bacteria exhibits a known 
resistance against at least one antimicrobial agent. Moreover, bacteria that are resistant 
to all available antibiotics have been described (402). Major factors contributing to this 
phenomenon are the overuse and misuse of antibiotics in human medicine and their use 
as growth-promoters in food-producing animals (403). With few new antibiotics in the 
pipeline coming to the market, the need for action to avert a developing global crisis is 
increasingly urgent (401, 404). Not only do infections with resistant bacteria lead to 
increased morbidity and mortality, they also often require a longer, more complex and 
thus more expensive treatment (405, 406). Besides having major implications for 
human health care, resistant bacteria are undeniably becoming important in veterinary 
medicine, aquaculture and agriculture (407-409). Therefore, the economic 
repercussions of this problem are immense. 
 In order to find a durable solution, the discovery of new, alternative therapeutic 
approaches is required (323). Targeting bacterial virulence is such an approach, since it 
inhibits pathogenesis and its consequences rather than placing immediate life-or-death 
pressure on the target bacterium. As it is generally recognized that a variety of 
pathogens use QS to control biofilm formation and the expression of their virulence 
factors, interfering with the bacterial communication system is considered as a 
promising new antipathogenic strategy (144, 324). A lot of effort has already been 
devoted to finding chemical inhibitors of the QS circuitry, and many components indeed 
exhibit QSI activity (325, 326). Unfortunately, due to poor characterization and/or 
limited activity in vivo, the majority of these compounds are not useful. Recently, 
however, various studies have reported that probiotic bacteria produce compounds 
interfering with QS (327, 328). Together with the growing interest in the application of 
bacteria as biotherapeutic microorganisms (228), this has raised the question whether 
QS and/or QSI play(s) a role in the biotherapeutic effects of some bacteria in a variety of 
microbial environments. Furthermore, similar observations in aquaculture, where 
probiotics are already used as biological control agents, have suggested that QSI by 
bacteria is also relevant in important economic ecosystems, besides in human health 
care (329). It has indeed been argued that prokaryotes producing QSI, which are 
- 126 - 
 
generally regarded as safe, are likely to be those with the most diverse potential for 
applications (176). 
 
In order to identify bacteria that are able to interfere with the QS system of 
pathogenic Gram-negative bacteria, and therefore have the potential to be used as 
biotherapeutic microorganisms, we have developed and optimized a method allowing 
isolation of QQ bacteria from environmental samples (Chapter III). By using repeated 
enrichment cycles with a mixture of a short chain AHL and a long chain AHL to culture 
the samples in a minimal medium, and by detecting AHL degradation with a biosensor 
unlikely to report false positives, we have circumvented the shortcomings of previously 
described procedures. Furthermore, the method we propose represents a high-
throughput alternative for time-consuming and more expensive protocols (302, 303, 
306, 307). Application of the method to various soil and water samples has both 
confirmed previous findings and has given new insights into QSI by environmental 
bacteria (Chapter III). Isolation of bacteria belonging to genera known to produce 
lactonases (e.g. Agrobacterium, Arthrobacter, Ochrobactrum and Microbacterium) or 
acylases (e.g. Pseudomonas, Comamonas, Shewanella and Delftia) confirms the validity of 
the method described (184, 185, 190, 192, 203, 204, 210). Moreover, it strengthens the 
awareness that these microorganisms indeed have a considerable biotherapeutic 
potential. The isolation of strains belonging to bacteria without known QSI activity, on 
the other hand, shows the added value of our procedure. It also highlights the need for 
further screening, since it is not unlikely that the list of QSI bacteria will grow 
tremendously taking into account bacterial diversity in various ecosystems (410).  
Following the isolation and identification of bacteria with QSI activity, we have 
investigated the biotherapeutic potential of these isolates in vitro and in vivo. To this end, 
the supernatant of the isolates with extracellular activity was tested for biofilm 
inhibitory and biofilm eradication properties against the opportunistic pathogen P. 
aeruginosa PAO1 (Chapter IV). Most of the isolates had a moderate inhibitory effect on 
biofilm formation, as shown by viability staining and/or staining of the biofilm biomass. 
A substantial part of the isolates did, however, greatly affect P. aeruginosa elastase 
production in a concentration dependent manner. Moreover, using C. elegans as an in 
vivo model system, we demonstrated that QSI isolates can increase survival of P. 
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aeruginosa PAO1 infected nematodes. To demonstrate that the principle of using 
biotherapeutic microorganisms for prevention or treatment of bacterial diseases can be 
extended towards Gram-negative pathogens other than P. aeruginosa, B. cenocepacia 
LMG16656 was also used (Chapter IV). Together, these data once more highlight the 
biotherapeutic potential of certain bacteria. 
Apart from the observation that a wide range of bacteria are able to inhibit QS 
and therefore have biotherapeutic potential, we also demonstrated that the mechanisms 
of action behind the inhibition of QS varies between isolates. In summary, we have 
collected and identified isolates with intracellular QSI activity as well as isolates with 
extracellular activity. Some isolates produce and secrete heat-stable, low molecular 
weight inhibitory compounds, whereas others have enzymatic QQ activity, or a 
combination of both. Furthermore, for a few isolates, heat treatment did not abolish 
enzymatic activity (Chapter III). Not only is this in accordance with the findings of 
others, it is also an interesting feature as far as applications are concerned (411). This 
diversity in mechanisms of action offers a great perspective regarding the use or 
application of QSI bacteria or of the active compounds they produce. Biotherapeutics, 
also known as biotech drugs or biologics, are derived from living organisms. By 
harnessing these living cells to make or modify products, therapies that treat illness and 
improve health are able to be made (225, 412, 413). Taking this definition and the 
discovered mechanisms of action into account, a broad range of possible applications 
comes to mind: the use of live bacteria as such, the use of genetically modified organisms, 
the use of purified active compounds (enzymes or small molecules), or the use of these 
components as a lead to develop more potent QSI. Each of those possibilities has its 
advantages and its shortcomings, which are all briefly discussed below.  
 A first possible application is the use of whole, live cells. For regulatory purposes, 
the US Food and Drug Administration (FDA) uses two terms for live microbes: live 
microbes added to animal feeds are called “direct-fed microbials”, and, when intended 
for use as human drugs, they are classified as “live biotherapeutic products” (LBPs) 
(414). Clearly, live organisms can not be administered without certain precautions. The 
current FDA guidelines emphasize standards for chemistry, manufacturing and controls 
to ensure that LBPs are produced in accordance with good manufacturing practice 
(GMP)-compliant standards. LPBs entering human trials should be characterized 
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genotypically or phenotypically (for safety issues), have defined potency (colony-
forming units per dose, or other assays predictive of therapeutic activity), satisfy quality 
acceptance criteria both for in-process steps and for product release, and are free of 
extraneous contaminant organisms (415). A common misconception is that 
microorganisms designated as GRAS for specified food use are automatically safe for use 
as a component of a drug or biological product, as they are not subject to food legislation 
(413). Whereas at this point no LBPs have reached stages of development further than 
Phase 2 clinical studies, administration of live bacteria as dietary supplements to 
substitute antibiotics, is widely employed in the aquaculture and livestock industry (329, 
415, 416). Secondly, expression of genes encoding AHL degrading enzymes in transgenic 
plants has also proven to be feasible as a means of biocontrol. Tobacco plants expressing 
aiiA genes, for instance, were much less vulnerable to infection by E. carotovora, 
compared to their wild-type counterparts (178, 417). Although the use of genetically 
modified organisms imposes important biosafety issues and certain ethical issues for 
some individuals, it most certainly is a plausible application and a research area to be 
invested in (418, 419). In contrast, the use of purified active compounds certainly 
represents the most classic pharmaceutical approach. When the active compounds of QQ 
isolates would be identified as secreted small molecules, solvent extraction and 
subsequent testing of individual fraction can provide information on the polarity of the 
active compound. More advanced techniques such as gas chromatography or high 
performance liquid chromatography coupled to mass spectroscopy, can elucidate the 
chemical structure of the active QSI compounds (420). These molecules can be used as 
such in further studies, or serve as lead molecules for drug development. In the latter 
case, structure-activity relationship testing can lead to improved biological activity 
and/or physicochemical properties of the compound. Not only small molecules, but also 
enzymes can be purified and used. For instance, it has recently been demonstrated that 
oral administration of thermostable AHL lactonase from a Bacillus sp. strain could 
attenuate Aeromonas hydrophila infection in zebrafish (411). Many enzymes have 
indeed already been approved as drugs and are currently on the market (421). 
In principle, QS inhibition would give the host immune system a better chance of 
clearing the infection before the bacteria cause too much tissue damage (422). Although 
it is sometimes said that QSI is unlikely to be a panacea, it is certainly widely recognized 
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as a promising novel strategy in the prevention and control of infectious diseases, with a 
lower risk of resistance development (290, 423, 424). 
 
 In addition to organisms producing compounds that inhibit QS, we have made the 
interesting observation that a functional luxS gene (encoding the AI-2 synthase) is 
widespread in Bifidobacterium (Chapter V), a genus containing several species with 
probiotic properties (425). Although the interspecies QS signal molecule AI-2 is 
commonly linked to virulence and pathogenicity (354, 355), our findings show that it’s 
synthase plays a crucial role in gut colonization and probiotic functionality of 
bifidobacteria. Furthermore, we have linked this LuxS-mediated general molecular 
mechanism underlying gut colonization and protection against pathogens to iron 
acquisition (Chapter V). This trait does not seem to be exclusive for bifidobacteria, since 
another probiotic bacterium, L. acidophilus NCFM, has also been shown to have a 
functional luxS gene. In this strain, AI-2 production was linked to the attachment 
properties of the probiotic bacterium, which is a prerequisite for probiotic functionality 
(357). In addition, luxS has been associated with a central metabolic role in L. reuteri 
100-23 and L. rhamnosus GG, and has been shown to influence adherence, biofilm 
formation and exopolysaccharide production in the latter (358-360). It is therefore 
important to realize that LuxS, apart from its involved in AI-2 QS in many pathogens, 
also plays an important role in central metabolism, and more importantly, that it is 
crucial for certain probiotics to exert their beneficial effects. This knowledge raises an 
important issue: if certain beneficial microbes use QS signaling molecules for their 
probiotic functionality, the interference with QS, which is generally accepted as a 
promising antipathogenic strategy, could also have unwanted effects towards members 
of a healty gut microbiota. Therefore, using QSI to combat diseases should not be done 
without precautions, and the effects of QSI on beneficial microbes should be carefully 
investigated. 
 Apart from being used and marketed as probiotics, bifidobacteria are also an 
important member of the human gut microbiome. In addition, a human gut microbiome 
consisting of bacteria belonging to the genera Clostridium, Bacteroides and 
Bifidobacterium is recognized as optimal for healthy infants (385). Still, an in depth 
understanding of molecular players involved in gut colonization and host protection in 
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particular with respect to Bifidobacterium sp., is lacking. Our data contribute to the 
unraveling of the molecular mechanisms behind the beneficial effects of bifidobacteria. 
Probiotic bifidobacteria are also of clinical importance. One example where 
administration of bifidobacterial strains may positively influence health is in the 
prevention of necrotizing enterocolitis (NEC) in premature infants. Although the precise 
causative agent of NEC is unknown, the preterm infant microbiota has been found to be 
dominated by pathogenic genera, with Proteobacteria and Enterobacteriaceae 
dominating rather than the species typically found in the infant gut (397, 398). Despite 
the safe use in practice and numerous randomized clinical trials indicating that 
probiotics can reduce the incidence of NEC by at least 30%, clinical guidelines by the 
American Society for Parenteral and Enteral Nutrition have the view that there are 
insufficient data to recommend the use of probiotics in infants at risk of NEC (399). 
Indeed, integral to the resistance to adopt probiotics as a prophylaxis against NEC in 
premature infants is the lack of knowledge on the mechanism of action (400). While the 
data presented here represent merely one molecular mechanism and one probiotic 
attribute that is conserved among all bifidobacteria, this research provides a key insight 
into a mechanism of gut pathogen protection conferred by bifidobacteria that is 
clinically relevant.  
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Synopsis 
 
Although resistance against antibiotics is a growing problem, very few new 
antibiotics have been developed the past years, or will be introduced in the near future. 
Another important factor is the increasing awareness that the majority of infections are 
biofilm-related. Therefore, there is an urgent need for new targets for therapy to prevent 
or treat bacterial infectious diseases. One alternative approach is targeting the bacterial 
communication system known as quorum sensing (QS). Since a variety of pathogens 
uses QS to control biofilm formation and the expression of their virulence factors, 
interfering with QS is considered an attractive and promising new antipathogenic 
strategy. To date, many components with QS inhibitory properties have been 
characterized. Unfortunately, the majority of these compounds are not very useful in 
vivo. The specific aim of this study was to explore the potential of interfering with QS by 
means of other, potentially biotherapeutic bacteria.  
In a first study we developed and evaluated a high-throughput approach for the 
isolation of QSI bacteria from environmental samples. Applying this method to various 
soil samples led to the isolation and identification of a large number of strains, able to 
use QS signal molecules as sole sources of carbon and nitrogen. Further experiments 
demonstrated that some of these isolates produce and secrete heat-stable, low 
molecular weight QS inhibitory compounds, whereas others degrade AHL signal 
molecules enzymatically. In a second study we evaluated the biotherapeutic potential of 
these isolates in vitro and in vivo. We showed that certain isolates with QS inhibitory 
properties are able to inhibit biofilm formation of the opportunistic pathogen P. 
aeruginosa PAO1. Another observation was that some of the isolates decrease elastase 
production by P. aeruginosa PAO1, which is a known virulence factor controlled by QS. 
Furthermore, administration of various QSI isolates increased survival of infected 
nematodes. Together, these data confirm the biotherapeutic potential of certain 
environmental isolates. However, more research is needed to determine whether these 
bacteria could be used as biotherapeutic microorganisms as such, or whether the 
characterized active compounds produced by these bacteria could serve as lead 
molecules for drug development.  
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In addition to organisms producing compounds that inhibit QS, we also observed 
that a functional luxS gene is widespread in bifidobacteria, which are commonly 
regarded as beneficial microbes. LuxS, the protein product of this gene, is responsible for 
the production of the QS signaling molecule AI-2. Although this molecule is generally 
linked to virulence and pathogenicity, our findings showed that AI-2 plays a crucial role 
in gut colonization and probiotic functionality of bifidobacteria. Furthermore, we linked 
this LuxS-mediated general molecular mechanisms underlying gut colonization and 
protection against pathogens to iron acquisition. Therefore, our data contributed to the 
unraveling of the molecular mechanisms behind the beneficial effects of bifidobacteria.  
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Samenvatting 
 
Hoewel resistentie ten opzichte van antibiotica een groeiend problem is, zijn er 
toch weinig nieuwe antibiotica ontwikkeld de laatste jaren, net zoals er maar weinig 
geïntroduceerd zullen worden in de nabije toekomst. Een andere belangrijke factor is 
het toenemende besef dat de meerderheid van bacteriële infecties biofilmgerelateerd is. 
Omwille van deze redenen is er dus dringend nood aan nieuwe therapeutische 
doelwitten voor de preventie of behandeling van bacteriële infectieziekten. Eén 
dergelijke strategie is interfereren met het bacteriële communicatiesysteem dat gekend 
staat als quorum sensing (QS). Aangezien immers verschillende pathogenen QS 
gebruiken om biofilmvorming en de expressie van virulentiefactoren te reguleren, wordt 
het interfereren met QS beschouwd als een aantrekkelijke en veelbelovende 
antipathogene strategie. Er werden tot op heden reeds verschillende componenten met 
QS inhiberende eigenschappen gekarakteriseerd, maar helaas is de meerderheid 
daarvan niet bruikbaar in vivo. Het specifieke doel van deze studie was om na te gaan 
welk potentieel er ligt in het interfereren van QS door andere, eventueel 
biotherapeutische bacteriën. 
 In een eerste studie werd een high-throughput methode ontwikkeld voor de 
isolatie van QS inhiberende bacteriën uit omgevingsstalen. Door het toepassen van deze 
methode op verschillende stalen werd een veelvoud aan stammen geïsoleerd en 
geïdentificeerd. Deze stammen konden QS signaalmoleculen gebruiken als enige bron 
van koolstof en stikstof. Verder onderzoek toonde aan dat sommige van deze isolaten 
kleine, hittestabiele QS inhiberende componenten produceren en secreteren, en dat 
andere isolaten AHL signaalmoleculen enzymatisch kunnen afbreken. In een tweede 
studie hebben we het biotherapeutische potentieel van deze isolaten in vitro en in vivo 
geëvalueerd. We konden aantonen dat bepaalde isolaten met QS inhiberende 
eigenschappen in staat zijn om biofilmvorming van het opportunistische pathogeen P. 
aeruginosa PAO1 te inhiberen. Een andere observatie was dat sommige van deze 
isolaten elastase productie door P. aeruginosa PAO1 verminderden. Elastase is een 
gekende virulentiefactor waarvan de expressie onder controle van QS staat. Verder is 
het zo dat het toedienen van verschillende QSI isolaten aan geïnfecteerde nematoden 
resulteert in een betere overleving. Samen bevestigen deze data het biotherapeutische 
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potentieel van bepaalde omgevingsisolaten. Verder onderzoek is uiteraard nog nodig om 
te bepalen of deze bacteriën als dusdanig kunnen worden gebruikt, dan wel of hun 
actieve componenten kunnen dienen als lead-molecule voor geneesmiddelontwikkeling.  
Naast organismen die componenten produceren die QS inhiberen, vonden we ook 
dat een functioneel luxS gen wijdverspreid is binnen de bifidobacteria, die als bacteriën 
met gezondheidbevorderende eigenschappen worden beschouwd. LuxS, het proteïne 
afkomstig van dit gen, is verantwoordelijk voor de productie van de QS signaalmolecule 
AI-2. Hoewel deze molecule doorgaans gelinkt wordt aan virulentie en pathogeniciteit 
toonden onze data aan dat het een cruciale rol speelt in het koloniseren van het 
gastrointestinaal systeem en in de probiotische functionaliteit van bifidobacteria. Voorts 
konden we dit onderliggende LuxS-gemedieerde mechanisme koppelen aan de 
ijzerhuishouding van bifidobacteria. Kortom, onze bevindingen hebbben bijgedragen tot 
het ontrafelen van de moleculaire mechanismen achter de positieve eigenschappen van 
bifidobacteria.  
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Dankwoord 
 
Het is een huizenhoog cliché, maar daarom niet minder waar: een 
doctoraatsonderzoek en de bijhorende thesis zijn niet louter het werk en de verdienste 
van de promovendus. Integendeel: zonder de uitstekende omkadering die ik zowel 
professioneel als privé de laatste jaren heb genoten, was dit werk nooit verworden tot 
wat het is. Daarom hou ik eraan om een aantal mensen uitdrukkelijk te bedanken, niet 
omdat het zo hoort, maar omdat ik dat heel graag wìl. Elk van onderstaande personen 
heeft helpen bouwen aan dit eindresultaat. Sommigen als architect, anderen als 
fundering, nog anderen als hoekstenen, maar allen van even onschatbare waarde. 
 Tom, bedankt dat ik de kans heb gekregen dit belangrijke hoofdstuk van mijn 
leven onder uw vleugels af te werken. Hoewel ik het met mijn grote mond en 
haantjesgedrag niet steeds heb laten uitschijnen, toch moet het gezegd dat uw 
wetenschappelijke begeleiding van een ongezien niveau is. Vijf jaar lang: van bij het 
schrijven van en voorbereiden voor een IWT-beursaanvraag, tot aan de allerlaatste 
loodjes van mijn doctoraat, bij elke stap was je uitermate betrokken. Altijd weer stond je 
paraat om nieuwe ideeën en inzichten te geven, steeds was je een vooruitstuwende 
kracht. Ad rem en straightforward als het moest, vriendschappelijk als het kon, maar 
altijd even benaderbaar. Ook bij het schrijven en nalezen van manuscripten als bij het 
voorbereiden van wetenschappelijke presentaties ging je altijd heel secuur te werk: 
niets verlaat het labo zonder dat het uitvoerig en verschrikkelijk efficiënt (Tom, de man 
die sneller leest en schrijft dan zijn schaduw) nagekeken en bijgeschaafd is. Ik heb de 
laatste jaren het labo onder uw impuls een ongelofelijke groei zien maken, en ik ben 
ervan overtuigd dat die trend zich de komende jaren zowel kwalitatief als kwantitatief 
zal blijven voortzetten. 
 Professor Nelis, door uw hoorcolleges tijdens mijn masterjaren is mijn interesse 
voor de microbiologie gegroeid. Het enthousiasme waarmee u uw vak doceerde (het 
lesgeven is eigenlijk een ambacht, en veel van uw collega’s onderschatten dit gegeven), 
heeft de basis gevormd voor de verdere keuzes in mijn academische loopbaan. Ook 
tijdens mijn doctoraat bleef u - hoewel drukbezet met eerder bestuurlijke en/of 
onderwijstaken – steeds oprecht geïnteresseerd in de vooruitgang van mijn onderzoek. 
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Niet alleen via Tom werd u op de hoogte gesteld van het reilen en zeilen in de labo’s, 
maar geregeld kwam u ook zelf een praatje slaan om up-to-date te blijven; iets wat ik 
altijd enorm geapprecieerd heb. Hetzelfde geldt voor de manuscripten die u steeds met 
oog voor detail nakeek, wat gegarandeerd tot een opmerkelijke verbetering van het 
eindproduct leidde. Samen met uw passie voor taal (zowel de Nederlandse als de 
Engelse) deel ik met u ook de passie voor computers van een niet nader genoemd merk. 
Bedankt om mij ook op deze vlakken veel bij te leren. 
 Voor mensen die er niet gewerkt hebben is het misschien moeilijk te vatten, maar 
op het LPM heb ik eigenlijk geen collega’s gehad, enkel vrienden. Het is met pijn in het 
hart dat ik deze prachtige groep verlaat, en ik besef dat de sfeer op eender welke 
werkvloer nooit nog dezelfde zal zijn. Hoewel een academisch labo een enorm 
dynamische omgeving is, de verbondenheid en amicaliteit zijn een unieke constante op 
het LPM, en dat zie ik nooit veranderen. Het jaarlijkse laboweekend en de ontelbare 
etentjes en drinks zijn daar het levende bewijs van. Wat zal ik het missen!  
De eerste jaren heb ik ontzettend veel geleerd van een immer bereidwille groep 
anciens: Kristof, Elke, Heleen, Lies, jullie hebben mij onmiddellijk opgevangen en wegwijs 
gemaakt in het labo. Ik keek op naar jullie en kan enkel hopen dat ikzelf op z’n minst half 
zo’n goede ancien ben geworden. Davy, mateke, squashpartner, bureaugenoot. Het is 
geen geheim dat we het uitstekend met mekaar konden vinden. Hoewel ik je oneer 
aandoe om je niet te prijzen omwille van je professionele kwaliteiten op het labo, wil ik 
toch vooral in de verf zetten dat je een vriend uit de duizend bent. Jij en Sofie staan dag 
en nacht voor mij paraat en bieden altijd een luisterend oor als het nodig is, en dat is het 
meer dan eens geweest. Merci ook om al die plaagstoten van mij met de glimlach te 
ondergaan, gelieve dat te blijven doen! Ik ben ervan overtuigd dat wij mekaar nooit uit 
het oog zullen verliezen en dat ik je zal blijven inmaken tijdens onze squashpartijtjes. 
Anne-Sophie, gij gekke West-Vlaamse doos! Onvoorstelbaar hoe jij soms met één woord 
iedereen voor een half uur de slappe lach kon doen krijgen, vaak niet eens beseffend 
waarom. Het was een plezier om 4 jaar lang mijn eigen kinderachtige zelf te kunnen zijn 
in jouw gezelschap, ik denk niet dat ik een grappigere vrouw ken dan jou. Vertel je me 
over een jaartje of twee aub nog eens het mopje van Jos? Tegen dan ben ik hem al 
vergeten en kan ik er weer een klein weekje van lopen na-glimlachen. Los van alle 
fratsen en gekkigheid kon ik bij jou ook alles kwijt en steeds terecht met problemen 
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allerhande. Merci meisje! Nele, ik ben voel me intussen al sinds 2006 je poulain. Al van in 
het practicum Microbiologie hadden wij onmiddellijk een klik. En door mijn 
masterthesisstage en later m’n doctoraat is onze band enkel maar gegroeid. Bedankt 
voor je niet-aflatende bezorgdheid, voor een knuffel als het nodig was, voor me graag te 
zien zoals ik ben, en uiteraard ook voor je enorme hulp bij het technische labowerk. 
Zonder jou was minstens 1 artikel er nooit gekomen, dank je wel. Ik weet dat je best een 
beetje afziet van het feit dat je zovele ex-collega’s uiteindelijk uit het oog verliest. Ik zal 
m’n best doen om dat niet te laten gebeuren. Rosina, ongelofelijk hoe jij op je eentje 
zovele administratieve taken tot een goed einde brengt. Je bent meer dan eens een 
reddende engel geweest in de bureaucratische mallemolen die SAP heet. Het is fijn om te 
weten dat ik ook in de toekomst steeds bij jou en Romain terecht kan! Inne, eeuwige 
twintiger en tegelijk mijn labo-moeke. Als draaiende motor van het labo zorgde je er 
steeds voor dat er voldoende glaswerk beschikbaar was, en voor een litertje of 10 agar 
meer of minder draaide je je hand niet om. Je Pyrex-pollen hebben me meer dan eens uit 
de nood geholpen, en je gedistingeerde Arendonkse tongval hebben me meer wél dan 
niet aan het lachen gekregen. Voor technische problemen op het LPM maar één adres: 
Petra, wandelende gereedschapskist. Hamers, vijsjes, labojassen, graveermachines,… 
werkelijk alles zit er in die wonderbaarlijke bureau van jou. Ik denk dat je een fortuin 
kan verdienen door het ontwerp van je bureau aan IKEA te verkopen, maar het siert je 
dat je niet voor het geld kiest en je ervaring wil doorgeven aan een jonge garde 
microbiologen. Gilles, jij bent de enige “leeftijdsgenoot” die m’n hele traject heeft 
meegemaakt: van m’n allereerste tot m’n allerlaatste dag op het labo. Bedankt om mijn 
partner-in-QS-crime te zijn geweest, en om altijd met een kamerbrede glimlach en 
fluitend (hoewel nooit simultaan, dat is nu eenmaal anatomisch onmogelijk) 
behulpzaam te zijn. Samen hebben we ook andere delen van de wereld ontdekt: van het 
exotische Oost-Duitse Jena tot het eerder saaie Miami Beach, je was een ideale reisgezel. 
En dat je ooit moedwillig de kuisvrouw van het hotel de badkamer in stuurde toen ik 
m’n gevoeg zat te doen: het is u vergeven… Ergens halverwege m’n termijn deed een 
andere West-Vlaamse deerne de intrede op het labo: een zekere Ilse. Een post-doc dan 
nog wel, én geen apotheker… Wat moest dat worden? Maar het bleek om een slimme, 
bezorgde, lieve, behulpzame, en uitermatige grappige vrouw. Onvoorstelbaar hoe 
iemand zo lang zich nauwelijks kan moeien in een gesprek en dan met één zin (die er 
boenk op is) iedereen plat kan krijgen van het lachen. Ook bij jou kon ik altijd terecht 
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voor verschillende technische, praktische, of persoonlijke bedenksels. Daarom: dank je! 
Heleen, stille primus. Jij bent zo iemand waar niemand ooit boos op kan worden, want je 
zal je niet laten betrappen op een verkeerd woord of op andere foutjes. Je bent daarom 
volgens mij zowel een ideale collega als een ideale werknemer; kortom: een plezier om 
in je team te hebben. Het labo boft met iemand als jij. Evelien, jou heb ik eerst gekend als 
een ijverige studente, en later op een gedreven en niet-op-haar-mondje-gevallen collega. 
Je hebt overal een uitgesproken mening over, en dat apprecieer ik aan jou. Je bakkunsten 
hebben de gemiddelde BMI van het labo vast geen goed gedaan, maar ik denk niet dat er 
iemand daar om geeft. Sarah, bij jou zijn de routine en het practicum in goede handen. 
Zelfs in hele moeilijke omstandigheden valt er aan jou niets te merken en blijf je uiterst 
gedreven en professioneel. Daar kunnen veel mensen iets van leren. Annelien en Freija, 
met jullie heb ik 1 jaartje mogen samenwerken, en daar ben ik heel blij mee. Ook jullie 
zijn twee prachtcollega’s die enorm goed in het team passen en altijd klaar staan voor 
een ander. Nog heel erg veel succes met jullie doctoraat, maar ik heb er alle vertrouwen 
in dat dat goed komt. Hetzelfde wens ik Sanne en Lisa toe. Onze samenwerking was van 
uiterst korte duur, maar het werd al snel duidelijk dat ook jullie onmiddellijk gingen 
integreren en mee de sfeer bepalen. Jullie hebben de toekomst van het labo mede in 
handen, draag er zorg voor! En tot slot: Andrea, ik vind het knap hoe jij zo op je eentje in 
een avontuur kan smijten en vastberaden je eigen ding doet. Sorry van alle grapjes over 
Duitsers trouwens! 
Enkele mensen die hier ook ontzettend op hun plaats zijn, zijn de verschillende 
studenten die vaak een extra paar handen betekenden. Marie-Solange, Laurens, Pieter-
Jan, Claudia, Helena en Mieke, bedankt om mijn onderzoek vooruit te helpen, en om 
steeds geïnteresseerd naar mijn raad te luisteren. 
Hoe graag ik ook op het labo vertoefde, de twee keer dat ik de kans kreeg om in 
het buitenland ‘op een ander’ te gaan werken, hebben een enorme impact gehad op mij 
als mens en wetenschapper. Het waren misschien wel de meest intense en leerrijke 
periodes van mijn doctoraat. Daarom hou ik eraan om Prof. Douwe Van Sinderen te 
bedanken voor de kans, voor zijn geloof in mijn onderzoek, voor zijn aanstekelijk 
enthousiasme en voor de vruchtbare samenwerking. Ook over de begeleiding van Mary 
alginds, en over de behulpzaamheid van de collega’s Muireann, Amy, Kerry, Debbie, 
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Heather, Lorena en Pat niets dan lof. Heather, a special thanks to you for making the IPC 
conference in Slovakia one of the nicest weeks during the course of my PhD. 
Zowel voor hun interesse in mijn werk als voor de vriendschappelijke of familiale 
ontspannende momenten tussenin wens ik tot slot graag nog enkele mensen uit mijn 
privéleven te bedanken. Ik heb het geluk te beschikken over een uitgebreide 
vriendengroep die voor mekaar door het vuur zouden gaan, één van de belangrijkste 
zaken in het leven. Ook ben ik gezegend met een weliswaar kleine, maar daarom niet 
minder liefdevolle familie. De kleine zus waar ik als klein manneke vaker ruzie mee had 
dan mee speelde, is uitgegroeid tot een zelfstandige en ambitieuze volwassen vrouw 
waar ik fier op ben. We hoeven mekaars deur niet plat te lopen om te weten wat we voor 
mekaar betekenen. Zelfs met mijn schoonzus Nathalie bof ik. Bedankt allebei. Ook mijn 
grootouders zou ik graag bedanken, ik heb met elk van hen een speciale band, en het 
doet verschrikkelijk veel deugd om te merken hoe trots ik hen soms maak. Dat het leven 
niet altijd over rozen gaat is gebleken gedurende het laatste jaar van mijn doctoraat. 
Enkele mensen maken dit belangrijke moment in mijn leven niet meer van op de eerste 
rij mee, om diverse redenen. Toch wens ik hen uitdrukkelijk te bedanken voor alles wat 
ze voor mij betekend hebben gedurende het grootste deel van mijn studies. Het laatste 
dankwoord moet vanzelfsprekend uitgaan naar de twee belangrijkste mensen. Mama en 
papa, ik kan niet beschrijven hoe dankbaar ik ben voor wat jullie voor mij gedaan 
hebben. Ik ben met mijn gat in de boter gevallen, dat besef ik elke dag meer en meer. Een 
onbezorgde kindertijd, de kans om te gaan studeren, onvoorwaardelijke steun bij elke 
grote of kleine beslissing in mijn leven; kortom, een perfecte thuis. Meer kan een kind 
zich niet wensen… Ik merk aan jullie interesse en medeleven dat jullie trots zijn dat ik 
dit academische avontuur tot een goed einde heb gebracht, en dat doet me 
verschrikkelijk veel plezier. Ik hoop dat ik jullie nog vaak en lang trots kan maken. 
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